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Background: Depression in older adults is common and is associated with poor quality of life, increased
morbidity and early mortality, and increased health and social care use. Collaborative care, a low-intensity
intervention for depression that is shown to be effective in working-age adults, has not yet been evaluated
in older people with depression who are managed in UK primary care. The CollAborative care for Screen-
Positive EldeRs (CASPER) plus trial fills the evidence gap identified by the most recent guidelines on
depression management.
Objectives: To establish the clinical effectiveness and cost-effectiveness of collaborative care for older
adults with major depressive disorder in primary care.
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Design: A pragmatic, multicentred, two-arm, parallel, individually randomised controlled trial with
embedded qualitative study. Participants were automatically randomised by computer, by the York Trials
Unit Randomisation Service, on a 1 : 1 basis using simple unstratified randomisation after informed consent
and baseline measures were collected. Blinding was not possible.
Setting: Sixty-nine general practices in the north of England.
Participants: A total of 485 participants aged ≥ 65 years with major depressive disorder.
Interventions: A low-intensity intervention of collaborative care, including behavioural activation,
delivered by a case manager for an average of six sessions over 7–8 weeks, alongside usual general
practitioner (GP) care. The control arm received only usual GP care.
Main outcome measures: The primary outcome measure was Patient Health Questionnaire-9 items score
at 4 months post randomisation. Secondary outcome measures included depression severity and caseness
at 12 and 18 months, the EuroQol-5 Dimensions, Short Form questionnaire-12 items, Patient Health
Questionnaire-15 items, Generalised Anxiety Disorder-7 items, Connor–Davidson Resilience Scale-2 items,
a medication questionnaire, objective data and adverse events. Participants were followed up at 12 and
18 months.
Results: In total, 485 participants were randomised (collaborative care, n = 249; usual care, n = 236),
with 390 participants (80%: collaborative care, 75%; usual care, 86%) followed up at 4 months, 358
participants (74%: collaborative care, 70%; usual care, 78%) followed up at 12 months and 344 participants
(71%: collaborative care, 67%; usual care, 75%) followed up at 18 months. A total of 415 participants were
included in primary analysis (collaborative care, n = 198; usual care, n = 217), which revealed a statistically
significant effect in favour of collaborative care at the primary end point at 4 months [8.98 vs. 10.90 score
points, mean difference 1.92 score points, 95% confidence interval (CI) 0.85 to 2.99 score points; p < 0.001],
equivalent to a standard effect size of 0.34. However, treatment differences were not maintained in the
longer term (at 12 months: 0.19 score points, 95% CI –0.92 to 1.29 score points; p = 0.741; at 18 months:
< 0.01 score points, 95% CI –1.12 to 1.12 score points; p = 0.997). The study recorded details of all serious
adverse events (SAEs), which consisted of ‘unscheduled hospitalisation’, ‘other medically important condition’
and ‘death’. No SAEs were related to the intervention. Collaborative care showed a small but non-significant
increase in quality-adjusted life-years (QALYs) over the 18-month period, with a higher cost. Overall, the mean
cost per incremental QALY for collaborative care compared with usual care was £26,016; however, for
participants attending six or more sessions, collaborative care appears to represent better value for money
(£9876/QALY).
Limitations: Study limitations are identified at different stages: design (blinding unfeasible, potential
contamination), process (relatively low overall consent rate, differential attrition/retention rates) and
analysis (no baseline health-care resource cost or secondary/social care data).
Conclusion: Collaborative care was effective for older people with case-level depression across a range of
outcomes in the short term though the reduction in depression severity was not maintained over the
longer term of 12 or 18 months. Participants who received six or more sessions of collaborative care did
benefit substantially more than those who received fewer treatment sessions but this difference was not
statistically significant.
Future work recommendations: Recommendations for future research include investigating the
longer-term effect of the intervention. Depression is a recurrent disorder and it would be useful to assess
its impact on relapse and the prevention of future case-level depression.
Trial registration: Current Controlled Trials ISRCTN45842879.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 67.
See the NIHR Journals Library website for further project information.
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Plain English summary
The ageing process increases the risk of depression in older people and, although depression is relativelycommon, it often goes unrecognised and untreated. Traditionally, feeling low was considered an
inevitable part of growing old about which nothing could be done.
The CollAborative care for Screen-Positive EldeRs with major depression (CASPER) plus trial aimed to see
if collaborative care, a new type of care involving a case manager who co-ordinates different aspects of a
participant’s care, could help to reduce depression severity. Case managers worked with participants for
an average of six sessions over 7–8 weeks, mainly over the telephone. In order to test whether or not
collaborative care worked, it was compared with usual general practitioner care. Each person taking part
was given one type of care, which was decided by chance, similar to the roll of a dice, to make sure it
was fair.
The trial took place in the north of England. In total, 485 older adults took part for up to 18 months.
After 4 months, the results showed a statistically significant benefit for collaborative care relating to the
primary outcome of depression severity. However, this improvement in people’s mental well-being was
not maintained in the longer term at 12 or 18 months. Collaborative care was more expensive than usual
general practitioner care but, as it may have improved the quality of people’s lives, particularly for people
who had six or more sessions, it might be value for money.
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Scientific summary
Background
Depression is one of the most common reasons for consulting with a general practitioner (GP), and
its associated personal and economic burden is considerable. Depression is often associated with
long-term medical conditions but is commonly unrecognised or suboptimally treated. Older people are
disproportionately affected by depression, which is associated with poor function and poor outcomes.
Strategies to encourage the recognition and management of depression among older people and those
with long-term conditions have been proposed. Guidance often encourages GPs to screen for depression,
and evidence-supported treatments include the prescription of antidepressants and/or the provision of brief
psychological treatments.
Collaborative care involves the provision of low-intensity psychosocial treatment by a case manager working
in collaboration with the primary care team. Psychological interventions form part of care and are delivered
over the telephone. Collaborative care has a strong evidence base among people with depression. The
majority of trials have been conducted in the USA, although evidence from UK trials on the effectiveness of
this approach is now accumulating. There are no large-scale trials that focus on older adults, who often have
long-term physical health problems. In this trial, we adapted collaborative care for a population of older people
whereby an evidence-supported treatment (including behavioural activation and medication management)
was delivered by primary care psychological well-being practitioners over the telephone.
Objectives
The CollAborative care for Screen-Positive EldeRs with major depression (CASPER) plus trial was a
randomised controlled trial (RCT) of usual GP care compared with the addition of collaborative care for
the treatment of clinical depression in older adults. This included concurrent qualitative and economic
evaluations. We first conducted an internal pilot trial, the objectives of which were to:
1. establish the clinical effectiveness of a low-intensity intervention of collaborative care for older adults
with screen-positive major depression disorder.
2. examine the cost-effectiveness of a low-intensity intervention of collaborative care for older adults with
screen-positive major depression disorder across a range of health and social care costs.
3. explore the views and experiences of the CASPER plus intervention within the collaborative care
framework for the management of depression in older people from the perspectives of participants,
case managers and GPs.
Method
Design
We conducted a pragmatic, multicentred, two-arm, parallel, open RCT. Participants with major depression
disorder were individually randomised (1 : 1) to receive either collaborative care in addition to usual GP
care, or just usual GP care.
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Setting
Participants were recruited from general practices in four centres in the north of England: (1) York centre
(the core centre) covering the city of York, Harrogate, Hull and the surrounding areas; (2) Leeds centre and
the surrounding area; (3) Durham centre and the surrounding area; and, (4) Newcastle upon Tyne centre,
including Northumberland and North Tyneside.
Participants
Potential participants were identified by postal questionnaire and were eligible if they reported depressive
symptoms (‘screened positive’) to the Whooley questions, and were then found to have major depressive
disorder according to standardised diagnostic criteria using the Mini International Neuropsychiatric
Interview. Respondents with less severe depression (‘subthreshold depression’) were offered the
opportunity to partake in a related Health Technology Assessment-funded trial (CASPER ISRCTN02202951)
that is not reported in this monograph. We excluded people with known alcohol dependency, psychotic
symptoms, recent evidence of suicidal risk or self-harm, significant cognitive impairment or other factors
that would make an invitation to participate in the trial inappropriate, such as recent bereavement or
terminal illness.
Interventions
Participants in the intervention group were allocated to receive a manualised low-intensity programme of
collaborative care using behavioural activation, designed specifically for those aged ≥ 65 years with depression.
Collaborative care was delivered by a case manager [a primary care mental health worker/Improving Access to
Psychological Therapies (IAPT) worker]. Participants received on average six sessions over 8–9 weeks, of which,
on average, one was delivered face to face and five were delivered over the telephone. Collaborative care in
the CASPER plus trial consisted of telephone support, medication management, symptom monitoring and
active surveillance, facilitated by a computerised case management. The first session was delivered face to face
and subsequent sessions via the telephone.
Participants in the control group were allocated to receive usual GP care; therefore, they received no
care additional to the usual primary care management of subthreshold depression offered by their GP.
Participants who were allocated to collaborative care received the intervention as well as usual GP care.
Main outcome measures
The primary outcome was self-reported symptoms of depression, assessed by the Patient Health
Questionnaire-9 items (PHQ-9) at 4 months post randomisation and also at 12 months and 18 months.
Secondary outcomes were, at 4, 12 and 18 months, a dichotomised measure of depression according to
‘caseness’ (PHQ-9 score of ≥ 10), anxiety [measured by the Generalised Anxiety Disorder-7 item (GAD-7)
scale], somatoform complaints [measured by the Patient Health Questionnaire-15 items (PHQ-15)] and
health-related quality of life [measured by the Short Form questionnaire-12 items (SF-12)]. We also
measured resilience (using the Connor–Davidson Resilience Scale-2 items) and antidepressant use.
The economic evaluation resource use was ascertained from administrative primary care records and
health-state utility was measured using the Short Form questionnaire-6 Dimensions.
Results
A total of 485 patients (mean age 72 years) were recruited to the trial between May 2012 and August 2014,
with 249 participants randomised to collaborative care and 236 to usual GP care. Of these, 390 participants
(80%: collaborative care, 75%; usual care, 86%) were followed up at 4 months, 358 participants (74%:
collaborative care, 70%; usual care, 78%) were followed up at 12 months and 344 participants
(71%: collaborative care, 67%; usual care, 75%) were followed up at 18 months. For those allocated to
collaborative care, 83% engaged with the intervention and the average number of sessions completed was
six out of the planned eight sessions.
SCIENTIFIC SUMMARY
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Clinical effectiveness
Adjusted PHQ-9 score means and group differences for the primary analysis model revealed significant
differences between trial arms at the 4-month primary outcome in favour of collaborative care [1.92 score
points; 95% confidence interval (CI) 0.85 to 2.99 score points; p < 0.001]. This represented a standard
effect size of 0.34. However, this difference in depression severity was not maintained at the long-term
follow-up at 12 months (p = 0.741) or 18 months (p = 0.997). The results were robust to a number of
sensitivity analyses, including adjustment for clustering at the level of the case manager. The proportion of
participants with case-level depression at 4 months was reduced in the collaborative care group (odds ratio
at 4 months 2.18, 95% CI 1.36 to 3.51; p = 0.001), but there was no clear advantage for collaborative
care at 12 months (odds ratio 1.40, 95% CI 0.72 to 2.72; p = 0.319) or 18 months (odds ratio 0.72,
95% CI 0.31 to 1.71; p = 0.461).
Between-group differences were observed in favour of collaborative care for a range of secondary
outcomes including anxiety and somatoform complaints. Anxiety was measured using the GAD-7 and
was reduced at 4 months (GAD-7 mean score difference 1.68, 95% CI 0.77 to 2.59; p < 0.001) and at
12 months (mean score difference 1.09, 95% CI 0.14 to 2.03; p = 0.024), but not at 18 months
(p = 0.511). Somatoform complaints as measured using the PHQ-15 were reduced at 4 months (PHQ-15
mean score difference 1.67, 95% CI 0.98 to 2.36; p < 0.001) and 12 months (PHQ-15 mean score
difference 1.19, 95% CI 0.47 to 1.90; p = 0.001), but not at 18 months (p = 0.423). Health-related quality
of life was improved in mental domains at 4 months (SF-12 mental component summary score mean score
difference 3.02, 95% CI –5.04 to –0.99; p = 0.004) but not at 12 months (p = 0.125) or 18 months
(p = 0.273), and there was no difference in physical domains (SF-12 physical component summary score
p = 0.583 at 4 months; p = 0.769 at 12 months; and p = 0.514 at 18 months).
Cost-effectiveness analysis
Providing collaborative care was estimated to cost an average of £495 per participant (accounting for
costs of training case managers, their expected rate of patient contacts and a standardised agenda case
manager). Analysis of routinely collected data collected during the delivery of collaborative care (i.e. as may
be provided within a typical IAPT service) suggests the expected cost of collaborative care is £198 per
patient and, therefore, lower than assumptions based on the treatment manual. The number of quality-
adjusted life-years (QALYs) gained was higher among articipants who were allocated to collaborative care
than in the control group (difference in adjusted QALY gains = 0.019; p = 0.338). In the base-case analysis,
the incremental cost-effectiveness ratio for collaborative care was £26,010 per QALY. The probability that
the incremental cost-effectiveness of collaborative care was < £20,000 per QALY was 39%, and the
probability that it fell below the £30,000 per QALY willingness-to-pay threshold was 55%. When only
participants who engaged with six or more sessions were included in the analysis, the cost per QALY
estimate fell to £9876.
Qualitative evaluation
The qualitative study suggests that the intervention was acceptable to a large proportion of participants
but that others did not engage. The main reasons for non-engagement were explored and were found to
be related to the misgivings of participants about the potential benefits of behavioural-based programmes.
The importance of the adaptation of treatment to those with long-term conditions or limitations was
underlined. The positive aspects of treatment included the fact that people saw the benefits of behavioural
activation and engaged well with their case managers, even if there were initial misgivings. The qualitative
evaluation also highlighted the paucity of psychosocial interventions that are available for older people in
primary care, and the potential role for collaborative care in ‘plugging these gaps’. The role of the case
manager was valued by participants in ensuring good communication with the GP and in the co-ordination
of care, as well as providing them with the opportunity to talk outside the clinical setting of the primary
care consultation room.
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Conclusions
This is the first large-scale trial in the UK to test the clinical effectiveness and cost-effectiveness of using
collaborative care to treat older people with depression. Collaborative care has been shown to be clinically
effective at reducing depression severity in the short term, at 4-month follow-up, but benefits were not
sustained at 12 or 18 months, so longer-term efficacy was not demonstrated. The effectiveness of collaborative
care for older people with depression was greater for those people who had six or more treatment sessions.
This intervention might be delivered as part of the IAPT services in the NHS at an acceptable ratio of benefits to
cost – if it were highlighted that a minimum of six sessions were needed for it to be cost-effective.
Implications for health care
l Collaborative care was acceptable for the majority of older people with depression and could readily be
delivered by low-intensity IAPT workers over the telephone, following a first face-to-face meeting.
l In this large-scale trial for older people with depression, collaborative care was clinically effective in
improving the primary outcome of depression and across a range of secondary outcomes.
l The cost-effectiveness of collaborative care for depression has been robustly estimated within the
CASPER plus trial and this could be viewed as cost-effective under conventional willingness-to-pay
thresholds.
Recommendations for research
l A significant proportion of older people in the CASPER plus trial had a long-term health problem,
and there were some improvements in quality of life across the trial population. Future adaptations and
trials of collaborative care could focus on its use in populations with serious physical comorbidities and
its impact on physical outcomes.
l More patients in the collaborative care arm discontinued treatment or dropped out of the trial. Further
qualitative and quantitative work should explore the reasons for this, how to maximise the acceptability
and effectiveness of collaborative care for this population and how to identify the most appropriate
target population for the intervention.
l Depression is a recurrent disorder and it would be useful to judge longer-term impact on relapse and
the prevention of future depression.
l This was a brief intervention and its benefits disappeared after 12 months. Future research should be
conducted to establish how minimal interventions may be offered to ensure that early gains from
treatment are sustained. Trials of 12-month top-up sessions for collaborative care (delivered by
telephone) are needed.
Trial registration
This trial is registered as ISRCTN45842879.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Depression in older adults
Depression accounts for the greatest burden of disease among all mental health conditions, and is
expected to become the second highest among all general health problems by 2020.1 It is currently
estimated that in the UK around 10–20% of people aged ≥ 65 years have depression.2 Projected
demographic changes mean that population strategies to tackle depression will increasingly have to
address the specific needs of older adults.3 Depression often occurs alongside long-term physical health
conditions4 and/or cognitive impairment and it is more prevalent among people who live alone in social
isolation. All these factors tend to disproportionately affect the older adult population. Among older
adults, a clinical diagnosis of a major depressive disorder is the strongest predictor for impaired quality of
life.5 Indeed, beyond personal suffering and family disruption, depression worsens the outcomes of many
medical disorders and promotes disability.6 In 2009, the National Institute for Health and Care Excellence
(NICE) published guidelines that acknowledged the coexistence of physical health problems and depression.7,8
Furthermore, it was recognised that the impairments in quality of life associated with depression are comparable
to those of major physical illness.5
Rationale for the CollAborative care for Screen-Positive EldeRs plus trial
Depression in older people is relatively common.9 The effects on the individual include poor quality of life,
increased morbidity and early mortality,10 and increased health and social care use.11 Depression is often
under-recognised and undertreated in primary care.12,13 At present, the management of depression tends to
be limited to the prescription of antidepressants, with poor adherance an associated problem.12 In particular,
older adults seem to be less likely than working-age adults to be offered psychological treatments.14,15 So far,
the evidence for psychological interventions relates to higher-intensity models of care that cannot feasibly be
delivered at scale in primary care. Collaborative care is a framework model for organising and delivering
psychosocial interventions at scale.16 It represents a brief, patient-centred, psychosocial package of care
delivered by a case manager who works to a defined protocol and co-ordinates the patient’s medication
management with their general practitioner (GP). The case manager is supervised by a specialist who facilitates
liaison across the primary care–secondary care interface.17 In the USA, collaborative care has shown promising
trial results among older people;16 however, the transferability of this model of service to the UK NHS cannot
be assumed. Consequently, the CollAborative care for Screen-Positive EldeRs with major depression (CASPER)
plus trial will substantially enhance the randomised evidence base in the care of older people with depression
and inform future service provision.
Collaborative care: an organisational model of providing care
The vast majority of depression in older adults is managed entirely in primary care without recourse to specialist
mental health services.3,18 Although a range of individual treatments have been shown to be effective in the
management of clinical depression in older adults, including antidepressants and psychosocial interventions,18
a repeated observation among those with depression has been the failure to integrate these effective elements
of care into routine primary care services.19 In addition, the implementation of any form of care will require a
strategy that is low intensity and can be offered within primary care.20
In recent years, an organisational model of care has been introduced called collaborative care.21
Collaborative care borrows much from chronic disease management and ensures the delivery of effective
forms of treatment (such as pharmacotherapy and/or brief psychological therapy) through augmenting
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the role of non-medical specialists in primary care. Collaborative care is a model whereby the non-medical
specialists, or case managers, form a close collaboration with the person with depression and others
involved in their care. The case manager acts as a conduit for the passage of information between all
individuals involved and supports the participant to enable effective discussion of important problems.
Case managers provide information and help participants to access appropriate services, such as social care
and voluntary sector services.
The ubiquity of depression in primary care settings, along with the poor integration and co-ordination
of care, has led to the development of, and increased use of, this model of care. In a 2012 Cochrane
review22 of 79 randomised controlled trials (RCTs) (24,308 participants), clear and robust evidence of the
effectiveness of collaborative care was shown. It improved depression outcomes in both the short and
medium term. Moreover, there was evidence to suggest that collaborative care can be cost-effective by
reducing health-care utilisation and improving overall quality of life.23,24 However, the greater proportion of
studies related to working-age adults. A relative lack of any evidence for older adults was identified, which
led to calls for further research on collaborative care among that age group. One important exception was
the evidence provided by the US Improving Mood-Promoting Access to Collaborative Treatment (IMPACT)
study of the effectiveness of collaborative care for older adults.
The IMPACT study was conducted by Unützer et al.16 for those aged > 60 years with case-level clinical
depression. The main finding was that, at 12 months, depression severity was at least 50% improved from
baseline in almost half the participants in the intervention group, but only one in five of those receiving
usual care. In 2007, a UK feasibility trial9 of collaborative care in older adults showed some positive results.
In recent years, the evidence base has expanded, although not with direct reference to older adults.
The CollAborative DEpression Trial (CADET)11 showed that collaborative care was effective at improving
depression outcomes in a UK primary care population, and the Collaborative Interventions for Circulation
and Depression: study protocol for a cluster randomized controlled trial of collaborative care for depression
in people with diabetes and/or coronary heart disease (COINCIDE) trial10 showed a modest effect at reducing
depression and improving self-management of chronic disease.
In addition to the provision of collaborative care, the studies also provide information and support to enable
participants to undertake brief psychological therapies, in this case behavioural activation. Behavioural
activation for the CASPER plus trial was adapted from the behavioural activation intervention delivered in
CADET.11 Manualised psychological interventions, such as behavioural activation, may benefit individuals
experiencing depressive symptoms. It focuses on addressing the behavioural deficits common among those
with depression by reintroducing positive reinforcement and reducing avoidance. Such interventions aim
to manipulate the behavioural consequence of a trigger (environmental or cognitive) rather than directly
interpret or restructure cognitions.25 Behavioural activation is about helping patients to ‘act their way out’ of
depression rather than wait until they are ready to ‘think their way out’. Helping people to identify and
reintroduce valued activities that they have stopped doing, or to introduce ones they would like to take up,
is an important component. The effectiveness of this psychological approach is now well demonstrated.26,27
Behavioural activation can be readily delivered by a trained case manager either over the telephone or face
to face (for those who experience difficulty using or accessing telephone-based therapy).28
Limitations of previous trials
The major limitation of previous trials was an absence of a definitive UK trial of collaborative care in older
adults with depression. The absence of UK trials of collaborative care was highlighted in 2009 guidance
for depression issued by NICE, and the need for such trials was highlighted as a research priority.7 We
proposed to measure the clinical effectiveness and cost-effectiveness of using collaborative care on older
adults with major depression in response to a lack of evidence of its benefit to the older population in UK
primary care.
INTRODUCTION
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Chapter 2 Research objectives
The research objectives of this trial were to:
1. establish the clinical effectiveness of a collaborative care intervention for older people with
screen-positive above-threshold (‘major depressive episode’) depression within a definitive RCT
2. examine the cost-effectiveness of a collaborative care intervention for older people with screen-positive
above-threshold (‘major depressive episode’) depression across a range of health and social care costs
within a definitive RCT.
The definitive RCT was preceded by a developmental phase to produce a manualised collaborative care
intervention for older people and an internal pilot trial to optimise recruitment, randomisation and
retention, and we report these preparatory objectives within the body of this report.
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Chapter 3 Methods
For CASPER plus, those patients identified at the screening phase as having above-threshold, case-leveldepression will be eligible to enter the CASPER plus substudy.
Trial design
We conducted a pragmatic, multicentred, two-arm, parallel, open RCT. Participants with major depression
were individually randomised (1 : 1) to receive either collaborative care in addition to usual GP care, or just
usual GP care.
Approvals obtained
This study was approved by NHS Leeds East Research Ethics Committee (REC) on 28 September 2010
(REC reference number 10/H1306/61). Research management and governance approval was obtained for
each trial centre thereafter (see Appendix 1). This trial was assigned the International Standard Randomised
Controlled Trial Number of ISRCTN45842879.
Trial centres
Four centres in the north of England were selected as trial sites: (1) York centre (the core study centre)
covering the city of York, Harrogate, Hull and the surrounding areas; (2) Leeds centre and the surrounding
area; (3) Durham centre and the surrounding area; and (4) Newcastle upon Tyne centre, including
Northumberland and North Tyneside. Each centre was responsible for co-ordinating the recruitment of
participants into the study (trial and epidemiological cohort).
Duration of follow-up
All participants were followed up by questionnaire at 4, 12 and 18 months (see Chapter 4).
Participant eligibility
Inclusion criteria
People for whom both of the following criteria applied:
l aged ≥ 65 years
l identified by GP practice as being able to take part in collaborative care.
Exclusion criteria
Potential participants were excluded if identified by primary care clinicians as meeting one of the
following criteria:
l known alcohol dependency (as recorded on GP records)
l known to be experiencing psychotic symptoms (as recorded on GP records)
l any known comorbidity that would, in the GP’s opinion, make entry to the trial inadvisable (e.g. recent
evidence of suicidal risk or self-harm, significant cognitive impairment)
l other factors that would make an invitation to participate in the trial inappropriate (e.g. recent
bereavement, terminal malignancy).
Sample size
To detect a minimum standard effect size of 0.35 (aligning with the US IMPACT study16 and our previous
CASPER trial29,30) with 80% power and a two-sided 5% significance level, 260 patients (130 per arm) would
be required. Although this is an individually randomised trial, there may be potential clustering at the
level of each collaborative care case manager, and hence the sample size was inflated to account for this.
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Based upon an estimated intracluster correlation coefficient (ICC) of 0.02 and a case load size of 20, the
design effect would be 1.38 {1 + [(20 – 1) × 0.02]} and 360 patients (180 in each arm) would be required.
Allowing for 20% loss to follow-up, the final sample size needed was 450 patients (225 per arm).
Epidemiological cohort
During the first year of the CASPER plus trial, an epidemiological cohort was assembled. This consisted of
people who had consented to participate in the trial but who were not depressed. Through our broad
inclusion criteria we successfully recruited a total of 4668 patients aged ≥ 65 years into the CASPER cohort,
from who we identified those with major depression who were eligible to participate in the CASPER plus
trial. The reasons for this strategy were twofold: first, to recruit an adequate number of potential participants
who would subsequently be identified as having depression, as we believed this would not always be
recorded on GP records; and, second, to establish an epidemiological cohort of older adults who could be
followed up and who would help inform the knowledge base around the health and well-being of older
adults. This type of study design is termed a cohort multiple RCT.31
Recruitment into the trial
Recruitment of all participants into the trial took place through primary care. GP practices agreed to
participate after a member of the study team had introduced it to them with written information, followed
by a face-to-face visit to explain the study and what participation would involve. Patients were identified by
a computer search and then invited to participate in the CASPER study by their general practice, which
posted an invitation pack to all eligible patients. The packs comprised an invitation letter (see Appendix 2)
signed from the general practice, a consent form (see Appendix 3), a decline form (see Appendix 4),
a participant information sheet (see Appendix 5), a background information sheet (see Appendix 6) and a
prepaid return envelope addressed to the core study centre. No patient-identifiable data were available to
the study teams until patients returned their consent form.
Consenting participants
During the consent stage, potential participants were asked to complete the Whooley questions,32
a two-item depression-screening/case-finding tool. These questions were asked at two different time
points – on the background information sheet at invitation and in the baseline questionnaire – both times
as self-reports. At the consent stage, participants were informed about the opportunity of participating in
other related studies (e.g. qualitative studies) and were asked to indicate if they agreed to be approached
in the future by ticking a box on the consent form. All participants who consented to take part in the
CASPER study at this stage became part of the CASPER cohort. Participants did not become part of the
CASPER plus trial until they had been subsequently assessed for suitability by completing a standardised
diagnostic interview and randomisation.
Baseline assessment
On receipt of written consent from participants by the return of their consent form via post, baseline data
were collected through a self-report questionnaire. All participants who returned completed consent
forms to the core study centre were sent a baseline questionnaire (see Appendix 7). Participants were
asked to respond to the Whooley questions32 for a second time and to provide self-report medication data.
They were also asked to complete a range of health surveys, which consisted of the Patient Health
Questionnaire-9 items (PHQ-9)33 – a measure of depression severity using a nine-item depression scale in
reference to how a respondent has been feeling over the past 2 weeks; the Short Form questionnaire-12
items (SF-12)34 – a measure of health-related quality of life to obtain health-state utility by estimating the
Short Form questionnaire-6 Dimensions (SF-6D); the EuroQol-5 Dimensions, 3 levels (EQ-5D-3L)35 – a
standardised measure of health-state utility, designed primarily for self-completion by respondents; the
Generalised Anxiety Disorder-7 item (GAD-7)36 scale – a severity measure of generalised anxiety used to
gauge the past 2 weeks; the Patient Health Questionnaire-15 items (PHQ-15)37 – a measure of somatic
complaints using a 15-item scale in reference to the last month; and the Connor–Davidson Resilience
Scale-2 items (CD-RISC2)38 – used to measure an individual’s resilience and ability to bounce back.
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Randomisation
Randomisation was carried out by the York Trials Unit Randomisation Service [www.yorkrand.com
(accessed 23 June 2016)], accessed by a trained researcher from the study team. Participants were
automatically randomised by a computer on a 1 : 1 basis by simple unstratified randomisation to either the
intervention group or control group, following the completion of a diagnostic interview. All diagnostic
interviews were conducted over the telephone by a trained researcher from the study team. The major
depressive episode module of the Mini International Neuropsychiatric Interview (MINI) was used to ascertain
the presence or absence of core depressive symptoms.39 The MINI shows good agreement with other
semistructured diagnostic interviews conducted to internationally recognised standards.40–42 This allowed
potential recruits to be identified as having major depressive disorder (five or more symptoms), subthreshold
depression (two to four symptoms) or no depression (one symptom) (Table 1).39,43,44 All participants
diagnosed with major depressive disorder were randomised to either the intervention or the control arm.
Once participants had been randomised, they were sent a letter informing them of the outcome of their
diagnostic interview. If their MINI outcome was major depression, they were informed of their group
allocation, either collaborative care or usual care. The participant’s GP was also sent a letter informing
them that the named patient was eligible to take part in the CASPER plus trial owing to the major
depression outcome of their diagnostic interview. It also specified which arm of the trial they had been
randomised to.
Ineligible participants
All participants whose outcome was not major depression (either non-depressed or subthreshold) were
sent a letter informing them that they were ineligible for the CASPER plus trial but that they would remain
in the CASPER epidemiological cohort and continue to be followed up via questionnaires. Their GPs were
also informed of this. This process of following up non-trial participants was discontinued once the original
CASPER trial completed (see Chapter 4).
Trial interventions
Control group
Participants in the control group were allocated to receive usual GP care. They received no care additional
to the usual primary care management of major depression offered by their GP in line with NICE
depression guidance as implemented by their GP and local service provision.7,8
Intervention group
Participants in the intervention group were allocated to receive a low-intensity programme of collaborative
care using behavioural activation, designed specifically for those aged ≥ 65 years with major depression.
TABLE 1 Symptoms of depressiona
Key symptoms Other symptoms
Depressed mood Substantial changes in weight/appetite
Loss of interest Change in sleep patterns
Change in energy levels
Movement slowing down or speeding up
Feeling guilty or worthless
Unable to make decisions
Thinking of death or suicide
a Based on the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition.43
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Collaborative care was delivered by a case manager [a primary care mental health worker/Improving
Access to Psychological Therapies (IAPT) worker] for an intended 8–10 weeks. This took place alongside
participants’ usual GP care. The defining feature of collaborative care is a collaboration of expertise to help
support the participant. A case manager works alongside the participant, sharing any relevant information
with the GP and a mental health specialist (psychiatrist or psychologist). The case manager is a cohesive
link between the participant and other professionals involved in their care. For example, a case manager
who deemed a participant’s depressive symptoms to have deteriorated would pass this information on to
the participant’s GP, who would optimise the management of the patient’s condition.
Collaborative care in the CASPER plus trial consisted of telephone support, symptom monitoring and
active surveillance, facilitated by a computerised Patient Case-Management Information System (PC-MIS)
[www.york.ac.uk/healthsciences/pc-mis (accessed 23 June 2016)] and low-intensity psychosocial
management (behavioural activation). Participants randomised to the collaborative care intervention group
were contacted by a case manager within 1 week of their randomisation to arrange their first collaborative
care session. This was carried out face to face, usually at the participant’s home unless an alternative venue
was preferred. After this initial meeting, subsequent sessions were carried out on a, more or less, weekly
basis by telephone unless the participant had sensory impairments or preferred face-to-face visits. Case
managers worked collaboratively with the participants, liaising with GPs and other health professionals
involved in their care to discuss issues relating to participants’ mental and physical health, both during
routine updates and when any concerns were identified. This included liaising with GPs as necessary to
consider reviews of medication, which could relate to depression but also to comorbid physical health
problems. It also included discussing with GPs referrals to other services, such as health services (e.g. pain
clinics) or engagement with social services. Case managers worked with the participants to identify
problems and agree goals for the intervention. They also worked with participants to identify, and
subsequently provide, information about other services that may be useful, such as voluntary and statutory
sector organisations and services.
Refinement of collaborative care/behavioural activation
The delivery of collaborative care and behavioural activation had been established in working-age adults
for whom an appropriate training package and manual already existed.28 However, these had not been
tailored for use with older adults diagnosed with major depression. Before the study began, necessary
changes were made to both the training package and manual (detailed in this section) to account for
differences that may exist in the older adult population.
Training occurred over 2 days and involved a combination of brief lectures and role-play. Topics covered
were the collaborative care approach as applied to older adults, medication management in older adults,
behaviour theory and behavioural activation as adapted for older adults.
Adaptations to language and content
Adaptations were made to the information gathered at the initial assessment. Older adults are more likely
to experience long-term health problems and a reduced level of functioning, with their psychological status
often closely linked to their physical functioning.45 Additional questions regarding health conditions and
their impact were added to the standard assessment format. However, case managers were reminded
to deliver a person-centred approach and not let preconceptions about the level of functioning of older
adults influence their information gathering. Liaison with health professionals who were involved in treating
the participant’s long-term health conditions was encouraged to promote a depth of understanding of
these issues. Depression in older adults is associated with impaired social support;46 therefore, additional
questions regarding social contacts and family were added. The risk assessment (see Appendix 8) was also
adapted to enquire about past passive and past active suicide ideation as well as current plans and
preparations, as past suicidality is a risk factor for current suicidal behaviour.47
Information in the manual was tailored to meet the needs of older adults. Age-appropriate examples
were used, such as bereavement and loss of role, to facilitate engagement and make it easier to relate to.
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The psychoeducation material given to participants was also modified to include information about
depressive symptoms that occur specifically in older adulthood. As depression is associated with cognitive
impairment in older people,48 a larger font and increased space for writing was introduced. In addition,
when individuals displayed mild cognitive impairment, simpler language was used and the number of steps
in each session, along with the homework, was reduced. Questions were also added to help the case
manager assess the participant’s understanding of the treatment principles.
Functional equivalence and keeping well
Case managers were made aware of the importance of helping patients to identify functionally equivalent
activities and a section was added to the Keeping Well Plan to prompt participants to identify functionally
equivalent activities that may replace enjoyable or rewarding activities they were no longer able to undertake.
Further details of the adaptations made can be found in Pasterfield et al.49
Participant follow-up
All participants in the CASPER plus trial were followed up with questionnaires at 4 months (see Appendix 9),
12 months (see Appendix 10) and 18 months (see Appendix 11). All post-randomisation questionnaires
were posted to participants from the York Trials Unit along with a pre-addressed prepaid envelope.
Participants could complete the questionnaires manually and return them by post to York Trials Unit or they
could complete the questionnaire online; an instruction sheet explaining how to log on to the CASPER study
site and complete the process was included with each questionnaire. Reminder letters were sent by post at
2 weeks to any participants who had not returned their questionnaire. Telephone follow-up by one of the
study team’s researchers was conducted for any participants who did not return the reminder questionnaire
in order to complete the primary outcome measure (PHQ-9) at the very least.
Trial completion and exit
Participants were deemed to have exited the trial when they:
l withdrew consent (wished to exit the trial with no further contact for follow-up or objective data)
l had been in the trial for 18 months post randomisation
l had reached the end of the trial
l died
l moved general practice to one not participating in the CASPER study
l had another reason to exit according to clinical judgement from a health professional.
Withdrawals
Withdrawal could occur at any point during the study at the request of the participant. If a participant
indicated that he or she wished to withdraw from the study, a researcher would speak to the participant
to clarify to what extent they wished to withdraw: from the intervention, from the follow-up or from all
aspects of the study. When withdrawal was only from the intervention, then follow-up data continued to
be collected. Data were retained for all participants up to the date of withdrawal, unless they specifically
requested for their details to be removed.
Objective data
Once the CASPER plus trial participants of a general practice had completed their follow-up, objective data
were collected for each trial participant. Objective data consisted of details on each participant’s prescribed
medication and the number of contacts they had with their general practice during their time in the trial.
The only exception was for those participants who had withdrawn in full, thereby withdrawing consent to
access their medical records. Objective data were collected from general practices via request from the
core study centre. A spreadsheet template was e-mailed to the key contact of each general practice that
included the identification codes of each trial participant for the practice with prewritten frozen headings:
there were no identifiable data. The search dates for each participant were also listed, from the date they
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were randomised until either the date they completed the study 18 months later or the date that they had
died, if that was the case. Data were still collected on participants who had withdrawn from treatment or
follow-up, as they had provided us with consent to access their health records for the 18 months that they
would have been in the study. The transfer of all objective data via e-mail was approved on the basis that
no identifiable data were shared either with the general practice at the request stage or with the core
study centre at the stage that objective data were returned.
Suicide protocol
A small but elevated risk of suicide and self-harm was inherent in the study population, all members of
which had been identified as having major depression. All participants (both usual care and collaborative
care) were subject to usual GP care and GPs were responsible for the day-to-day management of major
depression. GPs were accountable for all treatment and management decisions including prescribing of
medication, referral and assessment of risk. This arrangement was made clear to all clinicians and general
practices that agreed to participate in the study. The pragmatic nature of the CASPER plus trial meant
that we did not seek to influence this arrangement. However, we did follow good clinical practice by
monitoring for suicide risk during all our encounters with participants. When a patient expressed a risk
through thoughts of suicide or self-harm, we followed the study-specific procedure for suicide risk
(see Appendix 8).
Patient and public involvement in research
The CASPER plus trial was informed by the involvement of users of mental health services and carers
throughout the research period. An advisory group was established in the early stages of study. This
consisted of a number of older adults, some of whom had mental health conditions, along with a carer
representative. This group provided valuable insights into the relevance and readability of the study
documentation. In the future, we plan to engage patient and public involvement in our dissemination
strategies to guide on how best to share the findings.
Further studies
Following completion of the CASPER trial, the Self Help At Risk Depression (SHARD) substudy (not
described in this report) was introduced to randomise participants identified with subthreshold depression
to receive a self-help workbook or usual GP care. Results from the SHARD study will follow.
Clinical effectiveness
Primary outcome
The primary end point for the trial was patient-reported depression severity, as measured by the PHQ-933
at 4 months’ follow-up. Each item is scored from 0 to 3; thus, PHQ-9 scores can range from 0 to 27,
with higher scores indicating more severe depression. Total scores from 0 (non-depressed) to 27 (severely
depressed) were calculated based on the nine PHQ-9 items. These data were collected via self-report on
the follow-up questionnaires. Any participants who did not return a completed questionnaire were sent
a reminder, and those participants who did not respond were telephoned by one of the study team’s
researchers to ask them to complete the PHQ-9 over the telephone. Missing items were replaced with the
mean of the remaining items if one or two items were missing.
The PHQ-9 data were collected at baseline and randomisation (at the diagnostic interview), as well as at 4,
12 and 18 months’ follow-up. Scores at baseline and randomisation are reported in Chapter 5, Baseline
characteristics. When analyses were adjusted for initial PHQ-9 score, the score at randomisation was used.
The primary end point for the CASPER plus trial was at 4 months’ follow-up. At that point, treatment
differences in the magnitude of a standard effect size of 0.35 were sought, which is of moderate size for
psychological interventions and in line with collaborative care effects observed in other studies. Cohen50
classifies a standard effect size of 0.3 as a small to medium effect size, and this is in line with NICE
guidelines for depression, which adopts a similar grading of clinical significance. Four months was selected
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as the primary end point, because it would occur soon after the end of the planned treatment but allow
some additional time in the event that it was not possible to see participants on a weekly basis for practical
reasons (e.g. holidays).
Secondary outcomes
The secondary outcome measures used were:
l depression severity and symptomatology at 12 and 18 months (PHQ-9)
l binary depression severity at 4, 12 and 18 months (PHQ-9), using scores of ≥ 10 to designate moderate
depression caseness
l quality of life at 4, 12 and 18 months (SF-12 and EQ-5D-3L)
l psychological anxiety at 4, 12 and 18 months (GAD-7)
l mental health medication at 4, 12 and 18 months
l physical health problems at baseline, 4, 12 and 18 months (PHQ-15)
l psychological resilience at baseline, 4, 12 and 18 months (CD-RISC2)
l mortality at 4, 12 and 18 months.
Short Form questionnaire-12 items
The SF-1234 is a generic health status measure and a short form of the Short Form questionnaire-36 items
health survey. It consists of 12 questions measuring eight domains (physical, role physical, bodily pain,
general health, vitality, social functioning, role emotional and mental health) rated over the past month.
Questions have three or five response categories, and responses are summarised into a physical component
summary (PCS) score and mental component summary (MCS) score. The PCS and MCS scores range from 0
(the lowest level of health) to 100 (the highest level of health) and were designed to have a mean score of
50 in a representative sample of the US population. Therefore, scores > 50 represent above average health
status, and vice versa. The SF-6D was estimated from responses to the SF-12 questionnaire and provided
health-state utilities to inform cost–utility analysis.
EuroQol-5 Dimensions, 3 levels
The EQ-5D-3L35 is a standardised measure of current health status developed by the EuroQol Group
for clinical and economic appraisal. The EQ-5D-3L consists of five questions each assessing a different
quality-of-life dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Each dimension is rated on three levels: no problems (score = 1), some problems (score = 2) and extreme
problems (score = 3). A weighted summary index can be derived to give a score between 1 (perfect health)
and 0 (death). For the purpose of the clinical effectiveness analysis, only scores of the individual dimensions
were utilised. Health-state utilities (along with SF-6D) were estimated to potentially inform the cost–utility
analysis; however, the SF-6D was ultimately found to be more sensitive to change in this cohort.
Generalised Anxiety Disorder-7 items scale
The GAD-736 is a brief measure of symptoms of anxiety based on diagnostic criteria described in Diagnostic
and Statistical Manual of Mental Disorders-Fourth Edition.43 It consists of seven questions and is calculated
by assigning scores of 0, 1, 2 and 3 to the response categories of ‘not at all’, ‘several days’, ‘more than
half the days’ and ‘nearly every day,’ respectively. GAD-7 total score for the seven items ranges from 0 to
21. Scores of 5, 10 and 15 represent cut-off points for mild, moderate and severe anxiety, respectively.
Patient Health Questionnaire-15 items
The PHQ-1537 is a 15-item physical health problems questionnaire. Each health issue is rated as 0 (not
bothered), 1 (bothered a little) or 2 (bothered a lot). Items are added to form a scale from 0 to 30, higher
scores indicating worse symptom severity. Scores of 5, 10 and 15 have been used as cut-off points for low,
medium and high symptom severity. Item 4 of the PHQ-15 (menstrual problems) was deemed not relevant
for the older CASPER patient population and omitted from all questionnaires. Therefore, the total possible
PHQ-15 score was 28.
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Connor–Davidson Resilience Scale two-items
The CD-RISC238 is a two-item short form of the full Connor–Davidson Resilience Scale-25 items. It is a
psychological resilience measure with specific items for bounce-back from adversity and adaptability to
change. Agreement with the two items is scored from 0 to 4, resulting in a total score of 0 to 8, where a
higher score indicates greater resilience.
Mental health medication
Medication data were captured by self-report on the follow-up questionnaires. Participants indicated
prescribed medication by selecting from a list of 10 antidepressants, as well as listing any other
medications they were prescribed.
Mortality data
A data linkage service was established with the NHS Digital to provide regular updates from the Office
for National Statistics (ONS) mortality data on any trial participants who had died while in the study.
Members of the research team recorded any identified deaths, date and cause of death on the study
management database.
Other collected patient questionnaire data
Adverse events
The CASPER plus study was not a Clinical Trial of an Investigational Medicinal Product and was, therefore,
not subject to any additional restrictions. Decisions regarding prescription of medications were made by
the participant in conjunction with their GP: participation in the study had no bearing on this process.
Any participants who asked a member of the CASPER plus study team for an opinion on medication issues
were strongly encouraged to seek advice from their GP.
The study recorded details of all serious adverse events (SAEs). Any judged to have been related to the
study were required to be reported to the REC under the terms of the standard operating procedures for
RECs.51 In the context of the older adult population of the CASPER plus study, many of the SAEs were
expected: unscheduled hospitalisations, life-threatening conditions, incapacitating illnesses and deaths.
These were not perceived as unexpected events; therefore, they would be reported as SAEs only if they
appeared to be related to an aspect of taking part in the study (e.g. participation in treatment, completion
of follow-up questionnaires, participation in qualitative substudies or telephone contact).
When a SAE was identified, the trial manager was informed by e-mail using a participant’s trial identification
number, and not by any identifiable data. He or she then informed the chief investigator and two members
of the Trial Management Group, who jointly decided if the event should be reported to the REC as a SAE.
A SAE form was completed and a copy was filed securely at the core study centre. Any unexpected SAEs
that were also judged to have been related should have been reported to the main REC within 15 days of
the chief investigator becoming aware of the event. In the CASPER plus study, none of the SAEs were
judged to have been related to the trial.
The occurrence of adverse events during the trial was monitored by an independent Data Monitoring
Ethics Committee and the Trial Steering Committee. The Data Monitoring Ethics Committee/Trial Steering
Committee would have seen immediately all SAEs thought to be treatment related.
Data collection schedule
An overview of the time points at which trial data were collected is presented in Table 2.
Statistical assumptions
Participants, care deliverers and the study team were not blinded to treatment allocation. However, allocations
were concealed (group A and group B) for interim study reports, for example for the purpose of independent
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data monitoring reporting. The trial statistician who was responsible for the final statistical analysis was kept
blind to group allocation until the primary analysis had been completed.
All analyses were conducted on intention-to-treat basis, using a two-sided statistical significance level of
0.05 unless otherwise stated. A full specification of the statistical analyses is documented in the CASPER
plus statistical analysis plan (version 1.0). Any additional data assumptions for data, once received from the
York Trials Unit data management team and the CASPER plus trial management team, for the purpose of
this report, are documented separately.
Statistical analysis
Baseline characteristics
All participant baseline data (demographics from the background information form, outcome data from
the baseline questionnaire, PHQ-9 and MINI responses from the diagnostic interview) were summarised
descriptively by trial arm for all randomised participants and all participants included in the primary analysis.
The analysis population included all patients in their randomised groups with available outcome data
(for the primary analysis: PHQ-9 score at 4, 12 or 18 months’ follow-up) as well as complete baseline
covariates specified for the analysis.
Primary analysis
Unadjusted descriptives of depression severity (PHQ-9) at all follow-up time points were presented.
A covariance pattern linear mixed-effects model was used to compare collaborative care with usual care
on PHQ-9 scores at 4 months. Effects of interest and baseline covariates were specified as fixed effects,
and the correlation of observations within patients over time was modelled by a covariance structure to
describe the random effects. The mixed model provided increased statistical power by utilising all patients
with outcomes for at least one follow-up time point.
TABLE 2 Data collection schedule
Data collected
Time point
Invitation Baseline
Diagnostic
interview/
randomisation
4 months’
follow-up
12 months’
follow-up
18 months’
follow-up
Consent/decline ✓
Demographics ✓
Whooley questions ✓ ✓
Physical health problems ✓
MINI major depressive module ✓
PHQ-9 ✓ ✓ ✓ ✓ ✓
SF-12 ✓ ✓ ✓ ✓
EQ-5D-3L ✓ ✓ ✓ ✓
GAD-7 ✓ ✓ ✓ ✓
PHQ-15 ✓ ✓ ✓ ✓
CD-RISC2 ✓ ✓ ✓ ✓
Mental health medication ✓ ✓ ✓ ✓
Mortality ✓ ✓ ✓
SAEs ✓ ✓ ✓
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The outcome modelled was PHQ-9 at 4, 12 and 18 months. The model included time, trial arm and
time-by-treatment interaction as fixed effects, adjusting for PHQ-9 score at randomisation and physical/
functional limitations (as measured by the baseline SF-12 PCS score). Different covariance structures for the
repeated measurements available in the analysis software were explored, and the most appropriate pattern
was used for the final model based on the model Akaike information criterion. The primary end point was
the estimate of the effect of the intervention at 4 months, which is presented with 95% confidence
intervals (CIs) and associated p-values.
Secondary analyses
The primary analysis model was repeated (1) including case managers as a random effect to account for
clustering within case managers, (2) including additional covariates predictive of PHQ-9 scores at 4 months
as identified by univariate regressions, (3) including additional covariates predictive of non-response at
4 months as identified by univariate regressions and (4) using multiply imputed data. Results from the
secondary analyses were compared with those from the primary analysis in order to ascertain the robustness
of any observed treatment differences.
Secondary outcomes
Patient Health Questionnaire 9-items depression severity estimates at 12 and 18 months were extracted
from the primary analysis model and presented with 95% CIs and associated p-value. A logistic
mixed-effects model was used to compare PHQ-9 depression caseness (scores of ≥ 10), using the same
covariates as the primary analysis. Odds ratios and 95% CIs are presented for the effect of the intervention
at 4, 12 and 18 months. Analyses of other secondary outcomes were conducted using linear or logistic
mixed models, depending on the outcome measure, adjusting for PHQ-9 score at randomisation and
baseline SF-12 PCS score as well as the outcome measure at baseline. Treatment effects at each time
point were reported. EQ-5D-3L responses were reported descriptively as part of the statistical analysis and
analysed fully as part of the economic analysis. Frequencies of adverse events were reported descriptively by
treatment arm, including breakdown by type and estimated relatedness to the intervention. The number of
deaths occurring in the 18-month trial period was summarised by trial arm and overall. A chi-squared test
was used to compare proportions between trial arms if more than five participants died in each arm.
Economic analysis
Economic analysis took the form of a cost-effectiveness analysis and, in line with NICE guidance,52,53
adopted the perspective of the health and personal social services. The aim of the analysis was to estimate
the value for money of providing collaborative care as compared with usual care. The time horizon for the
analysis was 18 months from the date of randomisation; therefore, costs and quality-adjusted life-years
(QALYs) were discounted at 3% for observations beyond 12 months. The analysis was conducted in Stata®
version 13.1 (StataCorp LP, College Station, TX, USA).
Quality-adjusted life-years were estimated from responses to the SF-12 questionnaire to estimate SF-6D
health state utilities.54 This enables comparisons to be made across different health interventions and
provides extra information for decision-makers. QALYs were estimated by measuring the area under the
curve55 that joins the baseline and follow-up SF-6D utility scores, which was derived from population-
based values.
A base-case cost of collaborative care was estimated, based on the case manager training manual,
which describes the treatment protocol (the manual is available from the authors on request). Over the
full intended duration of the study (i.e. 18 months), participants’ health-care resource use was collected to
estimate total cost of health care during treatment and the follow-up period. Various methods of collecting
resource use data were initially considered (e.g. self-report questionnaires and medical record checks).
Objective data were obtained from general practices giving information on participants’ (1) contacts with
GPs (appointments, home visits or telephone consultations), (2) contacts with practice nurses (appointments
METHODS
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or telephone consultations) and (3) prescriptions (although we were unable to analyse these data owing to
methodological challenges). Given the sample age (≥ 65 years), additional ‘self-report questions’ were not
added in order to limit overall questionnaire burden. National unit costs applied to the quantities of
resources utilised.56
For decision analysis, costs of the intervention, health-care use and changes in QALYs in the RCT will be
combined to calculate the incremental cost-effectiveness ratio (ICER) using the following formula:
ICER =
ΔC
ΔE
=
C I− CC
EI− EC
, (1)
where C is the costs and E is the effects (as QALYs) in the intervention (I) or control (C) arm.
To estimate the joint distributions of cost and QALYs, non-parametric bootstrapping was conducted on the
observed data.57 This non-parametric bootstrap resampling technique allows us to assess uncertainty in the
ICER.58 First, results of the bootstrapped cost and QALYs are presented on the cost-effectiveness plane.
The confidence ellipse indicates the incremental costs and QALYs on the 50%, 75% and 95% CIs, indicating
the probability space in the cost-effectiveness plane within which we are confident that the true ICER is found.
To further evaluate the joint distributions of costs and benefits, a cost-effectiveness acceptability curve
(CEAC) is generated.59 The CEAC summarises information on uncertainty in cost-effectiveness estimate and
illustrates how the probability that collaborative care will be cost-effective as the willingness-to-pay of
decision-makers increases. According to NICE, the willingness-to-pay threshold for an additional QALY
ranges between £20,000 and £30,000; the CEAC indicates the probability that collaborative care is within
this range.
Participants’ take-up of collaborative care was recorded during sessions by case managers. This allowed
deterministic sensitivity analysis of the potential variation in direct costs of intervention. Over the course of
treatment, the case managers recorded information on the duration of the contact and how this took place
for each contact with the participants. This information was used to adjust the expected cost of collaborative
care when the patient, the case manager and supervisors agreed to deviation from the manualised
intervention. The results were expressed on a CEAC and adjusted probabilities of falling within the NICE range
of willingness to pay are presented.
Sensitivity analysis was performed to examine the implication to fidelity to intervention sessions and an ex
post adjustment of the expected direct cost of collaborative care. The prescription of a programme of
collaborative care is based on an assumption that all participants received the full course of treatment
(i.e. 8–10 sessions) and this is an ex ante assumption underlying our base-case cost-effectiveness analysis.
Given that a service provider has intention to treat, the resources required to supply all of the intended
sessions for collaborative care must be allocated and, therefore, the budget must include the total
expected cost. However, after the allocation of a treatment package, individuals will have varying levels
of fidelity to the programme and the expected direct cost of collaborative care may be adjusted when
non-attendance of sessions is clearly documented.
All case managers were asked to log their activities with patients on PC-MIS (Patient Case Management
Information System; www.york.ac.uk/healthsciences/pc-mis/; accessed 29 May 2016), which has been
designed for IAPT. As collaborative care involves both assessment and treatment, demand may vary in
relation to the specific levels of need of individuals. The number and duration of a participant’s contact
with the case manager was contemporaneously logged on PC-MIS. It was noted whether or not these
occurred face to face or by telephone.
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Chapter 4 Protocol changes
The following changes were made to the original protocol, after it was initially approved by the REC on28 September 2010 and the substantial amendment (number 6 of the CASPER trial) to run CASPER plus
was approved on 20 April 2012 (see www.ncbi.nlm.nih.gov/pubmed/25409776; accessed 7 June 2016).
CollAborative care for Screen-Positive EldeRs plus trial
In the original CASPER protocol, the objective was to evaluate the clinical effectiveness and cost-effectiveness
of a collaborative care intervention for older adults with subthreshold depression. In order to broaden the
reach of CASPER, the CASPER plus trial and qualitative substudy were introduced to run concurrently,
using the same recruitment procedure, interventions and measures to evaluate an adapted intervention for
case-level depression. A separate CASPER plus protocol and amended study documents were developed and
approved on 20 April 2012.
Recruitment methods
Direct referral
In order to maximise recruitment in an often difficult to reach group, an additional method of recruitment
was introduced. In addition to the original strategy of sending an invitation pack by post to all patients
(aged ≥ 65 years) who were identified by computer search as eligible for invitation by the general practice,
this was supplemented with direct GP referral at patient consultation. GPs from participating practices
were given a number of patient invitation packs (identical to those currently sent by post) that could be
handed to patients aged ≥ 65 years who may be consulting about depression and who did not meet the
exclusion criteria.
Targeted search
In order to optimise the search strategy, there was a move from an all-inclusive approach to a more
targeted approach. The targeted search strategy was developed to include only patients who had a
diagnosis of depression or those who were prescribed depression medication and had other conditions
associated with an increased risk of depression (e.g. depression, low mood, antidepressant medication,
ischaemic heart disease, diabetes, chronic obstructive pulmonary disease, arthritis or being a carer). This
was done using the aforementioned Read codes (a coded thesaurus of clinical terms that have been used
in the NHS since 1985), the choice of which was left to the discretion of the participating general practice.
Follow-up
Eighteen-month follow-up questionnaire
An 18-month follow-up questionnaire was introduced to obtain longer-term outcomes.
Cohort
In the original protocol, it was stated that all participants who returned screening questionnaires would be
followed up at 4 and 12 months via post or online. This included participants both in the RCT and those in
the epidemiological cohort. On completion of the CASPER trial of subthreshold depression, this policy was
discontinued in order to maximise recruitment and retention to the CASPER plus trial. For the remainder of
the trial, only CASPER plus trial participants were followed up. All potential cohort participants who had
consented but did not meet the criteria for major depression at diagnostic interview were not followed up.
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Inclusion/exclusion criteria
In the original protocol participants were excluded owing to alcohol dependency, any known comorbidity
that would, in the GP’s opinion, make entry to the trial inadvisable (e.g. recent evidence of self-harm,
known current thoughts of self-harm, significant cognitive impairment) and other factors that would
make an invitation to participate in the trial inappropriate (e.g. recent bereavement, terminal malignancy)
and/or because they were currently experiencing psychotic symptoms. During the trial there were several
withdrawals from CASPER plus collaborative care condition as participants were already undergoing
therapies and wished to continue with those therapies. Therefore, a screening question was added at the
end of the diagnostic interview. This was not done at the invitation stage, to allow for people who had
been referred to psychological services but had either not engaged with the service or who were still on a
waiting list to participate in the study. People who answered ‘yes’ to this question did not proceed with
the diagnostic interview and were excluded from the trial.
Recording of sessions
In the original protocol, there was no quality assurance procedure in place. In order to monitor and
improve the quality of the collaborative care intervention delivered during the trial, a purposive sample of
sessions was to be recorded. The sample was selected to reflect a range of backgrounds and experience of
case managers. The allocation letter received by participants following randomisation was adapted from
one that simply informed the participant that a case manager would be in touch shortly to a new letter
that informed participants that we may wish to record some of their sessions with their case manager as a
quality evaluation, stressing that the decision to agree to this was the participant’s alone and would not
affect the treatment that he or she would receive. They also received an additional participant information
sheet and consent form regarding the audio-recording.
Telephone delivery
In the original protocol all collaborative care participants were seen for their first session face to face. In
the final stages of recruitment it was necessary to enable initial contacts to also be delivered by telephone
to ensure that all participants could begin their collaborative care programme without delay. Some IAPT
services deal exclusively with their patients via the telephone and so this mix of contacts reflects current
practice in IAPT.
PROTOCOL CHANGES
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Chapter 5 Clinical results
Recruitment and flow of participants through the trial
Recruitment and follow-up
Participants were randomised into the CASPER plus trial between September 2012 and August 2014 from
four UK sites and their surrounding areas in the north of England: York, Leeds, Durham and Newcastle
upon Tyne. A total of 74 general practices screened their practice lists and identified patients who met the
initial inclusion criteria. Exclusion criteria consisted of any known alcohol dependency and/or psychotic
symptoms as recorded on GP records, any known adverse comorbidities or any other factors that GPs
deemed made it inadvisable to invite patients, such as recent bereavement.
A total of 64,214 patients were identified by GP practices between 5 May 2012 and 10 June 2014 and
invited by letter to take part in the CASPER study. Of 10,686 patients who consented, 3224 patients were
assessed for eligibility by diagnostic interview. Based on the diagnostic interview, 485 (15%) patients were
identified to have a major depressive episode and were randomised into the CASPER plus trial. Of the 485
participants randomised, 249 were allocated to collaborative care and 236 to usual care. The remaining
patients were classified as having either below threshold depression (n = 1525) or subthreshold depression
(n = 1214). They became part of the epidemiological cohort or were entered into the CASPER or CASPER
SHARD trials if within the recruitment window for these trials. The randomised number of 485 participants
exceeded that of the planned sample size of 450. The flow of participants is illustrated in Figure 1.
Trial withdrawals
Participants were able to withdraw from the study at any point. They were offered the options of withdrawing
from the intervention only, from questionnaire follow-up (allowing continued collection of objective data) or
from all aspects of the study. Data up to the date of withdrawal were retained for all participants, unless they
specifically requested for their details to be removed. This happened on one occasion. The total number of
trial withdrawals by trial arm is given in Table 3. Participants could withdraw from only collaborative care
treatment but remain in the trial for follow-up purposes. A total of 83 participants (33%) in the collaborative
care arm withdrew from treatment at some point, and the numbers of full or partial withdrawals were greater
in this arm (n= 55) than in the usual-care group (n= 24).
When reasons for withdrawal were provided by the participant, these were documented in the study
management database. Following completion of the trial, reasons were grouped into common categories,
and these are listed in Tables 4–6 for the different types of follow-up.
The trial sample size calculation allowed for losses to follow-up of 20% at the primary end point at
4 months. The primary outcome (PHQ-9 depression severity) was available for 390 patients at that point,
equating to an actual loss to follow-up of 19.6% (25.3% in the collaborative care arm and 13.6% in the
usual-care arm).
The intervention: collaborative care
Collaborative care was offered to all patients in the intervention arm. A total of 21 case managers were
trained to deliver the intervention, although only 12 delivered it in practice (a case load of 11.9 randomised
patients per case manager). In practice, the intervention was delivered by 20 case managers (a case load of
10.4 patients who completed at least one session). Further details on the case load of each individual case
manager are given as part of the practitioner analysis (see Chapter 3, Secondary analyses).
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Collaborative care
(n = 249)
Excluded from analysis
(n = 51)
• Received collaborative care, n = 207
   • Case managers
      (n = 20, mean 10.4 patients per case manager)
   • Number of sessions per patient
      (median 7, IQR 2–9, minimum 1, maximum 15)
• Did not receive collaborative care, n = 42a
• Withdrew from follow-up, n = 10
• Withdrew from trial, n = 11
• Died, n = 3
At 4 months’ follow-up
• Returned questionnaire, n = 186
• Did not return questionnaire, n = 39
• Withdrew from follow-up, n = 11
• Withdrew from trial, n = 7
• Died, n = 1
At 12 months’ follow-up
• Returned questionnaire, n = 173
• Did not return questionnaire, n = 33
At 18 months’ follow-up
• Returned questionnaire, n = 166
• Did not return questionnaire, n = 28
• Withdrew from follow-up, n = 8
• Withdrew from trial, n = 2
• Died, n = 2
A
n
al
ys
is
Primary analysis 
Analysed (valid PHQ-9 data at 4, 12 or 18 months 
and complete covariate data, n = 198)
• No valid PHQ-9 data at any follow-up, n = 47
• Missing covariate data, n = 2
• Missing PHQ-9 and covariate data, n = 2
Usual care 
(n = 236)
Excluded from analysis
(n = 19)
• Received usual care, n = 236
• Did not receive usual care, n = 0
• Withdrew from follow-up, n = 0
• Withdrew from trial, n = 1
• Died, n = 2
At 4 months’ follow-up
• Returned questionnaire, n = 204
• Did not return questionnaire, n = 29
• Withdrew from follow-up, n = 1
• Withdrew from trial, n = 7
• Died, n = 3
At 12 months’ follow-up
• Returned questionnaire, n = 185
• Did not return questionnaire, n = 37
At 18 months’ follow-up
• Returned questionnaire, n = 178
• Did not return questionnaire, n = 34
• Withdrew from follow-up, n = 5
• Withdrew from trial, n = 3
• Died, n = 2
Primary analysis 
Analysed (valid PHQ-9 data at 4, 12 or 18 months 
and complete covariate data, n = 217)
• No valid PHQ-9 data at any follow-up, n = 17
• Missing covariate data, n = 1
• Missing PHQ-9 and covariate data, n = 1
Invited between May 2012 and June 2014
(n = 64,214) Non-consent
(n = 53,528)
• Declined, n = 9315
• Did not return invitation, n = 44,213
Ineligible
(n = 2739)
• Non-depressed, n = 1525
• Subthreshold depression, n = 1214
Excluded/outside study window
(n = 7462)
Consented
(n = 10,686)
Randomised
(n = 485)
Assessed for eligibility (diagnostic interview)
(n = 3224)
FIGURE 1 Consolidated Standards of Reporting Trials diagram. a, Reasons for not receiving collaborative care:
Carer – no time (n=1), causing marital unrest (n = 2), cognitive impairment (n= 1), did not wish to engage (n = 10),
died (n= 2), invasive (n= 6), lost interest (n= 3), not low in mood (n= 1), physical disability (poor hearing) (n = 1),
physical ill health (n= 8), receiving other counselling (n= 1), too busy (n= 2), too severely depressed (n= 1) and
unable to contact (n= 3). IQR, interquartile range.
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TABLE 3 Participant withdrawal from follow-up or full withdrawal (by each time point)
Type of withdrawal
Trial arm
Collaborative care (N= 55 withdrawn) Usual care (N= 24 withdrawn)
n % of 249 n % of 236
By 4 months’ follow-up
Withdrawal from follow-up 10 4.0 0 0.0
Full withdrawal 11 4.4 1 0.6
Died 3 1.2 2 1.1
By 12 months’ follow-up
Withdrawal from follow-up 21 8.4 1 0.4
Full withdrawal 18 7.2 8 3.4
Died 4 1.6 5 2.1
By 18 months’ follow-up
Withdrawal from follow-up 29 11.7 6 2.5
Full withdrawal 20 8.0 11 4.7
Died 6 2.4 7 3.0
TABLE 4 Reasons for withdrawal from treatment
Reason for withdrawal
Trial arm
Collaborative care (N= 83 withdrawn) Usual care (N= 0 withdrawn)
n % n %
Carer – no time 4 4.8 – –
Causing marital unrest 3 3.6 – –
Cognitive impairment 1 1.2 – –
Did not wish to engage 23 27.7 – –
Died 2 2.4 – –
Does not need further support 2 2.4 – –
Intervention not useful 1 1.2 – –
Invasive 7 8.4 – –
Lost interest 3 3.6 – –
Not low in mood 5 6.0 – –
Physical disability (poor hearing) 1 1.2 – –
Physical ill health 13 15.7 – –
Receiving other counselling 3 3.6 – –
Too busy 5 6.0 – –
Too severely depressed 1 1.2 – –
Unable to contact 7 8.4 – –
Unknown 2 2.4 – –
Total 83 100.0 – –
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An overview of received treatments is provided in the Consolidated Standards of Reporting Trials diagram
in Figure 1 and further details are presented in Tables 7 and 8. Of 249 randomised patients, 83% had at
least one collaborative care session. Participants received on average six sessions over 8–9 weeks, of which,
on average, one was delivered face to face and five were delivered over the telephone. The average
session duration was 37 minutes. The most frequent reasons for not wanting to receive any collaborative
care were not wishing to engage, physical ill health and invasiveness (Table 9).
TABLE 5 Reasons for withdrawal from follow-up
Reason for withdrawal
Trial arm
Collaborative care (N= 29 withdrawn) Usual care (N= 6 withdrawn)
n % n %
Carer – no time 1 3.5 0 0.0
Did not wish to engage 1 3.5 0 0.0
Invasive 3 10.3 0 0.0
Lost interest 14 48.3 1 16.7
Moved out of area 1 3.5 2 33.3
Physical disability (poor sight) 1 3.5 1 16.7
Physical ill health 4 13.8 0 0.0
Suffered recent bereavement 1 3.5 0 0.0
Too busy 2 6.9 1 16.7
Too much effort 0 0.0 1 16.7
Too severely depressed 1 3.5 0 0.0
Total 29 100.0 6 100.0
TABLE 6 Reasons for full withdrawal
Reason for withdrawal
Trial arm
Collaborative care (N= 20 withdrawn) Usual care (N= 11 withdrawn)
n % n %
Carer – no time 0 0.0 1 9.1
Cognitive impairment 1 5.0 1 9.1
Did not wish to engage 5 25.0 0 0.0
Does not need further support 1 5.0 0 0.0
Invasive 2 10.0 3 27.3
Lost interest 2 10.0 2 18.2
Moved out of area 2 10.0 2 18.2
Physical ill health 4 20.0 1 9.1
Too much effort 1 5.0 0 0.0
Unable to contact 1 5.0 1 9.1
Unknown 1 5.0 0 0.0
Total 20 100.0 11 100.0
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TABLE 9 Reasons for not receiving any collaborative care
Reason
Patients who received no collaborative care (N= 42)
n %
Carer – no time 1 2.4
Causing marital unrest 2 4.8
Cognitive impairment 1 2.4
Did not wish to engage 10 23.8
Invasive 6 14.3
Lost interest 3 7.1
Not low in mood 1 2.4
Physical disability (poor hearing) 1 2.4
Physical ill health 8 19.1
Receiving other counselling 1 2.4
Too busy 2 4.8
Too severely depressed 1 2.4
Unable to contact 3 7.1
Died 2 4.8
TABLE 7 Collaborative care received
Collaborative care status
Patients randomised to collaborative care (N= 249)
n %
Did not start treatment 42 16.9
Started treatment 207 83.1
TABLE 8 Average characteristics of collaborative care
Collaborative care details
Patients who received some collaborative care (N= 207)
n Mean SD Median Minimum Maximum
Days from referral to first session 207 34.4 25.5 27 7 220
Number of sessions received 207 6.0 3.48 7 1 15
Face to face 207 1.3 1.44 1 0 11
Telephone 207 4.8 3.37 5 0 11
Average length of session (minutes) 207 36.7 8.24 37 0 62
Days from first to last session 207 62.0 50.38 58 0 333
SD, standard deviation.
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Baseline characteristics
Characteristics at consent, baseline and diagnostic interview (point of randomisation) for randomised
participants and participants included in the primary analysis (‘as analysed’ population: patients with a valid
PHQ-9 score at 4, 12 or 18 months’ follow-up) and valid covariate data (PHQ-9 score at randomisation and
baseline SF-12 PCS score) are presented in Tables 10–12.
TABLE 10 Baseline characteristics (demographics and general health at consent)
Characteristic
As randomised As analyseda
Collaborative
care (N= 249)
Usual care
(N= 236)
Collaborative
care (N= 198)
Usual care
(N= 217)
Age at consent (years)
n 248 236 198 217
Mean (SD) 72.5 (6.57) 71.8 (6.07) 71.9 (6.03) 71.6 (5.96)
Median (minimum, maximum) 71 (64, 98) 70 (65, 92) 70 (64, 88) 70 (65, 92)
Sex, n (%)
Male 98 (39.4) 85 (36.0) 81 (40.9) 80 (36.9)
Female 150 (60.2) 151 (64.0) 117 (59.1) 137 (63.1)
Educated past 16 years of age, n (%) 108 (43.4) 101 (42.8) 88 (44.4) 95 (43.8)
Degree or equivalent professional qualification 57 (22.9) 68 (28.8) 44 (22.2) 62 (28.6)
Smoking (yes), n (%) 30 (12.0) 28 (11.9) 25 (12.6) 27 (12.4)
Three or more alcohol units/day, n (%) 31 (12.4) 26 (11.0) 23 (11.6) 23 (10.6)
Ethnicity, n (%)
White 241 (96.8) 233 (98.7) 193 (97.5) 215 (99.1)
Asian or Asian British 1 (0.4) 0 (0) 1 (0.5) 0 (0)
Black or black British 1 (0.4) 0 (0) 1 (0.5) 0 (0)
Other 3 (1.2) 2 (0.8) 3 (1.5) 2 (0.9)
Health problems, n (%)
Diabetes 59 (23.7) 47 (19.9) 49 (24.7) 42 (19.4)
Osteoporosis 36 (14.5) 25 (10.6) 28 (14.1) 22 (10.1)
High blood pressure 120 (48.2) 111 (47.0) 96 (48.5) 103 (47.5)
Rheumatoid arthritis 50 (20.1) 36 (15.3) 38 (19.2) 31 (14.3)
Osteoarthritis 81 (32.5) 75 (31.8) 60 (30.3) 71 (32.7)
Stroke 21 (8.4) 22 (9.3) 18 (9.1) 18 (8.3)
Cancer 31 (12.4) 21 (8.9) 23 (11.3) 20 (9.2)
Respiratory conditions 71 (28.5) 68 (28.8) 52 (26.3) 64 (29.5)
Eye condition 84 (33.7) 67 (28.4) 64 (32.3) 62 (28.6)
Heart disease 55 (22.1) 71 (30.1) 42 (21.2) 64 (29.5)
Other 63 (25.3) 50 (21.2) 54 (27.3) 47 (21.7)
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TABLE 10 Baseline characteristics (demographics and general health at consent) (continued )
Characteristic
As randomised As analyseda
Collaborative
care (N= 249)
Usual care
(N= 236)
Collaborative
care (N= 198)
Usual care
(N= 217)
Whooley: Over the past month have you been bothered by feeling down, depressed or hopeless?, n (%)
Yes 227 (91.2) 202 (85.6) 178 (89.9) 186 (85.7)
No 21 (8.4) 34 (14.4) 20 (10.1) 31 (14.3)
Whooley: Over the past month have you been bothered by having little or no interest or pleasure in doing things?, n (%)
Yes 210 (84.3) 186 (78.8) 164 (82.8) 171 (78.8)
No 38 (15.3) 50 (21.2) 34 (17.2) 46 (21.2)
SD, standard deviation.
a All patients who were included in the primary analysis, that is patients with a valid PHQ-9 score at 4, 12 or 18 months’
follow-up and valid covariate data (PHQ-9 score at randomisation and baseline SF-12 PCS score).
TABLE 11 Baseline characteristics (outcomes at baseline)
Characteristic
As randomised As analyseda
Collaborative
care (N= 249)
Usual care
(N= 236)
Collaborative
care (N= 198)
Usual care
(N= 217)
PHQ-9
n 248 236 198 217
Mean score (SD) 12.4 (5.43) 12.1 (5.31) 12.3 (5.43) 12.0 (5.32)
Median score (minimum, maximum) 12 (0, 27) 12 (1, 27) 12 (0, 27) 12 (1, 27)
PHQ-9 grouping, n (%)
No depression 19 (7.6) 15 (6.4) 16 (8.1) 15 (6.9)
Mild depression 64 (25.7) 64 (27.1) 52 (26.3) 59 (27.2)
Moderate depression 79 (31.7) 85 (36.0) 61 (30.8) 77 (35.5)
Moderately severe depression 67 (26.9) 51 (21.6) 53 (26.8) 47 (21.7)
Severe depression 19 (7.6) 21 (8.9) 16 (8.1) 19 (8.8)
PHQ-15
n 246 234 196 215
Mean score (SD) 12.3 (4.51) 11.9 (4.33) 12.0 (4.46) 11.9 (4.36)
Median score (minimum, maximum) 12 (2, 26) 11 (2, 24) 12 (2, 24) 11 (2, 24)
SF-12 (PCS)
n 245 234 198 217
Mean score (SD) 35.6 (13.08) 36.8 (13.32) 36.1 (13.16) 36.6 (13.39)
Median score (minimum, maximum) 34.5 (7.1, 66.3) 35.8 (5.9, 69.6) 34.9 (7.1, 66.3) 38.8 (5.9, 69.6)
SF-12 (MCS)
n 245 234 198 217
Mean score (SD) 35.4 (9.51) 35.7 (10.53) 35.5 (9.66) 36.0 (10.52)
Median score (minimum, maximum) 35.8 (10.3, 60.2) 36.2 (2.2, 62.9) 35.9 (10.3, 60.2) 36.4 (2.2, 62.9)
continued
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TABLE 11 Baseline characteristics (outcomes at baseline) (continued )
Characteristic
As randomised As analyseda
Collaborative
care (N= 249)
Usual care
(N= 236)
Collaborative
care (N= 198)
Usual care
(N= 217)
GAD-7
n 247 234 197 215
Mean score (SD) 9.4 (5.03) 9.3 (4.92) 9.4 (5.12) 9.2 (4.95)
Median score (minimum, maximum) 9 (0, 21) 9 (0, 21) 9 (0, 21) 9 (0, 21)
EQ-5D-3L, n (%)
Mobility
No problems 71 (28.5) 76 (32.2) 61 (30.8) 70 (32.3)
Some problems 176 (70.7) 157 (66.5) 136 (68.7) 144 (66.4)
Confined to bed 0 (0.0) 2 (0.8) 0 (0.0) 2 (0.9)
Self-care
No problems 163 (65.5) 175 (74.2) 134 (67.7) 160 (73.7)
Some problems 75 (30.1) 55 (23.3) 58 (29.3) 52 (24.0)
Unable to wash/dress 5 (2.0) 4 (1.7) 2 (1.0) 3 (1.4)
Usual activities
No problems 64 (25.7) 66 (28.0) 52 (26.3) 62 (28.6)
Some problems 159 (63.9) 151 (64.0) 131 (66.2) 138 (63.6)
Unable to perform 24 (9.6) 18 (7.6) 14 (7.1) 16 (7.4)
Pain/discomfort
No pain 34 (13.7) 27 (11.4) 30 (15.2) 24 (11.1)
Moderate pain 156 (62.7) 152 (64.4) 129 (65.2) 140 (64.5)
Extreme pain 57 (22.9) 54 (22.9) 38 (19.2) 50 (23.0)
Anxiety/depression
Not anxious/depressed 26 (10.4) 25 (10.6) 21 (10.6) 25 (11.5)
Moderately anxiety/depression 176 (70.7) 178 (75.4) 141 (71.2) 161 (74.2)
Extremely anxiety/depression 44 (17.7) 31 (13.1) 34 (17.2) 29 (13.4)
Prescribed antidepressants 82 (32.9) 79 (33.5) 67 (33.8) 77 (35.5)
Whooley: Over the past month have you been bothered by feeling down, depressed or hopeless?, n (%)
Yes 238 (95.6) 219 (92.8) 190 (96.0) 201 (92.6)
No 10 (4.0) 17 (7.2) 8 (4.0) 16 (7.4)
Whooley: Over the past month have you been bothered by having little or no interest or pleasure in doing
things?, n (%)
Yes 220 (88.4) 210 (89.0) 177 (89.4) 195 (89.9)
No 28 (11.2) 26 (11.0) 21 (10.6) 22 (10.1)
SD, standard deviation.
a All patients who were included in the primary analysis, that is patients with a valid PHQ-9 score at 4, 12 or 18 months’
follow-up and valid covariate data (PHQ-9 score at randomisation and baseline SF-12 PCS score).
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Primary outcome
Near-complete PHQ-9 responses were available for participants at diagnostic interview (one participant
asked for all data to be destroyed at the point of withdrawal). At follow-up, 300 patients (62%) had valid
PHQ-9 scores at all three follow-up times, 118 patients (24%) had a valid PHQ-9 score at 4 months or
12 months only, and for 67 patients (14%) no PHQ-9 scores were available at 18 months’ follow-up.
Score distribution
Figure 2 illustrates the distribution of PHQ-9 scores for each trial arm over time. At randomisation, scores
were distributed approximately normal with a slight right skew, which became more pronounced over the
follow-up period, as patients in both arms improved.
TABLE 12 Baseline characteristics (outcomes at diagnostic interview/randomisation)
Characteristic
As randomised As analyseda
Collaborative
care (N= 249)
Usual care
(N= 236)
Collaborative
care (N= 198)
Usual care
(N= 217)
PHQ-9
N 248 236 198 217
Mean score (SD) 14.0 (5.37) 14.0 (4.93) 13.9 (5.42) 13.9 (4.80)
Median score (minimum, maximum) 14 (3, 27) 14 (4, 27) 14 (3, 26) 14 (4, 27)
PHQ-9 grouping, n (%)
No depression 2 (0.8) 4 (1.7) 1 (0.5) 4 (1.8)
Mild depression 60 (24.1) 46 (19.5) 51 (25.8) 41 (18.9)
Moderate depression 77 (30.9) 77 (32.6) 57 (28.8) 73 (33.6)
Moderately severe depression 69 (27.7) 76 (32.2) 57 (28.8) 73 (33.6)
Severe depression 40 (16.1) 33 (14.0) 32 (16.2) 26 (12.0)
From MINI: Were you ever depressed or down, most of the day, nearly every day for 2 weeks?, n (%)
Yes 213 (85.5) 207 (87.7) 170 (85.9) 191 (88.0)
No 35 (14.1) 29 (12.3) 28 (14.1) 26 (12.0)
From MINI: For the past 2 weeks, were you depressed or down, most of the day, nearly every day?, n (%)
Yes 182 (73.1) 172 (72.9) 141 (71.2) 157 (72.4)
No 31 (12.4) 35 (14.8) 29 (14.6) 34 (15.7)
From MINI: Were you ever much less interested in most things or much less able to enjoy things you used to enjoy most of
the time for 2 weeks?, n (%)
Yes 234 (94.0) 218 (92.4) 190 (96.0) 202 (93.1)
No 14 (5.6) 18 (7.6) 8 (4.0) 15 (16.9)
From MINI: In the past 2 weeks, were you much less interested in most things or much less able to enjoy the things you
used to enjoy, most of the time?, n (%)
Yes 214 (85.9) 205 (86.9) 178 (89.9) 190 (87.6)
No 20 (8.0) 13 (5.5) 12 (6.1) 12 (5.5)
SD, standard deviation.
a All patients who were included in the primary analysis, that is patients with a valid PHQ-9 score at 4, 12 or 18 months’
follow-up and valid covariate data (PHQ-9 score at randomisation and baseline SF-12 PCS score).
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FIGURE 2 Distribution of PHQ-9 scores by trial arm. (a) Randomisation, collaborative care; (b) randomisation, usual
care; (c) 4 months’ follow-up, collaborative care; (d) 4 months’ follow-up, usual care; (e) 12 months’ follow-up,
collaborative care; (f) 12 months’ follow-up, usual care; (g) 18 months’ follow-up, collaborative care; and (h) 18 months’
follow-up, usual care. (continued)
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FIGURE 2 Distribution of PHQ-9 scores by trial arm. (a) Randomisation, collaborative care; (b) randomisation, usual
care; (c) 4 months’ follow-up, collaborative care; (d) 4 months’ follow-up, usual care; (e) 12 months’ follow-up,
collaborative care; (f) 12 months’ follow-up, usual care; (g) 18 months’ follow-up, collaborative care; and (h) 18 months’
follow-up, usual care. (continued )
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FIGURE 2 Distribution of PHQ-9 scores by trial arm. (a) Randomisation, collaborative care; (b) randomisation, usual
care; (c) 4 months’ follow-up, collaborative care; (d) 4 months’ follow-up, usual care; (e) 12 months’ follow-up,
collaborative care; (f) 12 months’ follow-up, usual care; (g) 18 months’ follow-up, collaborative care; and (h) 18 months’
follow-up, usual care. (continued)
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FIGURE 2 Distribution of PHQ-9 scores by trial arm. (a) Randomisation, collaborative care; (b) randomisation, usual
care; (c) 4 months’ follow-up, collaborative care; (d) 4 months’ follow-up, usual care; (e) 12 months’ follow-up,
collaborative care; (f) 12 months’ follow-up, usual care; (g) 18 months’ follow-up, collaborative care; and (h) 18 months’
follow-up, usual care.
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Unadjusted summary statistics
Summary statistics of the raw PHQ-9 scores are given in Table 13 and are illustrated in Figure 3. Average
depression severity, as measured by the PHQ-9, was around 14 score points at randomisation. Scores in
both treatment arms improved between randomisation and 4 months’ follow-up, but to a greater extent in
the collaborative care group (to a score of around 9) than in the usual-care group (to a score of around 11).
By 12 and 18 months’ follow-up, average depression scores continued to improve slightly in the usual-care
group, whereas scores in the collaborative care group increased again to similar levels.
TABLE 13 Unadjusted PHQ-9 descriptive statistics
Time
Trial arm
Total (N= 485)Collaborative care (N= 249) Usual care (N= 236)
Randomisation, n (%) 248 (99.6) 236 (100) 484 (99.8)
Mean (SD) 14.0 (5.37) 14.0 (4.93) 14.0 (5.15)
Median (minimum, maximum) 14 (3, 27) 14 (4, 27) 14 (3, 27)
4 months, n (%) 186 (75) 204 (86) 390 (80)
Mean (SD) 8.9 (5.53) 10.9 (5.89) 9.9 (5.79)
Median (minimum, maximum) 8 (0, 24) 11 (0, 26) 9 (0, 26)
12 months, n (%) 172 (69) 185 (78) 357 (74)
Mean (SD) 10.4 (6.25) 10.6 (5.52) 10.5 (5.87)
Median (minimum, maximum) 10 (0, 25) 10 (0, 25) 10 (0, 25)
18 months, n (%) 165 (66) 178 (75) 343 (71)
Mean (SD) 10.4 (6.09) 10.3 (5.50) 10.4 (5.79)
Median (minimum, maximum) 10 (0, 25) 9 (0, 26) 10 (0, 26)
SD, standard deviation.
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FIGURE 3 Unadjusted mean PHQ-9 scores (with 95% CIs).
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Primary analysis
The primary outcome was analysed by a covariance pattern linear mixed model using PHQ-9 score at 4 and
12 months as the outcome. The model included as fixed effects: time, trial arm and time-by-treatment
interaction, adjusting for PHQ-9 depression at randomisation and physical/functional limitations as measured
by the baseline SF-12 PCS score. Patients were included in the analysis if they had a valid PHQ-9 score at
4, 12 or 18 months’ follow-up and complete covariate data. Patients were analysed as part of the group to
which they had been randomised (intention to treat).
The correlation of observations within patients over time was modelled by a covariance structure to describe
the random effects. Different types of available covariance structures were investigated for this model
(unstructured, independent, exchangeable, autoregressive and exponential). The exchangeable covariance
structure (estimating one covariance parameter to model the relatedness between any two time points)
displayed the lowest and therefore best-fitting log likelihood values, and was not significantly worse fitting
than the full-parameter unstructured model when compared using the chi-squared test. Therefore, the
exchangeable covariance pattern was selected.
Diagnostics of model fit showed an acceptable distribution of standard residuals with a small number of
outliers at the higher end of the distribution. There was uniform variance between predicted and actual
residuals, and no transformation of PHQ-9 scores was carried out for the analysis.
Adjusted PHQ-9 score means and group differences for the primary analysis model as specified above are
presented in Table 14. The analysis revealed significant differences between trial arms at each 4 months’
follow-up in favour of collaborative care, but not at 12 or 18 months’ follow-up: 1.92 score points (95% CI
0.85 to 2.99 score points; p < 0.001) for the primary end point at 4 months; 0.19 score points (95% CI –0.92
to 1.29 score points; p = 0.741) at 12 months and 0.002 score points (95% CI –1.12 to 1.12 score points;
p = 0.997) at 18 months. Using the overall residual standard deviation (SD, 5.72), the score difference at
4 months equates to a standard effect size of 0.34 (the trial was powered for a standard effect size of 0.35).
Secondary outcomes analyses
Adjusting for clustering by case manager
It was expected in the planning and sample size calculation for this trial that collaborative care case
managers would work with an average case load of 20 patients, and the clustering of outcomes within
case managers was expected to be described by an ICC of 0.02. In total, there were 20 case managers
(four in York, four in Leeds, 10 in Durham and two in Newcastle upon Tyne) for a total of 246 participants
in the collaborative care arm, that is, an average case load of 12.3 randomised patients per case manager.
TABLE 14 Group difference in mean PHQ-9 score: primary analysis
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 monthsa 198 8.98 8.20 to 9.75 217 10.90 10.16 to 11.64 1.92 0.85 to 2.99 < 0.001
12 months 198 10.44 9.65 to 11.24 217 10.63 9.87 to 11.40 0.19 –0.92 to 1.29 0.741
18 months 198 10.53 9.72 to 11.34 217 10.53 9.76 to 11.31 0.002 –1.12 to 1.12 0.997
a Primary end point.
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation and baseline SF-12 PCS score.
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Case loads varied considerably between 1 and 46 patients. Three patients withdrew before they were
assigned a case manager.
The average ICC for clustering within case managers was found to negligible: ICC ≤ 0.0001 (95% CI 0 to
0.0757) for PHQ-9 scores at 4 months.
In order to quantify the impact of the grouping by case managers with respect to the primary outcome,
case manager identifiers were included as a random effect in the primary linear mixed-analysis model,
nested within treatment arm. Participants in the usual-care arm were coded as their own case managers
for the purpose of analysis, and the covariance structure was estimated separately for each treatment arm
in order to account for the differences in variability for the random effect.
Adjusted PHQ-9 score means and group differences for this analysis are given in Table 15. Group differences
remained significant in favour of collaborative care at 4 months’ follow-up (a difference of 1.92 PHQ-9 score
points), and outcomes did not significantly differ between groups at 12 or 18 months. Thus, accounting for the
clustering by case manager did not affect the size of the treatment effect compared with the primary analysis.
Adjusting for covariates predictive of Patient Health Questionnaire 9-items at 4 months
The primary analysis was adjusted for PHQ-9 depression at randomisation and baseline physical limitations
(SF-12 PCS score). In order to identify any other relevant covariates of depression severity at follow-up, a
number of selected demographics and baseline measures were used as predictors of PHQ-9 depression at
4 months in individual regressions followed by a combined regression to avoid issues of multicollinearity,
using a non-conservative significance level of p < 0.10 at each stage. All analyses adjusted for PHQ-9
scores at randomisation.
Considered predictors were age, sex, an indicator of whether or not any selected antidepressants had been
prescribed at baseline, a history of depression [as measured by two questions of the MINI at randomisation:
(1) whether or not patients had ever been consistently depressed for a minimum of 2 weeks and (2) whether
or not patients had ever experienced a lack of interest or enjoyment for a minimum of 2 weeks], baseline
anxiety (as measured by the GAD-7) and baseline physical functioning (as measured by the PHQ-15).
Results of the individual regressions and summary regression are given in Table 16. Positive coefficients
indicate increased depression at 4 months for higher values of the predictor variable (or for the condition
specified in the table for categorical variables). Initial identified predictors following individual regressions
were prescribed medication, a history of depression (both indicators) as well as baseline GAD-7 and
PHQ-15 scores. Higher levels of anxiety, physical health problems, a greater likelihood of being described
antidepressants and having a history of depression were associated with higher PHQ-9 depression severity
at 4 months. Of these predictors, all but prescribed antidepressants remained significant in a summary
TABLE 15 Group difference in mean PHQ-9 score: adjusted for clustering by case manager
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 198 8.98 8.20 to 9.76 217 10.90 10.16 to 11.63 1.92 0.85 to 2.99 < 0.001
12 months 198 10.45 9.65 to 11.25 217 10.63 9.87 to 11.39 0.18 –0.92 to 1.29 0.744
18 months 198 10.54 9.73 to 11.35 217 10.53 9.76 to 11.30 –0.01 –1.13 to 1.11 0.991
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation and baseline SF-12 PCS score, including case manager as random effect.
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regression and were included in the primary analysis model. Age and sex were not significant predictors of
PHQ-9 scores.
Adjusted PHQ-9 score means and group differences for the primary analysis model [additionally adjusting
for history of depression (two questions), GAD-7 and PHQ-15 at baseline] are given in Table 17. Group
differences remained significant in favour of collaborative care at 4 months’ follow-up (a difference of 1.95
PHQ-9 score points), whereas differences at 12 and 18 months remained not statistically significant. Thus,
accounting for additional predictors of the primary outcome did not affect treatment differences. An
overall comparison of treatment effects for PHQ-9 depression severity from different analyses is presented
in Table 18.
TABLE 16 Predictors of PHQ-9 scores at 4 months, controlling for PHQ-9 at randomisation
Characteristic Coefficient Standard error p-valuea
Individual regressions
Age –0.04 0.046 0.363
Sex (being female) 0.70 0.567 0.217
Prescribed antidepressants (any) 1.18 0.578 0.043
Ever having been depressed or down for 2 weeks 2.90 0.804 < 0.001
Ever having lost interest or enjoyment for 2 weeks 2.78 1.189 0.020
Baseline GAD-7 score 0.33 0.056 < 0.001
Baseline PHQ-15 score 0.21 0.066 0.002
Summary regression
Prescribed antidepressants (any) 0.63 0.558 0.259
Ever having been depressed or down for 2 weeks 2.65 0.788 0.001
Ever having lost interest or enjoyment for 2 weeks 2.20 1.174 0.062
Baseline GAD-7 score 0.26 0.058 < 0.001
Baseline PHQ-15 score 0.14 0.065 0.034
a Bold p-values indicate inclusion of the covariate at the next analysis stage, that is a p-value of < 0.10.
TABLE 17 Group difference in mean PHQ-9 score: adjusted for predictors of PHQ-9 score at 4 months
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 196 7.68 6.41 to 8.94 214 9.62 8.41 to 10.84 1.95 0.92 to 2.98 < 0.001
12 months 196 9.09 7.81 to 10.37 214 9.35 8.12 to 10.58 0.26 –0.81 to 1.32 0.633
18 months 196 9.21 7.93 to 10.49 214 9.25 8.02 to 10.47 0.04 –1.04 to 1.11 0.945
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation, baseline SF-12 PCS score, ever having been depressed or down for 2 weeks, ever having lost interest or
enjoyment for 2 weeks, baseline GAD-7 score and baseline PHQ-15 score.
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TABLE 18 Summary of PHQ-9 group differences from different analyses
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
Unadjusted means
4 months 186 8.94 8.14 to 9.74 204 10.87 10.06 to 11.68 1.93 – –
12 months 172 10.44 9.50 to 11.38 185 10.59 9.79 to 11.39 0.15 – –
18 months 165 10.38 9.44 to 11.32 178 10.33 9.51 to 11.14 –0.05 – –
Primary analysisa
4 monthsb 198 8.98 8.20 to 9.75 217 10.90 10.16 to 11.64 1.92 0.85 to 2.99 < 0.001
12 months 198 10.44 9.65 to 11.24 217 10.63 9.87 to 11.40 0.19 –0.92 to 1.29 0.741
18 months 198 10.53 9.72 to 11.34 217 10.53 9.76 to 11.31 0.00 –1.12 to 1.12 0.997
Analysis adjusted for clustering by case managerc
4 months 198 8.98 8.20 to 9.76 217 10.90 10.16 to 11.63 1.92 0.85 to 2.99 < 0.001
12 months 198 10.45 9.65 to 11.25 217 10.63 9.87 to 11.39 0.18 –0.92 to 1.29 0.744
18 months 198 10.54 9.73 to 11.35 217 10.53 9.76 to 11.30 –0.01 –1.13 to 1.11 0.991
Analysis adjusted for additional covariates predictive of PHQ-9 score at 4 monthsd
4 months 196 7.68 6.41 to 8.94 214 9.62 8.41 to 10.84 1.95 0.92 to 2.98 < 0.001
12 months 196 9.09 7.81 to 10.37 214 9.35 8.12 to 10.58 0.26 –0.81 to 1.32 0.633
18 months 196 9.21 7.93 to 10.49 214 9.25 8.02 to 10.47 0.04 –1.04 to 1.11 0.945
Analysis adjusted for covariates predictive of non-response at 4 monthse
4 months 196 8.94 7.77 to 10.11 215 10.91 9.81 to 12.00 1.97 0.93 to 3.00 < 0.001
12 months 196 10.35 9.16 to 11.53 215 10.60 9.49 to 11.72 0.26 –0.81 to 1.33 0.637
18 months 196 10.47 9.28 to 11.66 215 10.54 9.42 to 11.65 0.07 –1.01 to 1.15 0.903
Analysis using multiply imputed dataf
4 months 249 9.01 8.21 to 9.81 236 10.94 10.20 to 11.68 1.93 0.89 to 2.96 < 0.001
12 months 249 10.51 9.70 to 11.33 236 10.74 9.96 to 11.52 0.23 –0.86 to 1.32 0.679
18 months 249 10.66 9.82 to 11.51 236 10.57 9.78 to 11.37 –0.09 –1.18 to 1.00 0.869
a Primary analysis: mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction,
PHQ-9 score at randomisation and baseline SF-12 PCS score.
b Primary end point.
c As primary analysis model, additionally including case manager as random effect.
d As primary analysis model, additionally adjusting for ever having been depressed or feeling down for 2 weeks,
ever having lost interest or enjoyment for 2 weeks, baseline GAD-7 score and baseline PHQ-15 score.
e As primary analysis model, additionally adjusting for age at consent, baseline SF-12 MCS score, baseline PHQ-15 score,
prescription of any antidepressants and ever having lost interest or enjoyment for 2 weeks.
f As primary analysis model, based on complete data obtained by multiple imputation using chained equations (outcomes
predicted from available PHQ-9 scores, allocation, baseline SF-12 PCS score and all additional predictors identified in
footnotes d and e).
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Adjusting for missingness
No valid PHQ-9 response at the primary end point of 4 months’ follow-up was available for 25.3%
(n = 63) of patients in the collaborative care arm and 13.6% (n = 32) of patients in the usual-care arm.
In order to investigate the impact of missing data on the treatment effect, any baseline predictors of
non-response at 4 months’ follow-up (no valid PHQ-9 score) were identified by individual and a summary
logistic regression using p < 0.10 and included as covariates in the primary analysis model.
Considered predictors were age, sex, an indicator of whether or not any selected antidepressants had been
prescribed at baseline, a history of depression (as measured by two questions of the MINI at randomisation),
depression at randomisation (PHQ-9 score), baseline mental well-being (SF-12 MCS score), baseline anxiety
(GAD-7 score) and baseline physical functioning (PHQ-15 score, SF-12 PCS score).
The results of the individual and summary regressions are presented in Table 19. Odds ratios > 1 indicate a
greater likelihood of non-response at 4 months for higher values of the predictor variable (or for the condition
specified in the table for categorical variables). The initial identified predictors were age, GAD-7 score, SF-12
MCS score, PHQ-15 score, prescribed antidepressants and ever having lost interest or enjoyment for ≥ 2 weeks.
PHQ-9 response at 4 months was more likely to be missing for older participants, participants with greater
anxiety, reduced mental functioning or more physical problems, those not on antidepressants and those who
reported ever having lost interest or enjoyment for more than 2 weeks. Of these predictors, age, the SF-12
MCS score, PHQ-15 score, antidepressant use and loss of interest remained significant in a summary regression
and were included in the primary analysis model.
TABLE 19 Predictors of non-response (missing PHQ-9 scores) at 4 months
Characteristic Odds ratio Standard error p-valuea
Individual regressions
Age 1.04 0.018 0.005
Sex (being female) 1.09 0.260 0.715
Baseline GAD-7 score 1.04 0.024 0.074
Baseline SF-12 MCS score 0.98 0.011 0.059
Baseline SF-12 PCS score 0.99 0.009 0.207
Baseline PHQ-15 score 1.07 0.037 0.011
Randomisation PHQ-9 score 1.03 0.023 0.164
Prescribed antidepressants (any) 0.63 0.164 0.078
Ever having been depressed or down for 2 weeks 1.05 0.361 0.884
Ever having lost interest or enjoyment for 2 weeks 0.50 0.201 0.085
Summary regression
Age 1.05 0.019 0.007
Baseline GAD-7 score 1.01 0.030 0.738
Baseline SF-12 MCS score 0.98 0.014 0.085
Baseline PHQ-15 score 1.06 0.030 0.058
Prescribed antidepressants (any) 0.62 0.171 0.084
Ever having lost interest or enjoyment for 2 weeks 0.44 0.186 0.051
a Bold p-values indicate inclusion of the covariate at the next analysis stage, that is a p-value of < 0.10.
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Adjusted PHQ-9 score means and group differences for the primary analysis model are given in Table 20.
Group differences remained significant in favour of collaborative care at 4 months’ follow-up (a difference
of 1.97 PHQ-9 score points), and remained not statistically significant at 12 and 18 months’ follow-up.
Thus, accounting for predictors of non-response did not affect the treatment effect. An overall comparison
of treatment effects for PHQ-9 depression severity from different analyses is presented in Table 18.
In addition, the primary analysis was repeated using complete data derived from multiple imputation by
chained equations. Data were imputed from all additional predictors identified in the previous two analyses
(age, baseline SF-12, GAD-7 and PHQ-15 scores, antidepressant use and depression history) as well as
treatment allocation and available PHQ-9 scores at any time points. Adjusted PHQ-9 score means and
group differences for the primary analysis model are given in Table 21 (results based on 20 imputations).
Group differences remained significant in favour of collaborative care at 4 months’ follow-up (a difference
of 1.93 PHQ-9 score points), and remained not statistically significant at 12 and 18 months’ follow-up.
Thus, using complete data did not affect the treatment effect. An overall comparison of treatment effects
for PHQ-9 depression severity from different analyses is presented in Table 18.
Summary of Patient Health Questionnaire-9 items analysis models
Table 18 provides an overview of group means and treatment effect estimates from the primary analysis
and secondary analyses of depression severity at 4, 12 and 18 months as measured by PHQ-9 scores.
Unadjusted means are presented for reference. Adjusted average estimates of group differences at the
primary end point at 4 months ranged from 1.92 to 1.97 PHQ-9 score points in favour of collaborative care.
TABLE 20 Group difference in mean PHQ-9 score: adjusted for predictors of non-response
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 196 8.94 7.77 to 10.11 215 10.91 9.81 to 12.00 1.97 0.93 to 3.00 < 0.001
12 months 196 10.35 9.16 to 11.53 215 10.60 9.49 to 11.72 0.26 –0.81 to 1.33 0.637
18 months 196 10.47 9.28 to 11.66 215 10.54 9.42 to 11.65 0.07 –1.01 to 1.15 0.903
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation, baseline SF-12 PCS score, ever having been depressed or down for 2 weeks, ever having lost interest or
enjoyment for 2 weeks, baseline GAD-7 score and baseline PHQ-15 score.
TABLE 21 Group difference in mean PHQ-9 score: using imputed data
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 249 9.01 8.21 to 9.81 236 10.94 10.20 to 11.68 1.93 0.89 to 2.96 < 0.001
12 months 249 10.51 9.70 to 11.33 236 10.74 9.96 to 11.52 0.23 –0.86 to 1.32 0.679
18 months 249 10.66 9.82 to 11.51 236 10.57 9.78 to 11.37 –0.09 –1.18 to 1.00 0.869
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation, baseline SF-12 PCS score (outcomes derived by multiple imputation).
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Binary Patient Health Questionnaire 9-items outcome
Using the cut-off point of ≥ 10 PHQ-9 score points, Table 22 presents the number and percentage of
moderately to severely depressed participants at randomisation and follow-up by treatment arm. The
figures are illustrated in Figure 4. Approximately 77% of randomised CASPER plus participants were
depressed at randomisation. At 4 months’ follow-up, this percentage improved to 40% in the collaborative
care arm and 55% in the usual-care arm. This difference was not maintained at 12 or 18 months’
follow-up.
Data were analysed by logistic mixed-effects modelling, including moderate to severe PHQ-9 depression
(yes or no) at 4, 12 and 18 months as the outcome, predicted by trial arm, time (4, 12 or 18 months),
group by time interaction, depression severity at randomisation (PHQ-9 score) and baseline physical
functioning (SF-12 PCS score). Resulting treatment effect estimates are presented in Table 23.
The greater reduction in moderately to severely depressed cases seen in the collaborative care arm
compared with the usual-care arm was statistically significant at 4 months’ follow-up (odds ratio 2.18,
95% CI 1.36 to 3.51; p < 0.001), but was not statistically significant at 12 or 18 months.
Secondary outcomes
Continuous and binary secondary outcomes were analysed by longitudinal linear and logistic mixed
models, adjusting for the baseline assessment of the outcome, PHQ-9 score at randomisation and SF-12
PCS score. Estimates of the effect of the intervention were derived and are presented for each follow-up
time point. In addition, adverse events are reported descriptively and the number of deaths are compared
by chi-squared test.
Antidepressants
Patients indicated on questionnaires whether or not they were currently prescribed any of a list of 10
antidepressants (see Table 24 for details and the frequencies of prescriptions by trial arm). Citalopram was the
most commonly prescribed antidepressant.
A binary variable was created to indicate whether or not patients had been prescribed any of the listed
antidepressants. Table 25 presents the number and percentage of patients on antidepressants at baseline
and follow-up by treatment arm. The figures are illustrated in Figure 5. Approximately 33% of patients
were prescribed antidepressants at baseline. Of the participants remaining in the trial at follow-up,
antidepressants were prescribed to a greater percentage at 4, 12 and 18 months than at baseline, around
36% on average. Differences between treatment arms were small.
TABLE 22 Cases of moderate to severe depression (PHQ-9 score of≥ 10)
Time point
Trial arm
TotalCollaborative care Usual care
n Total % n Total % n Total %
Randomisation 186 248 75.0 186 236 78.8 372 484 76.9
4 months 75 186 40.3 113 204 55.4 188 390 48.2
12 months 87 172 50.6 103 185 55.7 190 357 53.2
18 months 88 165 53.3 88 178 49.4 176 343 51.3
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TABLE 23 Group difference in proportions of moderate to severe PHQ-9 depression
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n
Odds
ratio 95% CI n
Odds
ratio 95% CI
Odds
ratio 95% CI p-value
4 months 198 0.95 0.58 to 1.33 217 2.08 1.27 to 2.89 2.18 1.36 to 3.51 0.001
12 months 198 1.65 0.79 to 2.52 217 2.31 1.14 to 3.49 1.40 0.72 to 2.72 0.319
18 months 198 2.29 0.76 to 3.81 217 1.66 0.62 to 2.69 0.72 0.31 to 1.71 0.461
Mixed-effects logistic model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation and baseline SF-12 PCS score.
TABLE 24 Number of patients being prescribed specific antidepressants
Antidepressant
Trial arm
TotalCollaborative care Usual care
Month Month Month
0 4 12 18 0 4 12 18 0 4 12 18
Dosulepin 3 3 3 2 8 4 4 3 11 7 7 5
Sertraline 17 18 17 16 13 14 17 16 30 32 34 32
Venlafaxine 10 7 9 8 6 6 4 5 16 13 13 13
Lofepramine 1 1 0 1 4 3 2 1 5 4 2 2
Fluoxetine 14 8 7 7 15 13 9 6 29 21 16 13
Duloxetine 2 1 2 2 1 1 2 1 3 2 4 3
Citalopram 27 19 17 19 24 18 18 19 51 37 35 38
Paroxetine 3 3 4 3 2 3 2 1 5 6 6 4
Trazodone 6 3 1 2 3 4 5 6 9 7 6 8
Mirtazapine 9 9 5 7 11 8 11 10 20 17 16 17
TABLE 25 Number of patients being prescribed any antidepressants
Time point
Trial arm
TotalCollaborative care Usual care
n Total % n Total % n Total %
Baseline 82 248 33.1 79 236 33.5 161 484 33.3
4 months 70 186 37.6 68 204 33.3 138 390 35.4
12 months 61 173 35.3 68 185 36.8 129 358 36.0
18 months 61 166 36.8 61 178 34.3 122 344 35.5
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Data were analysed by a logistic mixed-effects model, including prescribed medication (yes or no) at
4, 12 and 18 months as the outcome, and were predicted by trial arm, time (4, 12 and 18 months), group
by time interaction and prescribed antidepressants at baseline. Treatment effect estimates are presented in
Table 26.
The adjusted relative odds of being prescribed antidepressants were higher in the collaborative care arm
than the usual-care arm at 4 months (odds ratio 0.39, 95% CI 0.17 to 0.89; p = 0.025); however,
differences between treatment arms were not statistically significant at 12 or 18 months’ follow-up.
Generalised Anxiety Disorder-7 item scale psychological anxiety
The GAD-7 is a brief measure of symptoms of anxiety with a score range of 0–21, with higher scores
indicating more severe anxiety. Unadjusted means for psychological anxiety based on the GAD-7 are
presented in Table 27 and Figure 6, and the results of the formal statistical analysis by mixed modelling are
given in Table 28.
TABLE 26 Group difference in proportions of patients with prescribed antidepressants
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n
Odds
ratio 95% CI n
Odds
ratio 95% CI
Odds
ratio 95% CI p-value
4 months 198 6.86 1.22 to 12.50 217 2.70 0.88 to 4.53 0.39 0.17 to 0.89 0.025
12 months 198 2.77 0.40 to 5.15 217 4.03 0.62 to 7.45 1.45 0.55 to 3.88 0.454
18 months 198 2.28 0.15 to 4.40 217 2.07 0.17 to 3.97 0.91 0.30 to 2.79 0.868
Mixed-effects logistic model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, baseline
antidepressant prescriptions, PHQ-9 score at randomisation and SF-12 PCS score.
TABLE 27 Unadjusted GAD-7 descriptive statistics
Time
Trial arm
Total (N= 485)
Collaborative care
(N= 249)
Usual care
(N= 236)
Baseline n 247 234 481
Mean (SD) 9.4 (5.03) 9.3 (4.92) 9.4 (4.97)
Median (minimum, maximum) 9 (0, 21) 9 (0, 21) 9 (0, 21)
4 months n 181 191 372
Mean (SD) 6.7 (5.07) 8.3 (5.25) 7.5
Median (minimum, maximum) 6 (0, 20) 7 (0, 21) 6 (0, 21)
12 months n 166 176 342
Mean (SD) 7.4 (5.71) 8.4 (5.36) 7.9 (5.55)
Median (minimum, maximum) 6 (0, 21) 8 (0, 21) 7 (0, 21)
18 months n 161 171 322
Mean (SD) 7.5 (5.22) 7.9 (4.94) 7.7 (5.07)
Median (minimum, maximum) 7 (0, 21) 8 (0, 20) 7 (0, 21)
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The figures indicate that anxiety was on average at around nine score points for all participants at baseline.
Both trial arms improved anxiety levels at 4 months’ follow-up, significantly more so in the collaborative
care arm (mean score difference 1.68, 95% CI 0.77 to 2.59; p < 0.001). Group differences decreased
in magnitude but remained statistically significant at 12 months’ follow-up (mean score difference 1.09,
95% CI 0.14 to 2.03; p = 0.024), but not at 18 months.
Short Form questionnaire-12 items physical component summary score
The SF-12 PCS score ranges from 0 to 100, with higher scores indicating better functioning. Unadjusted
means for physical functioning are presented in Table 29 and Figure 7, and the results of the formal
statistical analysis by mixed modelling are given in Table 30.
The figures indicate that physical functioning was below average adult physical health status (scores of
< 50) for participants throughout the trial period, as would be expected in an elderly population. Patients
maintained similar functioning levels between baseline and 18 months, and group differences in physical
functioning were not statistically significant based on the mixed-effects analysis at 4 months (mean score
difference –0.44, 95% CI –2.00 to 1.23; p = 0.583) or any other follow-up.
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FIGURE 6 Unadjusted mean GAD-7 scores (with 95% CIs).
TABLE 28 Group difference in mean GAD-7 scores
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 195 6.60 5.94 to 7.25 210 8.27 7.64 to 8.91 1.68 0.77 to 2.59 < 0.001
12 months 195 7.33 6.65 to 8.01 210 8.42 7.76 to 9.07 1.09 0.14 to 2.03 0.024
18 months 195 7.59 6.91 to 8.27 210 7.91 7.25 to 8.57 0.32 –0.63 to 1.27 0.511
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation, baseline SF-12 PCS score and baseline GAD-7 scores.
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Short Form questionnaire-12 items mental component summary score
The SF-12 MCS scores range from 0 to 100, with higher scores indicating better functioning. Unadjusted
means for psychological functioning are presented in Table 31 and Figure 8 and the results of the formal
statistical analysis by mixed modelling are given in Table 32.
The figures indicate that participants’ average mental functioning was below the general average for adults
(scores of < 50) throughout the trial period, which may be expected in a population with major depressive
episodes. At 4 months’ follow-up, mental functioning had improved in patients in both arms, but to a greater
TABLE 29 Unadjusted SF-12 PCS score descriptive statistics
Time
Trial arm
Total (N= 485)Collaborative care (N= 249) Usual care (N= 236)
Baseline n 245 234 479
Mean (SD) 35.6 (13.08) 36.8 (13.32) 36.2 (13.20)
Median (minimum, maximum) 34.5 (7.1, 66.3) 35.8 (5.9, 69.6) 35.3 (5.9, 69.6)
4 months n 178 188 366
Mean (SD) 35.2 (13.53) 35.8 (12.14) 35.5 (12.82)
Median (minimum, maximum) 33.5 (7.3, 64.0) 34.0 (12.9, 65.5) 33.8 (7.3, 65.5)
12 months n 166 171 337
Mean (SD) 34.3 (13.17) 34.3 (12.02) 34.3 (12.58)
Median (minimum, maximum) 33.8 (7.7, 69.6) 33.0 (9.4, 61.0) 33.7 (7.7, 69.6)
18 months n 158 167 325
Mean (SD) 34.0 (13.51) 35.1 (12.11) 34.6 (12.80)
Median (minimum, maximum) 30.7 (8.7, 70.9) 33.7 (11.8, 63.0) 33.3 (8.7, 70.9)
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FIGURE 7 Unadjusted mean SF-12 PCS scores (with 95% CIs).
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extent in the collaborative care arm, and this difference between arms was statistically significant (mean score
difference –3.02, 95% CI –5.04 to –0.99; p= 0.004). Participants in both trial arms maintained a score of
around 40 at 12 and 18 months’ follow-up, and group differences were not statistically significant at these
time points.
EuroQol-5 Dimensions, 3 levels
Quality of life using the EQ-5D-3L is measured on five dimensions – mobility, self-care, usual activities,
pain/discomfort and anxiety/depression – and participants are given three response options to indicate
their level of problems for each dimension. The weighted summary index derived from these dimensions is
summarised and formally analysed as part of the CASPER plus health economic evaluation. For the purpose
of exploring differences in quality of life between treatment arms, the frequencies of responses for each
category in each dimension are presented descriptively in Table 33 and illustrated in Figures 9–13.
The majority of CASPER plus participants indicated no problems or some problems in each of the EQ-5D-3L
areas, with few patients having severe difficulties. The most frequent use of the severe category was in the
pain/discomfort dimension (around one-quarter of participants). The greatest trial arm differences were
seen for usual activities, with the number of patients who had no problems performing usual activities
TABLE 31 Unadjusted SF-12 MCS score descriptive statistics
Time
Trial arm
Total (N= 485)Collaborative care (N= 249) Usual care (N= 236)
Baseline (n) 245 234 479
Mean (SD) 35.4 (9.51) 35.7 (20.53) 35.5 (10.01)
Median (minimum, maximum) 35.8 (10.3, 60.2) 36.2 (2.2, 63.9) 35.9 (2.2, 62.9)
4 months (n) 178 188 366
Mean (SD) 41.6 (11.22) 38.6 (10.86) 40.1 (11.12)
Median (minimum, maximum) 41.6 (13.4, 65.5) 37.8 (7.8, 71.3) 39.7 (7.8, 71.3)
12 months (n) 166 171 337
Mean (SD) 40.4 (12.12) 38.9 (10.82) 39.7 (11.49)
Median (minimum, maximum) 40.4 (9.6, 67.4) 38.5 (16.0, 68.6) 39.5 (9.6, 68.6)
18 months (n) 158 167 325
Mean (SD) 40.1 (11.34) 38.9 (10.84) 39.5 (11.09)
Median (minimum, maximum) 41.3 (14.5, 62.9) 38.4 (1.7, 63.0) 39.0 (1.7, 63.0)
TABLE 30 Group difference in mean SF-12 PCS score
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 196 35.5 34.4 to 36.7 211 35.1 34.0 to 36.2 –0.44 –2.00 to 1.23 0.583
12 months 196 34.7 33.6 to 35.9 211 34.5 33.4 to 35.6 –0.24 –1.86 to 1.37 0.769
18 months 196 34.1 33.0 to 35.3 211 34.7 33.5 to 35.8 0.55 –1.09 to 2.18 0.514
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation and baseline SF-12 PCS score.
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FIGURE 8 Unadjusted mean SF-12 MCS scores (with 95% CIs).
TABLE 32 Group difference in mean SF-12 MCS scores
Estimate at
Trial arm
Group differenceCollaborative care Usual care
N Mean 95% CI N Mean 95% CI Mean 95% CI p-value
4 months 196 41.7 40.2 to 43.1 211 38.7 37.3 to 40.1 –3.02 –5.04 to –0.99 0.004
12 months 196 40.5 39.0 to 42.0 211 38.9 37.4 to 40.3 –1.63 –3.73 to 0.46 0.125
18 months 196 40.0 38.5 to 41.5 211 38.8 37.3 to 40.3 –1.18 –3.30 to 0.93 0.273
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation, baseline SF-12 PCS score and baseline SF-12 MCS score.
TABLE 33 EQ-5D-3L descriptive statistics
Severitya
Trial arm
Collaborative care (N= 249) Usual care (N= 236)
Total n n % Total n n %
EQ-5D-3L mobility
Baseline
Level 1 247 71 29 235 76 32
Level 2 247 176 71 235 157 67
Level 3 247 0 0 235 2 1
4 months
Level 1 181 56 31 193 36 36
Level 2 181 124 69 193 69 64
Level 3 181 1 1 193 1 1
continued
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TABLE 33 EQ-5D-3L descriptive statistics (continued )
Severitya
Trial arm
Collaborative care (N= 249) Usual care (N= 236)
Total n n % Total n n %
12 months
Level 1 168 48 29 175 49 28
Level 2 168 119 71 175 124 71
Level 3 168 1 1 175 2 1
18 months
Level 1 161 49 30 171 51 30
Level 2 161 111 69 171 120 70
Level 3 161 1 1 171 0 0
EQ-5D-3L self-care
Baseline
Level 1 243 163 67 234 175 75
Level 2 243 75 31 234 55 24
Level 3 243 5 2 234 4 2
4 months
Level 1 179 127 71 192 145 76
Level 2 179 50 28 192 45 23
Level 3 179 2 1 192 2 1
12 months
Level 1 168 115 68 175 119 68
Level 2 168 48 29 175 55 31
Level 3 168 5 3 175 1 1
18 months
Level 1 161 110 68 171 121 71
Level 2 161 49 30 171 48 28
Level 3 161 2 1 171 2 1
EQ-5D-3L usual activities
Baseline
Level 1 338 136 40 356 124 35
Level 2 338 189 56 356 209 59
Level 3 338 13 4 356 23 6
4 months
Level 1 253 123 49 314 108 34
Level 2 253 116 46 314 187 60
Level 3 253 14 6 314 19 6
12 months
Level 1 231 112 48 277 89 48
Level 2 231 108 47 277 165 47
Level 3 231 11 5 277 23 5
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TABLE 33 EQ-5D-3L descriptive statistics (continued )
Severitya
Trial arm
Collaborative care (N= 249) Usual care (N= 236)
Total n n % Total n n %
18 months
Level 1 247 64 26 235 66 28
Level 2 247 159 64 235 151 64
Level 3 247 24 10 235 18 8
EQ-5D-3L pain/discomfort
Baseline
Level 1 247 34 14 233 27 12
Level 2 247 156 63 233 152 65
Level 3 247 57 23 233 54 23
4 months
Level 1 180 26 14 192 26 14
Level 2 180 113 63 192 121 63
Level 3 180 41 23 192 45 23
12 months
Level 1 168 25 15 176 20 11
Level 2 168 102 61 176 114 65
Level 3 168 41 24 176 42 24
18 months
Level 1 161 23 14 171 23 13
Level 2 161 95 59 171 115 67
Level 3 161 43 27 171 33 19
EQ-5D-3L anxiety/depression
Baseline
Level 1 246 26 11 234 25 11
Level 2 246 176 72 234 178 76
Level 3 246 44 18 234 31 13
4 months
Level 1 178 49 28 192 42 22
Level 2 178 116 65 192 130 68
Level 3 178 13 7 192 20 10
12 months
Level 1 168 46 27 177 38 21
Level 2 168 104 62 177 123 69
Level 3 168 18 11 177 16 9
18 months
Level 1 161 36 22 172 34 3
Level 2 161 104 65 172 123 72
Level 3 161 21 13 172 15 1
a Severity: level 1, no problems; level 2, some/moderate problems; and level 3, severe problems.
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FIGURE 9 The EQ-5D-3L mobility dimension: per cent of patients in each severity category.
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Unable to wash 
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FIGURE 10 The EQ-5D-3L self-care dimension: per cent of patients in each severity category.
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Unable to perform 
usual activities
Some problems 
performing usual 
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performing usual 
activities
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FIGURE 11 The EQ-5D-3L usual activities dimension: per cent of patients in each severity category.
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Extreme pain or 
discomfort
Moderate pain 
or discomfort
No pain or 
discomfort
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FIGURE 12 The EQ-5D-3L pain/discomfort dimension: per cent of patients in each severity category.
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Extremely anxious 
or depressed
Moderately anxious 
or depressed
Not anxious or 
depressed
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FIGURE 13 The EQ-5D-3L anxiety/depression dimension: per cent of patients in each severity category.
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increasing from 40% to 49% at 4 months’ follow-up in the collaborative care arm, whereas rates remained
stable in the usual-care arm. This difference was maintained at 12 months but not at 18 months. Relatively
greater improvements in favour of the intervention arm were also seen for anxiety and depression at 4 and
12 months, the number of people not anxious or depressed being higher in the collaborative care arm,
although group differences were of moderate magnitude (around 6%). There were no substantial group
differences in the mobility, self-care or pain/discomfort dimensions.
Patient Health Questionnaire-15 items physical health problems
The PHQ-15 is a measure of physical health problems. In this study it had a score range of 0–28 (usual
maximum is 30), as a question regarding menstrual problems was removed for the elderly CASPER plus
patient population.
Unadjusted means for physical health problems are presented in Table 34 and Figure 14, and the results
of the formal statistical analysis by mixed modelling are given in Table 35. Physical health problems
significantly decreased in the collaborative care arm at 4 months’ follow-up; in contrast, in the usual-care
group, symptoms remained constant throughout follow-up (mean score difference 1.67, 95% CI 0.98
to 2.36; p < 0.001). This difference became smaller but remained statistically significant at 12 months
(mean score difference 1.19, 95% CI 0.47 to 1.90; p = 0.001), whereas follow-up scores returned to near
baseline levels for both groups at 18 months.
Connor–Davidson Resilience Scale-2 items resilience
The two-item CD-RISC2 resilience measure has a score range of 0 to 8, with a higher score indicating greater
psychological resilience. Unadjusted means for psychological resilience are presented in Table 36 and Figure 15,
and the results of the formal statistical analysis by mixed modelling are given in Table 37. Average resilience at
baseline was around 5 score points and remained consistent over the 18 months’ follow-up for patients in the
usual-care group. Among patients in the collaborative care group, average resilience marginally improved but
dropped back to baseline levels at 18 months. The group difference was statistically significant at 12 months’
follow-up (mean score difference –0.35, 95% CI –0.68 to –0.03; p= 0.034).
TABLE 34 Unadjusted PHQ-15 descriptive statistics
Time
Trial arm
Total (N= 485)Collaborative care (N= 249) Usual care (N= 236)
Baseline n 146 234 480
Mean (SD) 12.3 (4.51) 11.9 (4.33) 12.1 (4.42)
Median (minimum, maximum) 12 (2, 26) 11 (2, 24) 12 (2, 26)
4 months n 178 187 365
Mean (SD) 9.9 (4.63) 11.5 (4.60) 10.7 (4.68)
Median (minimum, maximum) 10 (2, 22) 11 (1, 22) 10 (1, 22)
12 months n 165 178 343
Mean (SD) 10.5 (4.65) 11.7 (4.59) 11.1 (4.64)
Median (minimum, maximum) 10 (3, 23) 11.5 (1, 23) 11 (1, 23)
18 months n 161 168 329
Mean (SD) 11.2 (5.22) 11.4 (4.73) 11.3 (4.97)
Median (minimum, maximum) 11 (2, 23) 11 (1, 22) 11 (1, 23)
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Adverse events
A total of 81 SAEs including deaths were identified in CASPER plus participants over the 18-month follow-up
period: 47 events occurred in 41 patients in the collaborative care arm and 34 events occurred in 33 patients
in the usual-care arm (Table 38). The maximum number of SAEs per person was three, and the average
number of SAEs experienced per CASPER plus participant was 0.19 in the collaborative care arm and 0.14 in
the usual-care arm.
The majority of SAEs (98%) were assessed as being unrelated to the intervention, and the remaining SAEs
were unlikely to be related. A breakdown of these figures by trial arm, as well as by the type and nature
of the events, is presented in Table 39. The majority of events were unscheduled hospitalisations, with
cardiovascular and miscellaneous events being the most likely reason for admissions. Causes of death are
further detailed in the Mortality section of this report.
TABLE 35 Group difference in mean PHQ-15
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 195 10.02 9.52 to 10.52 209 11.69 11.21 to 12.17 1.67 0.98 to 2.36 < 0.001
12 months 195 10.42 9.91 to 10.94 209 11.61 11.12 to 12.10 1.19 0.47 to 1.90 0.001
18 months 195 10.04 10.53 to 11.56 209 11.34 10.84 to 11.84 0.30 –0.43 to 1.02 0.423
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation, baseline SF-12 PCS score and baseline PHQ-15 score.
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FIGURE 14 Unadjusted mean PHQ-15 scores (with 95% CIs).
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Mortality
A total of 13 participants died during the 18-month follow-up period, six patients in the collaborative care
arm (2.4% of randomised patients) and seven patients in the usual-care arm (3.0% of randomised
patients). Causes of death are summarised in Table 40. A chi-squared test revealed that the difference in
mortality rates between treatment arms was statistically significant (χ21 = 0.14; p = 0.705).
TABLE 36 Unadjusted CD-RISC2 descriptive statistics
Time
Trial arm
Total (N= 485)Collaborative care (N= 249) Usual care (N= 236)
Baseline n 247 235 482
Mean (SD) 4.9 (1.81) 4.9 (1.74) 4.9 (1.78)
Median (minimum, maximum) 5 (0, 8) 5 (0, 8) 5 (0, 8)
4 months n 176 191 367
Mean (SD) 5.2 (1.78) 5.0 (1.91) 5.1 (1.85)
Median (minimum, maximum) 5 (0, 8) 5 (0, 8) 5 (0, 8)
12 months n 168 177 345
Mean (SD) 5.1 (1.84) 4.9 (1.82) 5.0 (1.83)
Median (minimum, maximum) 5 (0, 8) 5 (0, 8) 5 (0, 8)
18 months n 161 171 332
Mean (SD) 5.0 (2.03) 4.9 (1.88) 5.0 (1.95)
Median (minimum, maximum) 5 (0, 8) 5 (0, 8) 5 (0, 8)
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FIGURE 15 Unadjusted mean CD-RISC2 scores (with 95% CIs).
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All deaths were further recorded as SAEs, and potential relatedness to the trial treatment was assessed as
part of the adverse event processing. In total, 92% (12 events) of deaths were categorised as being
unrelated to treatment, and 8% (one event) as unlikely to be related to treatment.
Summary of clinical effectiveness analysis
A total of 485 elderly patients in the north of England with a major depressive episode were randomised
into the CASPER plus trial: 249 participants were allocated to collaborative care and 236 participants were
allocated to usual care. Of those in the collaborative care arm, 83% received at least one treatment session
and, on average, participants received a total of six sessions (one face to face and five over the telephone).
A total of 83 participants (33%) withdrew from collaborative care treatment before or during treatment,
with the most common reasons being not wishing to engage and physical ill health.
Participants were followed up by postal questionnaire at 4 months (80%), 12 months (74%) and 18 months
(71%). Trial dropout was greater in the collaborative care arm (22% withdrew) than in the usual-care arm
(10%). The primary trial outcome was PHQ-9 depression severity, analysed by a covariance pattern mixed
model, adjusting for PHQ-9 depression at randomisation and baseline SF-12 physical functioning. As data
from all time points were included in the model, 415 participants (86%) participants were included in the
primary analysis. Model estimates at the primary end point of 4 months revealed a statistically significant
effect in favour of collaborative care (mean difference 1.92 score points, 95% CI 0.85 to 2.99 score points;
p < 0.001). However, this difference was not maintained during the long-term follow-up at 12 months
(p = 0.741) or 18 months (p = 0.997).
TABLE 37 Group difference in mean CD-RISC2 score
Estimate at
Trial arm
Group differenceCollaborative care Usual care
n Mean 95% CI n Mean 95% CI Mean 95% CI p-value
4 months 196 5.19 4.96 to 5.42 211 4.91 4.69 to 5.13 –0.28 –0.59 to 0.04 0.089
12 months 196 5.21 4.97 to 5.44 211 4.86 4.63 to 5.08 –0.35 –0.68 to –0.03 0.034
18 months 196 5.01 4.77 to 5.25 211 4.85 4.62 to 5.08 –0.16 –0.49 to 0.17 0.352
Mixed-effects model adjusted for trial arm, time (4, 12 and 18 months), group × time interaction, PHQ-9 score at
randomisation, baseline SF-12 PCS score and baseline CD-RISC2 score.
TABLE 38 Summary of SAEs
Adverse event statistic
Trial arm
TotalCollaborative care Usual care
Total number of adverse events 47 34 81
Number of patients with any adverse event 41 33 74
Per cent of patients with any adverse event 16.5 14.0 15.3
Average number of events per patient
Mean 0.19 0.14 0.17
Median 0 0 0
Minimum, maximum 0, 3 0, 2 0, 3
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TABLE 39 Categories of SAEs
SAE characteristic
Trial arm
Total
(N= 81 events)
Collaborative care
(N= 47 events)
Usual care
(N= 34 events)
n % n % n %
Relatedness to the intervention
Unrelated 46 98.9 33 97.1 79 97.5
Unlikely to be related 1 2.1 1 2.9 2 2.5
Possibly related – – – – – –
Probably related – – – – – –
Definitely related – – – – – –
Type
Unscheduled hospitalisation 24 51.1 19 55.9 43 53.1
Other medically important condition 17 36.2 8 23.5 25 30.9
Death 6 12.8 7 20.6 13 16.1
Nature of adverse event
Cancer 3 6.4 3 8.8 6 7.4
Cardiovascular 15 31.9 10 29.4 25 30.9
Infection 5 10.6 5 14.7 10 12.4
Acute infection 4 8.5 1 2.9 5 6.2
Injury from falls 5 10.6 4 11.8 9 11.1
Miscellaneous 14 29.8 11 32.4 25 30.9
Unknown 1 2.1 0 0.0 1 1.2
TABLE 40 Cause of death by trial arm
Trial arm Cause of death
Collaborative care 11436 – bilateral pneumonia
Collaborative care 12507 – pneumonia
Collaborative care 15355 – ischaemic heart disease and duodenal adenoma
Collaborative care 16870 – congestive cardiac failure
Collaborative care 17898 – chronic obstructive pulmonary disease and breast cancer
Collaborative care 18977 – congestive cardiac failure
Usual care 13133 – cardiac failure
Usual care 15608 – myocardial infarction and bronchial pneumonia
Usual care 18051 – cardiac failure
Usual care 18497 – double pneumonia and kidney failure
Usual care 18913 – lung cancer
Usual care 21395 – ischaemic colitis
Usual care 21800 – small cell carcinoma of the lung
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Secondary analyses demonstrated robustness of these results when adjusting for clustering by case
managers (20 case managers, ICC < 0.001), additional predictors of depression severit or predictors of
non-response and when using multiply imputed data. All mean group differences at 4 months ranged
between 1.92 and 1.97 score points. Results were mirrored by the greater reduction of moderately to
severely depressed cases (PHQ-9 score of ≥ 10) for collaborative care patients at 4 months’ follow-up
(p = 0.001), which was not maintained long term.
Of the secondary outcomes, collaborative care was associated with decreased anxiety (GAD-7 score) at
4 and 12 months (p < 0.001 and p = 0.024, respectively), better mental health functioning (SF-12 MCS
score) at 4 months (p = 0.004) and greater psychological resilience at 12 months (p = 0.034). Self-reported
prescription of selected antidepressants increased among collaborative care patients at 4 months (p = 0.025).
Although there were no trial arm differences in physical functioning (SF-12 PCS score), patients in the
collaborative care arm had fewer physical health problems (PHQ-15 score) at 4 and 12 months’ follow-up
than patients in the usual-care arm (p < 0.001 and p = 0.001, respectively). Group differences were not
statistically significant for any of the outcomes at 18 months’ follow-up.
A comparable number of SAEs occurred in each trial arm (collaborative care, 47 events; usual care,
31 events). Six participants in the collaborative care arm died during the trial, compared with seven in the
usual-care arm (χ21 = 0.14; p = 0.705).
CLINICAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
Chapter 6 Health economics
The health economic component of the CASPER plus trial was an incremental cost-effectivenessanalysis exploring the value for money of the intervention over and above usual care. An analysis of
uncertainty is also included to demonstrate the robustness of the results. First, the resource use and costs
are estimated, including the costs of providing collaborative care and associated training of health-care
professionals, and also the wider costs to the NHS. Second, health outcomes are quantified using QALYs
using the SF-6D algorithm.
Resource use and costs
Collaborative care: required resources and associated costs
Case managers were psychological well-being practitioners (PWPs) employed at NHS band 5. Case
managers each received training to provide collaborative care as part of the CASPER plus trial. In total,
three training events were held covering four regions of the study (York, Leeds, Durham and Newcastle
upon Tyne), each consisting of 2 consecutive days of training. The number of attendees per training event
varied and efforts were made to provide training in a manner that ensured that the overall costs of travel
and accommodation were minimal.
During the training, PWPs were orientated to the case managers’ manual, which outlined the overall
principles of collaborative care and a ‘session-by-session overview’ of what case managers aimed to achieve
with patients. The training courses for case managers were predominantly provided by two trainers;
subsequently, these trainers also supervised case managers during implantation of the collaborative care
programme implementation.
The manual stipulated that the programme of treatment should consist of ‘8–10 mainly telephone
contacts with occasional face-to-face contacts over a period of 12 weeks’. In terms of the expectation for
each session, it further stated that ‘contacts last 45 minutes for session one and 20–30 minutes for each
subsequent contact’. The first session was generally held face to face and took place at participants’
homes, GP surgeries or other community venues.
Case managers received weekly supervision from a designated supervisor. The schedule of supervision
followed a standardised agenda whereby for each patient there was a weekly discussion and case managers
would prepare feedback to discuss each case with their supervisor. Supervisors were responsible for providing
support to case managers on the process of collaborative care and medication management and on specific
psychological interventions. On average, each patient contact was discussed between the case manager and
supervisor for approximately 5 minutes.
Case managers provided participant-specific feedback to GPs. In the first instance, case managers worked
with and advised participants’ GPs on their care. During treatment, case managers would provide a letter
to update the GP on participants’ progress and, when appropriate, whether or not GPs might consider
further treatment. At the end of the programme, case managers also sent a participant-specific summary
report to the GP. Supervisors were available to advise case managers on next steps and consultation with
GPs. Three letters were prepared and sent over the 12 weeks, requiring approximately 30 minutes of
administration per letter. Case managers would also speak to GPs directly if they had any concerns about a
participant’s medication or overall well-being.
Case managers were also charged with a duty of care to engage outside agencies (such as social services
or in response to safeguarding issues) in situations in which they became aware of safety or risk (including
abuse). However, the client group had a generally low level of clinical need in this respect, and this
additional responsibility was not generally required.
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To estimate the personnel costs required to provide collaborative care (as intended within the manual),
estimates of NHS unit costs were derived from national reference costs56 (Table 41).
Table 42 summarises the resources required over the 12-week programme of collaborative care and
indicates our estimate of the direct cost for base-case analysis. The direct cost of collaborative care (based
on the prior estimation within the manual) was calculated to be £494.73. This cost is adopted for the
base-case cost as, ex ante, there is insufficient information to anticipate actual levels of required care;
however, deviation that did occur will be explored within our sensitivity analyses.
Consequences for health care by trial arm
Patient contacts over the duration of the trial are presented in Table 43, which compares the summary
statistics for those who accessed collaborative care with the summary statistics for those who accessed
usual care. Initial observation suggests that collaborative care in depression results in a small marginal
increase in contacts with most services (except GP home visits). However, the mean contact rate with any
service is dependent on access to the service and the subsequent level of utilisation.
To test whether or not differences in service use may be attributed to collaborative care, statistical tests must
accommodate highly skewed distributions with significant numbers of zero service users and, therefore,
specific analytical procedures are required.60 Applying zero-inflated negative binomial regression61 allows
inference on the effect of collaborative care on two factors: access (using the logistic model) and overall
change in the contact rate (using the full model). For full regression outputs see Appendix 12.
Having any access to services is indicated by outputs of the logistic models. Across all five resource use
categories we may conclude that participants are generally unlikely to access any services. Examining logistic
regression outputs related to nurse appointment (see Appendix 12, Table 55) suggest that collaborative care
may increase the likelihood of access (log odd = 14.1944; p = 0.01). However, small sample numbers
available from this trial mean that inferences regarding the effect of collaborative care should be made
with caution.
TABLE 41 Personnel costs required to provide collaborative care
Item Unit cost (£) Referencea
PWP (band 5)
Per hourb 39 Nurse (mental health)
Patient-related workb 52 Nurse (mental health)
Face-to-face contactb 74 Nurse (mental health)
PWP (band 6)
Supervisionb 49 Nurse team leader
GP
Appointment 45 ‘Per patient contact lasting 11.7 minutes’
Home visit 114 ‘Per out of surgery visit lasting 23.4 minutes’
Telephone consultation 27 ‘Per telephone consultation lasting 7.1 minutes’
Practice nurse
Appointment 13.43 ‘£52 per hour of face-to-face contact, duration of contact 15.5 minutes’
Telephone consultation 6.15 ‘£52 per hour of face-to-face contact, assumed similar time as GP: 7.1 minutes’
a From Curtis.56
b In the absence of specific unit costs for PWPs and supervisors, proxy values of roles at the same NHS band are taken.
All price years were 2012/13.
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The full model specification accounts for access and subsequent use to test any overall change in the
contact rate. Over resource use categories, there is generally no significant difference between groups.
However, inference of the effect of collaborative care on nurse telephone consultations suggests an overall
increase in the contact rate of 2.25 (95% CI 0.9285 to 5.4403; p = 0.073). Again, given the sample size,
inferences on the effect of collaborative care should be made with caution.
Cost–consequences and total costs
Unit costs (as presented in Table 41) were multiplied by resource utilisation to derive patient-level costs of
health care (Table 44). Health-care costs of treatment therefore extend beyond the cost of the collaborative
care programme (£494.73), increasing wider costs by a mean of £682.27. Overall, the mean total cost in the
collaborative care group was £1171.45 (95% CI £1166.99 to £1175.92, n = 226), compared with £654.14
(95% CI £650.78 to £657.52, n = 221) in the usual-care group.
TABLE 42 Summary of the health-care resource required to train and provide collaborative care as an associated
base-case cost of the programme
Item Frequency Duration
Total
quantity Cost (£) Description
Training case managers
Case managers attending 16 case managers 13 hours 208 8112a 2 days, 6.5 hours
each
Supervision of course Two trainers,
three sessions
13 hours 96 hours 4704b 2 days, 6.5 hours
each
Manual One manual/case
manager
– 16 80 Printing
Travel and accommodation For two
trainers × two
sessions
1 night 4 nights 600 Sessions in Durham
and Leeds
Subtotal (total cost of training) 13,496 Cost to train all case
mangers
Subtotal (total cost of training per participant) 39.23 249 allocated to the
programme
Collaborative care
Session 1 One per patient 45 minutes 45 minutes 55.50 Assumed by home
visitc
Sessions 2–10 Median of nine
sessions per
patient
30 minutes 4.5 hours 234 Assumed by
telephoned
Supervisions One per week (12) 5 minutes 1 hour 88 1 hour over
12 weeksa,b
GP communication Three letters 30 minutes 1.5 hours 78 Patient-related
work4
Engaging outside agencies 0 0 0 0 Not required in
CASPER
Subtotal (total cost of intervention per participant) 455.50
Total cost (training + intervention) 494.73 Cost for base-case
analysis
PSSRU, Personal Social Services Research Unit.
a For different tasks performed by the PWP, different costs were associated. For example, for work not requiring any
patient contact, a general total staff hourly rate was applied for band 5 (£39 per hour).
b This was also the case for case manager supervision: for work not requiring any patient contact, a general total staff
hourly rate was applied for band 6 (£49 per hour).
c For contact in person, the PSSRU unit cost for ‘face-to-face time’ was applied (£74 per hour).
d For communication occurring over the telephone, the PSSRU unit cost of patient-related work was applied (£52 per hour).
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Health benefits
Health-state utility by time point
Utility scores for each participant were estimated from the responses to the SF-6D at baseline and at 4,
12 and 18 months. Table 45 presents a summary of the unadjusted utility scores by time point and trial
arm across all available respondents at each time point.
However, as we can observe, the available sample number by group and across time points declines as the
study progresses. For the purpose of illustration, health-state utilities were estimated using a linear-mixed
model and estimate group marginal effect for the mean for each time point; Figure 16 plots the outputs
and illustrates trends in estimated utilities by trial arm over the trial period.
Observing differences in baseline utility scores by trial arms suggests that control for baseline utility to
estimate cost-effectiveness is important.
TABLE 43 Mean use of health-care resources observed in the collaborative care and usual-care groups over
18 months
Categories
of health-care
resources
Trial arm
Intervention Usual care
Mean SD Minimum Maximum n Mean SD Minimum Maximum n
GP
Appointment 10.12 7.74 0 41 226 9.63 7.36 0 45 221
Home visit 0.76 2.48 0 21 226 0.80 2.52 0 26 221
Telephone
consultation
2.42 3.75 0 27 226 2.20 3.00 0 15 221
Practice nurse
Appointment 5.40 6.60 0 54 226 5.10 6.11 0 40 221
Nurse
Telephone
consultation
0.37 2.06 0 24 226 0.33 0.89 0 7 221
TABLE 44 Mean costs (£) associated with collaborative care and usual care over 18 months
Categories of cost
Trial arm
Intervention Usual care
Mean SD Minimum Maximum n Mean SD Minimum Maximum n
Collaborative care 489.18 0.00 489.18 489.18 249 0.00 0.00 0.00 0.00 236
GP
Appointment 455.18 348.12 0.00 1845.00 226 433.51 331.03 0.00 2025.00 221
Home visit 86.76 282.44 0.00 2394.00 226 90.79 286.95 0.00 2964.00 221
Telephone
consultation
65.47 101.30 0.00 729.00 226 59.38 81.07 0.00 405.00 221
Practice nurse
Appointment 72.58 88.62 0.00 725.40 226 68.44 82.02 0.00 537.33 221
Nurse
Telephone
consultation
2.29 12.68 0.00 147.68 226 2.03 5.49 0.00 43.07 221
Total cost 1171.45 523.60 489.18 4273.94 226 654.15 506.38 0.00 3548.87 221
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Quality-adjusted life-years
The QALYs were estimated by summing the time-weighted averages of the utility scores between the four
time points up to 18 months, for all individuals with information available for complete-case cost-effectiveness
analysis. Table 46 compares the undiscounted QALYs, as well as QALYs discounted at 3% beyond 12 months,
by trial arm.
The incremental QALY gained of collaborative care compared with usual care would be 0.011, and this
result did not change when QALYs were discounted beyond 12 months. To adjust for baseline utility,
we apply ordinary least squares to explain QALYs and controlled for trial arm, age and baseline utility.
Table 47 presents the outputs of the ordinary least squares regression.
Adjusting for baseline utility scores, the collaborative care baseline is associated with an incremental QALY
gain of 0.019 (95% CI –0.020 to 0.057; p = 0.338). Independent of treatment, baseline utility is significantly
predictive of overall QALYs. Given the potential implications of group differences in baseline utility and age,
the adjusted incremental QALY gain for collaborative care using the complete-case sample (n = 362) informs
all subsequent estimates of cost-effectiveness.
TABLE 45 Unadjusted utility scores by trial arm and time
Trial arm Mean SD Median Minimum Maximum n
Collaborative care (utility)
Baseline 0.551 0.105 0.543 0.345 0.863 243
4 months 0.580 0.144 0.580 0.000 0.937 180
12 months 0.565 0.153 0.569 0.000 0.922 171
18 months 0.540 0.154 0.553 0.000 0.895 175
Usual care (utility)
Baseline 0.559 0.100 0.565 0.345 0.863 233
4 months 0.566 0.139 0.566 0.000 0.922 195
12 months 0.550 0.143 0.580 0.000 0.859 179
18 months 0.535 0.159 0.545 0.000 0.895 165
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FIGURE 16 Plot of mean (95% CI) of SF-6D indexes over the trial period, by trial arm.
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Cost-effectiveness and uncertainty
Collaborative care for depression resulted in a small but non-significant mean increase in QALYs over the
18-month period, with a higher associated health-care cost. Based on the generic health gains, the mean
cost per incremental QALY was £26,016. Examining this ICER, collaborative care for depression falls within
the explicit willingness-to-pay range (£20,000–30,000 per QALY)53 and may represent value for money
to the NHS. However, a risk-averse decision-maker may wish to consider the uncertainty in the ICER.
Non-parametric bootstrap of the difference in cost and QALYs generates 10,000 replications.
Figure 17 presents results of the bootstrap, depicting the uncertainty surrounding the mean difference
in cost and QALYs on the cost-effectiveness plane. The results of the bootstrap indicate the average
incremental cost of collaborative care over usual care to be £479.58 (bootstrapped 95% CI £380.55 to
£578.61). This demonstrates that a large proportion of the replications fall within the north-east quadrant
(82.36%), suggesting that the most likely scenario is that collaborative care in depression increases costs
and also creates QALY gains. Figure 18 illustrates the uncertainty surrounding the ICER and provides 50%,
75% and 95% confidence ellipses. Inference on the 50% confidence ellipse suggests that, based on the
current sample size, we cannot absolutely exclude the possibility that collaborative care may reduce
health status.
Figure 19 presents the CEAC illustrating the relationship between willingness to pay and the probability
that collaborative care would be cost-effective. With reference to the NICE’s cost-effectiveness threshold,
the likelihood that collaborative care would be cost-effective at £20,000 per QALY is 38.84% and at
£30,000 per QALY is 54.94%.
TABLE 46 Comparison of QALYs with and without the application of 3% discount rate beyond 12 months
Trial arm Mean SD Median Minimum Maximum n
Without a 3% discount beyond 12 months
Collaborative care 0.900 0.241 0.889 0.036 1.573 175
Usual care 0.889 0.224 0.914 0.044 1.412 187
With a 3% discount beyond 12 months
Collaborative care 0.893 0.238 0.881 0.036 1.573 175
Usual care 0.882 0.222 0.907 0.044 1.395 187
TABLE 47 Regression analysis controlling for trial arm, age and baseline utility: QALYs
Variables Coefficient Standard error t p> t 95% CI
Baseline utility 1.275 0.091 14.070 0.000 1.097 to 1.453
Collaborative care 0.019 0.019 0.960 0.338 –0.020 to 0.057
Age –0.026 0.016 –1.570 0.118 –0.058 to 0.007
Constant 0.094 0.071 1.320 0.188 –0.046 to 0.233
n= 362; R2 = 0.3589.
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Sensitivity analysis
Sensitivity analysis: fidelity to intervention sessions and ex post adjustment of the
expected direct cost of collaborative care
This analysis seeks to examine documented fidelity of participants to treatment (as observed from data
collected using PC-MIS) and to consider how this may adjust our expectation of the cost of implementing
collaborative care. Figure 20 summarises distribution in the number of contacts. The total number of
registered sessions shows significant variation, and a bimodal distribution of participant sessions appears
evident. This raises the question of whether or not there exists a selection process in early sessions (by
consumer, provider or both) that divides patients into two groups. For example, 128 of participants (51%)
received five or fewer sessions in the early stage of care and the remaining 49% were most likely to
receive 10 sessions.
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FIGURE 17 Cost-effectiveness plane (controlling for baseline utility). Bootstrap with 10,000 replications.
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To examine if health status explains the number of received sessions, Table 48 presents baseline scores to
PHQ-9, GAD-7 and SF-6D contingent on whether or not participants received more or fewer than five
sessions. With respect to all three measures, this suggests that the group that received six or more sessions,
on average, had poorer health status at baseline. However, reference to 95% CIs would suggest that the
between-group difference is not significant.
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The next question is, therefore, whether or not the number of sessions is influential on the treatment effect.
Figure 21 illustrates the mean (95% CI) of SF-6D indexes over the trial period comparing usual care with
treatment. The trial arms are subdivided into participants who received five or fewer sessions of
collaborative care and those who received more than six sessions of care. This provides a clear illustration
that a dose–response relation is likely to exist between the number of sessions received and generic health
status. Fidelity to, and engagement with, the treatment programme appears to be an important feature in
threshold depression.
Table 49 calculates the adjusted direct costs of collaborative care using data from PC-MIS based on session
from 174 trial participants. This suggests that, on average, collaborative care received by participants cost
£198.25 (95% CI £196.16 to £200.35). Given the available information on health gains, it is difficult to
determine how this should be interpreted compared with the expected ex ante cost of £494.73. One
interpretation is that, in practice, collaborative care cost £296.48 less than expected.
To examine the value underlying the observed rate of fidelity to treatment, Figure 22 presents an adjusted
CEAC (with ICER) to examine whether, with an intention-to-treat perspective, collaborative care for
threshold depression represents value for money or not.
Firstly, given the ratio of average treatment effect to the adjusted cost of collaborative care, an ICER of
£10,216 per incremental QALY can be estimated. Costs and QALYs can also be examined by subgroup
(i.e. contingent on whether or not participants received more than five sessions of collaborative care).
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FIGURE 21 Mean (95% CI) of SF-6D indexes over the trial period comparing the usual-care group with trial arms
that received either five or fewer sessions of collaborative care or more than six sessions of collaborative care.
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TABLE 48 Scores at baseline (PHQ-9, GAD-7 and SF-6D index) and subsequent number of sessions
Collaborative care
Baseline scores, mean (95% CI)
PHQ-9 GAD-7 SF-6D
Number of sessions
≤ 5 12.01 (10.26 to 13.76) 9.2 (7.77 to 10.64) 0.553 (0.482 to 0.624)
≥ 6 12.75 (10.96 to 14.55) 9.67 (8.19 to 11.14) 0.548 (0.475 to 0.621)
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TABLE 49 Direct costs of collaborative care (ex post estimation using data from PC-MIS, n= 174)
Session
Type of contact (%)
Mean duration
(minutes) Mean cost (£) Poisson exact (95% CI) (£)Face to face Telephone E-mail
1 90.34 9.66 – 60 64.02 62.83 to 65.22
2 5.71 94.29 1.27 31 21.41 20.73 to 22.11
3 6.33 92.41 – 30 19.11 18.47 to 19.77
4 6.34 93.66 – 30 17.95 17.32 to 18.59
5 7.58 92.42 0.83 29 16.68 16.08 to 17.30
6 5.79 93.39 – 29 14.99 14.42 to 15.58
7 6.25 93.75 – 29 14.09 13.53 to 14.66
8 7.14 92.86 1.32 28 11.87 11.37 to 12.40
9 7.89 90.79 – 26 8.30 7.88 to 8.74
10 7.14 92.86 – 27 6.18 5.81 to 6.56
11 7.14 92.86 – 26 2.73 2.49 to 2.99
12 14.29 85.71 – 26 0.43 0.33 to 0.53
13 50 50 – 25 0.21 0.15 to 0.29
14 – 100 – 30 0.15 0.10 to 0.22
15 – 100 – 30 0.15 0.10 to 0.22
Total cost 198.25 196.16 to 200.35
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FIGURE 22 Cost-effectiveness acceptability curve (controlling for baseline utility) using ex post estimate of the
direct costs of collaborative care.
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Table 50 performs a seemingly unrelated regression to inform the cost-effectiveness analysis related to
these subgroups.
The results indicate that receiving five or fewer sessions of collaborative care is associated with an average
cost of £12 (95% CI –£120 to £143) and results in an average QALY gain of –0.0004 (95% CI –0.0517 to
0.0509); therefore, this strategy is dominated by usual care.
We can also determine that the overall cost of receiving six or more sessions of collaborative care is
associated with an average cost of £307 (95% CI £193 to £421.93; p < 0.001) and an average QALY gain
of 0.0311 (95% CI –0.01375 to 0.0760; p = 0.174). Although the statistical significance of the difference
in QALY gain is low, despite the reduction in sample size, it remains higher than the average treatment
effect presented in Table 47. Overall, this suggests that, for individuals who receive six or more sessions of
collaborative care, the ICER will be £9876 per QALY.
Figure 23 presents confidence ellipses on the cost-effectiveness plane for each subgroup and clearly
illustrates that collaborative care requires a strict minimum number of sessions (i.e. six). Examining the
CEAC, we can observe that (for session numbers greater than six) the probability that collaborative care is
cost-effective is significantly higher over the explicit reimbursement range (£20,000–30,000 per QALY).
These findings suggest that collaborative care may be cost-effective with improved fidelity and that further
research to better understand reasons why certain participants do not adhere to the treatment programme
(e.g. patient preferences or supply-side competing priorities) is required.
TABLE 50 Seemingly unrelated regression of change in total cost and QALYs explained by sessions of collaborative
care controlling for age and baseline utility
Coefficients Total costs (£) (95% CI) QALY (95% CI)
Collaborative care: five or fewer sessions £12 (–£120 to £143) –0.0004 (–0.0517 to 0.0509)
Collaborative care: six or more session £307 (£193 to £421.93)**** 0.0311 (–0.01375 to 0.0760)*
Age –£33 (–£117 to £51) –0.02533 (–0.0582 to 0.0075)*
Baseline utility – 1.2638 (1.0840 to 1.4436)****
Constant £560 (£302 to £819)**** 0.105 (–0.0365 to 0.2466)*
*p < 0.2, **p< 0.1, ***p < 0.01, ****p < 0.001.
Correlation of QALYs and costs = –0.0471; Breusch–Pagan χ2 = 0.790.
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FIGURE 23 (a) Confidence ellipses (comparing collaborative care with more or fewer than six sessions: session
number ≤ 5 vs. ≥ 6) and (b) CEAC (for collaborative care with six or more sessions: session number ≥ 6).
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Chapter 7 Qualitative findings
Background
Gunn et al.62 reported that GPs perceive patient engagement to be of fundamental importance in dealing
with depression. Older people may be reluctant to define their distress as a mental health problem,
with implications for treatment acceptance.13 Simpson et al.63 reported on the experiences of depressed
participants receiving collaborative care in the UK, finding that case managers were able to reduce the
sense of stigma of being diagnosed with a mental health problem and resolve misconceptions around
medication prescribed by the GPs.
Aims
The nested qualitative process evaluation explored the views and experiences of the CASPER plus
intervention within the collaborative care framework for the management of depression in older people
from the perspectives of participants, case managers and GPs. It considered:
1. Older people’s experiences of receiving treatment for depression within a collaborative care framework
and the acceptability of the collaborative care intervention. We sought participants’ views on depression
and their experiences of receiving the intervention from case managers.
2. Case managers’ experiences of delivering an intervention for depression within a collaborative care
framework.
3. GPs’ perspectives of the management of depression and views on the CASPER plus intervention.
The process evaluation explored patient and professional views to determine whether or not service-level
integration of care is effective and how it is experienced by participants. It explored whether or not the
model of collaborative care intervention fitted within routine practice and was viewed as sustainable.
The findings from the CASPER plus RCT (see Chapter 5) revealed a statistically significant difference in the
primary outcome of depression severity (PHQ-9) between trial arms at 4 months’ follow-up in favour of
collaborative care, but not at 12 or 18 months’ follow-up. Of the secondary outcomes, collaborative
care was associated with decreased anxiety (GAD-7 score) at 4 and 12 months, improved mental health
functioning (SF-12 MCS score) at 4 months and greater psychological resilience at 12 months. None of the
outcomes had a statistically significant difference at 18 months’ follow-up.
The qualitative data, presented here, provide insight into:
1. recognising and identifying depression in older people
2. components of the intervention within the collaborative care framework valued by participants
3. how the collaborative care framework fits into current practice.
Methods
Ethics approvals
Ethics approval for the RCT and this qualitative study was gained by Leeds East Research Ethics Committee,
Yorkshire & Humber (reference number 10/H1306/61).
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Design
We conducted semistructured interviews with trial participants, case managers and GPs to gather in-depth
information on their views and experiences of receiving and delivering the intervention and how they
perceived the acceptability, engagement and implementation of patient and collaborative care, respectively.
Interviews were conducted with trial participants at the end of the intervention period and with case
managers delivering the intervention and patient GPs during the intervention.
Sampling
Our aim was to interview a purposive sample of GPs and trial participants, including some participants
who declined to take part or who withdrew from the intervention, alongside all the case managers who
delivered the intervention. Our approach was to sample participants and GPs from recruiting practices in
both urban and rural areas in the north of England and to gather data from areas of differing deprivation
indices to achieve a spread in sex, age and socioeconomic status (SES). We aimed to interview all 12 case
managers and supervisors and up to 15–20 GPs (or until category saturation was achieved) along with
7–10 participants who did not engage in the intervention and 15 participants who completed the
intervention (or until category saturation achieved).
Initially, as numbers were small and recruitment to the trial was slow, we invited all participants who had
completed the intervention to take part in a semistructured interview of up to 1 hour. All case managers
were invited to be interviewed once they had delivered a course of treatment to at least three participants,
and GPs from practices with at least five participants from the collaborative care arm of the trial were invited
to be interviewed. Once we had recruited approximately half of our participants this way, we then used a
purposive sampling strategy with the aim of gaining a more varied sample of patient and GP participants.
At the start of the CASPER plus qualitative study, following the order of GP practice recruitment, all
participants invited to take part were from the central site of York, which included urban and rural
practices in the surrounding areas from Harrogate to Hull. Given that most of these areas are of relatively
low to moderate deprivation, we used an active selection process to ensure some participants from areas
of higher deprivation were invited to be interviewed, such as inner-city Hull.
Participants were sent an invitation pack by post, which comprised a letter, an information leaflet and a
consent form with a pre-paid envelope to return to the research team. GPs and case managers were sent
an invitation letter, information leaflet and a consent form by e-mail. Before interviews commenced,
written informed consent was obtained from all participants (see Appendices 13–15).
Data collection
Interviews were carried out by Karen Overend, Katherine Bosanquet and Sarah Nutbrown in a place convenient
to the participant and lasted between 20 and 60 minutes. The majority of GPs chose to be interviewed at their
practice, although 5 out of 12 asked to be interviewed by telephone. Ten out of the 12 participants requested
to be interviewed in their home, with the remaining two choosing to be interviewed by telephone. Nearly all
case managers were interviewed in the researcher’s office, with three opting for a telephone interview.
Interviews were conducted between May 2013 and November 2014. All interviews were digitally recorded
(with participants’ signed consent), transcribed verbatim and anonymised before data analysis.
A topic guide was developed for each of the three groups (see Appendices 16–18). The topic guides were
designed with reference to the literature, approved by the research team and developed iteratively as data
collection commenced.
Consent
In accordance with ethics guidelines, informed consent was gained by the researcher from each study
participant before the interview commenced. An information sheet was sent to the participant in advance, as
part of the invitation pack. Before starting the interview, the researcher (interviewer) ensured that this was
signed by the participant (interviewee), repeated the main points of the information sheet and aim of the
study and gave the participant an opportunity to ask any questions. The researcher assured the participant of
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the anonymity and confidentiality of their personal information. GPs and case managers were also given the
opportunity to ask questions about the study and were assured anonymity and confidentiality. Consent was
obtained from GPs and case managers using the same process as for trial participants.
Data analysis
The interview transcriptions formed the data, through the use of thematic analysis and principles of constant
comparison.64 This was developed iteratively and the topic guides were modified as analysis progressed. The
main qualitative researcher on the project (KO) worked closely with the data to identify descriptive coding;
this was informed by regular discussion with qualitative supervisor (CC-G) and co-researcher (KB). Analysis
was undertaken by individual researchers Karen Overend, Carolyn Chew-Graham and Katherine Bosanquet.
Data analysis involved a process of organising the data, descriptive coding, interpretive coding, writing and
theorising. Deviant cases were actively sought throughout the analysis and emerging ideas and themes
modified in response. Following analysis by individual researchers, themes were agreed during discussion
with the full research team.
Findings
In total, 12 GPs, 13 participants (12 who had completed the intervention and one who had withdrawn
before commencing therapy) and eight case managers were interviewed (see Appendix 19). The main
themes identified in the data were ‘revealing hidden depression’, ‘reducing the blind spots’, ‘an opportunity
to talk’ and ‘moving on’ from depression. Our findings are reported in a recent qualitative paper.65
Data are presented to support analysis and are labelled by identifier and number.
Revealing hidden depression
For most of the older people we interviewed, being invited to participate in the CASPER plus study seemed
to raise their awareness of low mood:
It crept up on me really, how I felt. I think it had been coming on for a long time and I didn’t realise
how bad I’d got until I filled that form in and I just ticked the boxes and posted it.
Participant (PT)6
Several GPs described how taking part in the CASPER plus trial helped to raise awareness of depression in
their older population. One GP said:
I think it’s probably alerted us to one or two of the . . . more needy participants who perhaps were not
coming to us for help . . . people have been brought into the system that . . . had sort of dropped out
from seeing the GP.
GP3
Some case managers described how some participants admitted they had not spoken to others, including
their GPs, about how low they felt:
One gentleman that I saw, he said the most useful thing had been the diagnostics, as risk was
identified, and so we wrote to the GP about that. And it was . . . the risk was still there when I saw
him for the first time so I put that in a letter as well and he said that had kind of opened the door.
He would have never gone and spoken to his GP about it.
Case manager (CM)2
. . . they [the patient] wouldn’t do anything and they wouldn’t commit suicide but they feel ashamed I
guess of having some thoughts [that they’d be better off dead] . . . and those are the sorts of things
they don’t always like us to share with the GP because it’s back to that stigma, isn’t it?
CM1
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Although some patient participants did not use labels such as ‘depression’ or ‘low mood’, those who did
suggested that other older people may fail to recognise or admit their feelings because of the perceived
stigma of doing so:
. . . people don’t talk about it do they, they think it’s a weakness don’t they? But it is something that
you can’t help when you are in it, you know as I say you don’t realise you are going in it and as much
as you try you know sometimes you can’t get out it, it gets deeper you know.
PT6
A few patient participants commented on the ‘invisibility of depression’:
. . . you know if I broke an arm I’d get a sling wouldn’t I, you know it’s fairly obvious, but I suppose
with any mental illness you can’t see it, you don’t know.
Withdrawn participant (PTW)1
Several GPs reported an awareness of the stigma associated with depression, especially in this age group,
that may impact on whether or not the patient would raise it within a consultation:
It’s sort of an age group where they’re not as open about depression as maybe younger people are,
there’s a bit of a stigma attached to it still.
GP8
A few GPs described how they normalised depression in older people; one admitted possibly colluding
with the patient in ignoring cues within the primary care:
You’re sort of aware there are people who have depressive episodes that aren’t possibly addressed,
they may themselves not really recognise it, and they just think it’s part of, you know, getting older.
GP3
You’d like to think that primary care is fairly aware of it [depression] anyway. But maybe the
temptation is to let sleeping dogs lie, I don’t know. So you know, if you diagnose someone with
depression you’ve got to do something about it haven’t you?
GP6
Some GPs described a tension between a desire to consider the ‘whole’ patient and, owing to limited time
and treatment options, a tendency to prescribe antidepressants to older people:
We often go down a medication route because, well it does help them, and it’s very difficult to get
other services. And the psychiatry for the elderly tends to be more focused on dementia.
GP8
Several GPs recognised that depression in older people often materialises alongside complex physical
conditions or social problems, including loneliness. Some of these GPs disclosed a reluctance to identify
the condition, partly because of the absence of a psychological treatment pathway for depression in the
over-sixty-fives and a tendency to prioritise physical symptoms over emotional health:
I suppose in a busy clinic we probably don’t have time to sort of delve into depression along with the
sort of 12 and a half minutes of consulting on chronic diseases that’s squeezed into 10 minutes, so
depression would take another 5 or 6, so . . . we’ll probably skip over that unless they bring it to us.
GP12
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Being invited to participate in the CASPER plus trial provided an opportunity for some people to talk about
depression, enabling them to recognise and seek help for low mood.
Reducing the ‘blind spots’
Several case managers and three GPs described how two practitioners working with a patient helped to
reduce the ‘blind spots’, as each professional offered a different perspective:
So you’ve got the benefit of somebody who’s looking at a person, never having met them before who
can see certain things, versus somebody who has known somebody for some time and can see certain
things but, those two people, will have, probably have, blind spots . . . because one person doesn’t
know that person very well and the other has maybe, over the years, has just sort of formed a fixed
idea about somebody. Collaborative working, not only will it progress the patient forward but it will
also . . . reduce blind spots, I think, in their care.
GP1
One GP saw the case manager as helping to ‘patch up’ the gaps in the patient’s support network:
I think a lot of the difficulty . . . is their support networks have become a bit more fragmented . . .
especially those that are bereaved, or have families spread around the country or spread around the
world . . . so I can see that maybe we can patch that fragmentation up a little bit . . . it’s not the same
as having your relatives but having some kind of support, I can see that as a benefit.
GP3
The case managers viewed their role as a facilitator, or ‘go-between’, who is able to convey information to
the GP that the patient may be reluctant to disclose directly:
Sometimes, if people can’t talk to their GP or don’t understand that maybe they had a problem like
depression, and don’t know how to approach a GP because of stigma and things like that then I’ve
been that facilitator, I’ve helped them with that process.
CM1
For example, one case manager reported advocating on behalf of a patient who was having problems
with pain:
. . . she was using cannabis to manage the pain and she felt there was nothing else the doctors could
do, so I spoke to her GP and they said she could get a referral to the pain clinic . . . She [the patient]
had given up all hope, but she was happy for me to pester them a little bit.
CM3
The GPs and case managers offered different perspectives on participants’ health needs, which was seen
to reduce ‘blind spots’ in depression care.
An opportunity to talk
Being offered an opportunity to talk outside the GP consulting room was valued by the majority
of participants:
The most startling thing about the experience was all my life I’ve never had anybody to talk to,
there’re things I wouldn’t even discuss with my wife and to have an outsider person that didn’t really
know me who was impartial . . . that helped me a great deal, just by having someone to discuss
things with.
PT5
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. . . having someone to talk to . . . about things in my life that I would talk to say the family about or
friends unless they were extremely close friends, it gave me someone objective to talk to you know,
that was removed from my situation.
PT2
Some participants suggested that GPs were not always receptive to discussing problems with mood:
You know and the GPs, well they don’t, they don’t seem to be interested I don’t think. Oh, it’s
depression, take a pill, go away.
PT12
I just have a bit of a problem with doctors because I just don’t think they do the job that they maybe
should be doing, it’s a 2-minute interview or whatever, they don’t really know your records, they don’t
know the history, they don’t tie things up.
PTW1
In contrast, most participants described the case manager as providing empathic support, being able to
offer more time than the GP and knowing how to direct participants to voluntary organisations:
. . . she did everything she possibly could . . . I mean she went the extra mile. She spoke to the people
at Parkinson’s – Parkinson’s UK – to see if there was a network somewhere, an advice centre, and
things I didn’t know she found out for me.
PT7
Patient participants spoke about the benefit of having someone to talk to in confidence, outside the
primary care consultation, who was said to listen without judging, allowing them to talk openly about
feelings and personal issues:
I thought it was very good. And I think the fact that people were bothered, to see how the older
people felt . . . I think that was good. You didn’t feel like you just got a script thrown at you and you
were waiting for God sort of thing . . . it was the fact that someone was interested in how you felt.
PT1
Giving participants an opportunity to talk outside the clinical setting of the primary care consultation room
appears to be valued by most of the older people we interviewed and by their GPs.
‘Moving on’ from depression
Some participants reported how the case manager encouraged them to increase activity and social
contact, which the participants felt had improved both their physical health and mood. For example:
The telephone conversations for me were helpful. She got me to think about doing things. I’m doing a
computer course now and there’s a chance I might be able to help them at [voluntary organisation].
PT9
It has helped me thinking about things I can do . . . I go in the pool, only in the baby pool but it’s
good for my legs and my shoulder . . . and you know it makes you feel better once you’ve done it, not
just my legs, but in yourself, you know . . .
PT6
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A few participants valued the practical aspects and the techniques learned from the case manager:
I’ve kept a diary all my working life and by going – a daily diary that is – and by going through it we
could highlight various things that tip the balance if you like of the scales of happiness and depression
and it was highlighted [depression] and between us we figured out a way of coming through
it basically.
PT5
When we moved onto the technical part of it where they are asking specific questions and giving
specific ideas, I find these very useful and in fact I’ve continued to do those. The ones I am talking
about are where you identify things to do . . . and make a list.
PT4
Case management with behavioural activation provides older people with tools to help manage their
depressive symptoms and to understand that behaviour and mood are closely linked. Behavioural activation
promotes participation in social and physical activity, which may enable older people to ‘move on’ from
depression and to experience improved well-being.
Discussion
To our knowledge this is the first qualitative study to explore the perspectives of older people, case
managers and GPs, all of whom were participants in a trial of collaborative care for older people. Our
findings support previous studies that suggest that depression in older people may be hidden and that
invitation to participate in a trial can serve to uncover depression in participants and to raise awareness in
GPs. The findings also illustrate that interaction with the case manager provides older participants with an
opportunity to talk outside the primary care consultation, to deal with their low mood and to move forward.
The findings support the literature, which suggests that participation in a trial and active case management
can help to reduce stigma and may improve the care for mental health problems, such as depression,10,66
and that being invited to participate in a trial acted as a catalyst for older people to reflect on their feelings
and depression, which may not have been identified outside the trial setting.
Both GPs and participants may normalise depression and view it as an expected consequence of having
one or more chronic health conditions.12,67 GPs may be reluctant to address signs and symptoms of the
condition, partly because of the lack of treatment options for older depressed adults and the limited
consultation time in which to address the problem. Our results add to the evidence that there is insufficient
capacity within existing primary care for psychosocial support of older people with depression68 and that
older people may value a separate space to discuss their problems.
Strengths and weaknesses
This study explored multiple perspectives on the views and experiences of those receiving and delivering a
psychosocial intervention for depression within a collaborative care framework. Although we aimed to
interview people across a wide demographic range, we found it difficult to recruit GPs and participants from
areas of low SES. We believe this may be a reflection of the demographics of trial participation, as people
with higher levels of deprivation are less likely to respond to invitation. This means that the group of CASPER
plus trial participants we recruited from was disproportionately less deprived than the general population.
Similarly, GPs in areas of lower SES were less likely to respond to an invitation to be interviewed. In addition,
ethnicity was poorly recorded at GP practices so we were unable to sample on this basis.
DOI: 10.3310/hta21670 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 67
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bosanquet et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79
Conclusions
Depression is commonly hidden and coexists with physical conditions that are prioritised by both participants
and GPs. Being invited to participate in a trial about depression seems to facilitate acceptance of symptoms
and may reduce stigma and allow older people to disclose their feelings, name the problem and access
care. Older people value an opportunity to talk outside the GP consultation. The findings from this nested
qualitative study suggest that a psychosocial intervention delivered by a case manager can provide a valuable
resource, which fills a gap in the care of older people with depression. Behavioural activation encourages
increased activity and social contact, which may improve physical health symptoms as well as mood.
Furthermore, it can enable older people to ‘move on’ from depression, providing them with the tools to
manage their symptoms.
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Chapter 8 Discussion
The CASPER plus trial is, to our knowledge, the first large-scale evaluation of the clinical effectivenessand cost-effectiveness of collaborative care in older adults with case-level depression in the UK. The
area of research was one that was prioritised by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and was identified as a research priority in NICE guidelines on the
management of depression.7 We designed a collaborative care intervention suitable for older people
with clinical depression that could feasibly be delivered via expansion of psychological care by the IAPT
programme. In the CASPER plus trial outcomes were measured across a broad range of domains including
psychological well-being, quality of life, resilience and health-state utility. Important aspects of health
service resource use were also recorded. The CASPER plus trial included concurrent qualitative and
economic evaluations.
The main findings of the CASPER plus study in relation to (1) trial-based estimates of the clinical
effectiveness of collaborative care, (2) trial-based estimates of cost-effectiveness and (3) qualitative
examination of acceptability and use of collaborative care will now be discussed in turn.
Trial-based estimate of the clinical effectiveness of collaborative care for
subthreshold depression
A group of older adults with Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition Major
Depressive Disorder were recruited to the CASPER plus study. The mean age of the population was
72 years. There was a high prevalence of coexisting long-term health problems, such as diabetes, arthritis,
ischaemic heart disease or chronic respiratory illness.
When offered collaborative care, the majority of participants (83%) engaged with this telephone-based
intervention and the mean number of sessions was six.
At 4 months’ follow-up there was improvement over time in both groups in terms of depression severity
as measured by a commonly used measure of depression severity (the PHQ-9), but a greater level of
improvement was recorded in the collaborative care group. There was a statistically significant benefit for
collaborative care in terms of the primary outcome of depression severity at 4 months. The magnitude
of difference in favour of collaborative care at 4 months was 1.92 PHQ-9 score points (95% CI 0.85 to
2.99 score points; p < 0.001). This benefit for collaborative care was not sustained at 12 or 18 months.
The score difference at 4 months equates to a standard effect size of 0.34 and is in the range of the effect
size that the trial was powered to detect. This finding was robust to a range of sensitivity analyses.
An effect in reducing the prevalence of case-level depression at 4 months was also observed. At 4 months’
follow-up, 40% of participants in the collaborative care arm were found to be moderately to severely
depressed, compared with 55% in the usual-care group (odds ratio 2.18, 95% CI 1.36 to 3.51). By 12 and
18 months there was no effect for collaborative care.
When a number of secondary outcomes were analysed there was also a benefit for collaborative care.
There was a significant and sustained 4- and 12-month improvement in anxiety (as measured by the
GAD-7) and somatic complaints (as measured by the PHQ-15). Of note was the fact that common somatic
complaints among older people (such as pain, constipation and disrupted sleep patterns) were found to be
specifically improved in the collaborative care group compared with the usual-care group.
The population of older adults had important limitations of function consistent with the high levels of
physical comorbidity, and this was reflected in low scores on the SF-12 PCS. Physical functioning was below
average adult physical health status (scores of < 50) for participants throughout the trial period, as would be
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expected in an older population; however, collaborative care had little impact on physical function.
Improvements and between-group differences were observed for the MCS of the SF-12 in favour of
collaborative care, and in line with changes on other psychological function scales. Improvements were also
noted for resilience, as measured by the CD-RISC2 measure at 12 months.
In summary, statistically significant improvements in depression severity were observed in favour of
collaborative care in both the short term (4 months) and the medium term (12 months) for secondary
outcomes of anxiety and somatisation.
Summary of trial-based estimates of the cost-effectiveness of
collaborative care
There was a concurrent cost-effectiveness analysis within the CASPER plus trial, and we were able to
derive utility-based estimates of quality of life alongside resource use derived from scrutiny of routinely
collected administrative data (GP databases and IAPT databases). Collaborative care was a relatively brief
intervention delivered by a low-intensity IAPT therapist. When all costs associated with a fully completed
episode of collaborative care were accounted for, the cost to the NHS was £495 per patient. Only around
half of the collaborative care participants completed six or more of the eight planned sessions and, when
the costs of collaborative care as may be delivered within a typical IAPT service were accounted for, the
cost was £198 per patient. There was a non-significant improvement in health-state utilities associated
with collaborative care compared with usual care (adjusted QALY gains = 0.019; p = 0.338). Resource use
was not substantially offset in the collaborative care group, with the total costs reduced by around £51 in
the collaborative care group. In the base-case analysis, the incremental cost-effectiveness of collaborative
care achieved gains at a cost of £26,010 per QALY. The probability that the incremental cost-effectiveness
of collaborative care was less than £20,000 per QALY was 39% and the probability that it fell below the
willingness-to-pay threshold of £30,000 per QALY was 55%. When participants who engaged with six or
more sessions were included in the analysis, the cost per QALY estimate fell to £9876 per QALY.
Summary of main findings from qualitative examination of acceptability
and uptake of collaborative care
The qualitative evaluation explored the perspectives of older people with depression being offered and
receiving treatment for depression within a collaborative care framework. It obtained multiple perspectives
on the understanding of depression and depression management in older people by investigating both
patient and professional views, which provided bottom-up evidence on the acceptability and practicality
of the intervention. This type of collaborative care represents an innovative treatment in the NHS, as it
involves the delivery of a psychological intervention by a novel mode of delivery (over the telephone).
The qualitative evaluation showed that the intervention was acceptable to a large proportion of
participants but that some did not engage with it. Some participants had misgivings about the potential
benefits of behaviourally based programmes. Some participants disliked certain aspects of behavioural
activation, such as the need to reflect and self-monitor. Others found the activity diaries and ‘homework’
difficult, requiring too much time and effort. However, case managers learned to adapt treatment and
tailor collaborative care to the individual, and this process improved as case managers gained experience.
The qualitative evaluation provided evidence that participants appreciated their personal relationship with
the case manager, who was able to facilitate communication with their GP as well as provide them with the
opportunity to talk, outside the clinical setting of the primary care consultation room.
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Discussion of main findings
The observed standard effect of 0.34 for the primary outcome represents a moderate effect size according
to criteria used to classify the magnitude of effect for psychological interventions.50 The effect size is
consistent with findings from systematic reviews of collaborative care, as summarised in a recent Cochrane
review,22 and is also of the same order of magnitude as that seen in UK trials of collaborative care for
working-age adults, such as those observed in the recently published CADET69 and also in the recently
completed CASPER trial for older people with lower-severity depression.29,30 The CASPER plus trial also
showed benefits across a range of secondary outcomes, and it was notable that there were improvements
in anxiety symptoms, somatoform symptoms and quality of life (mental domain as measured by the SF-12).
These benefits were seen in the short term (4 months) and were also sustained at 12 months for secondary
outcomes (but not for the outcome of depression severity). At 18 months’ follow-up there were no
discernible differences between groups.
The proportion of participants with case-level depression at 4 months was reduced among those who
received collaborative care. We note that other studies have found longer-term benefits of collaborative
care,70 including studies of collaborative care for older populations,16 but this finding was not replicated
in the CASPER plus trial. When we looked at the prescription of antidepressants in this population, we
noted that only a minority of participants were in receipt of any kind of antidepressant. The provision of
collaborative care had an impact on the prescription of antidepressants in the short term, with a doubling
of antidepressant prescriptions at 4 months’ follow-up, but this was not sustained at 12 months. It was
in the short term that the greatest benefits were apparent for collaborative care, and this is in line with
research which shows a strong relationship between antidepressant prescription rates and the magnitude
of benefit from collaborative care.21 Collaborative care is a complex intervention with multiple components
and it is, as yet, unclear how the different components of treatment relate to outcome both in the short
and longer term.
We noted from the rates of uptake of the intervention that the majority of participants (83%) engaged
well and completed a large number of planned sessions (median six out of eight planned sessions). The
qualitative evaluation of collaborative care pointed to aspects of the intervention that participants found
helpful. The initial appointment was face to face in order to establish a relationship between the case
manager and participant before continuing the sessions as telephone appointments. What was notable was
that participants were generally happy to receive collaborative care over the telephone, but that the initial
face-to-face meeting was felt to be important. There was some uncertainty whether or not a telephone
intervention would be acceptable to older people with depression. It was encouraging to find, from the
qualitative study and comments made to case managers, that this was seen by most people to be an
acceptable method of delivery. This is important for those who plan services or for therapists who may have
misgivings about the telephone-based mode of delivery of a psychosocial intervention. These results are in
line with our earlier study of the use of collaborative care for older people with subthreshold depression.
The evidence-supported psychological intervention at the centre of collaborative care in the CASPER plus
trial was behavioural activation.71 The psychological intervention was adapted for use in an older age group
at the developmental pilot phase of the CASPER and CASPER plus studies.49 A reduction in social isolation
is an important aspect of the intervention and much of the collaborative care for some participants was
focused around this. Although face-to-face contact with the case manager may have provided initial social
contact, it would only be in the short term. The case managers sought to reduce social isolation in the long
term by ascertaining a participant’s needs and preferences regarding social contact. Putting them in touch
with organisations, groups and individuals who could help them to increase their social network and
opportunities for interaction afforded them long-term benefits.
Case managers worked in a patient-centred way with each participant. There was also a significant use of
‘functional equivalence’. If the participant had identified an activity that they had been forced to stop doing
in the past, the way they had managed this could be used to illustrate the principle of functional equivalence.
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We also found that a small but significant minority of participants did not engage with a psychologically
based intervention. Nevertheless, it is notable that the uptake of collaborative care in the context of the
CASPER plus trial was broadly in line with (or higher than) a range of primary care-based low-intensity
interventions, such as those offered by IAPT services.72 The results of the CASPER plus trial, therefore,
add to an emerging evidence base that behavioural activation is effective for older adults.73
The results of the economic evaluation provide robust evidence relating to cost-effectiveness of collaborative
care for older people with depression. The CASPER plus trial provides estimates of the overall costs of the
intervention, which will be useful for those who may plan services. Within a range of scenarios, collaborative
care was found to provide QALY gains within a range of willingness-to-pay thresholds. There are relatively
few cost-effectiveness analyses of collaborative care from the perspective of the UK health-care system.
The randomised economic research worldwide generally shows that collaborative care is cost-effective.23 The
results of the CASPER plus trial add to emerging evidence of cost-effectiveness of collaborative care in the
UK. The economic results of the CASPER trial are broadly in line with the only other UK cost-effectiveness
analysis of collaborative care (reporting results of cost per QALY of £14,248 in working-age adults69) and also
replicate findings from large-scale US studies of collaborative care in older people.74
The most recent NICE guidance7 in relation to the management of depression was unable to recommend
collaborative care in this population, and the CASPER plus trial represents a significant advance in the
development of randomised knowledge in this area. This research knowledge will be helpful to those who
formulate guidelines in the management of depression, including the next iteration of NICE guidelines
in the care of depression and the care of psychological problems in the context of long-term physical
ill health.8
Limitations
The results of the CASPER plus trial need to be considered in the light of limitations that emerged during
the study. First, regarding trial design, blinding was not feasible, which means there was potential for
contamination at the GP level as well as at an individual level. In addition, many participants would be
living geographically close to one another in the same catchment area and in a population of that age it is
reasonable to assume that some participants would know each other and share their trial experiences. In
either case, we expect that contamination would result in additional benefits to control arm participants,
thereby reducing any group differences during follow-up and rendering our result a conservative estimate
of the treatment effect. In addition, relating to study design, participants were recruited by means of
postal screening of general practice lists, which included patients without a diagnosis of depression;
therefore, participants who were identified with depression may not have necessarily presented in usual
GP care. Therefore, the results of the CASPER plus trial may not automatically apply to older people who
screen-positive for depression in the context of primary care attendance or physical health checks for
older people.
Retention and differential attrition between the trial arms was a further limitation. Although follow-up rates
were high overall (80% at 4 months), and exceeded the expected trial retention on which the trial was
powered, there was a higher rate of attrition in the collaborative care arm compared with the usual-care
arm (25% in the collaborative care arm and 14% in the usual-care arm). This was in part accounted for by a
number of participants who disengaged from the collaborative care intervention and fully withdrew from
the trial at the same time. It remains possible, however, that the patients who withdrew from the trial and
did not provide outcome data may have presented a very different outcome profile to those who continued,
which may have biased the treatment effect. Based on the very similar baseline characteristics between
randomised patients and those available for the primary analysis, as well as our exploration of the impact
of missingness, such bias appears less likely. In addition, results of statistical tests relating to the trial’s
secondary outcomes should be interpreted as exploratory, as no adjustments for multiple testing were made
for these analyses.
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Another limitation relates to the trial recruitment method whereby participants were invited by their
general practices. This resulted in a large number of patients aged ≥ 65 years being invited from each
practice, although with relatively low consent rates (mean average 17%), which reduces generalisability.
This will have produced a selective sample; however, given that everyone who was invited had equal
opportunity to take part and participation was based on patient choice, it was a pragmatic method that
would produce similar results if the intervention was rolled out in practice.
Finally, we did not formally assess cognitive impairment. Instead, we asked GPs to screen out any
participants with known marked cognitive impairment. For randomised participants, if cognitive
impairment was suspected, we informed the GP of this, but we also sought to engage the participant in
the intervention for those who were allocated to collaborative care. We do not know the level of cognitive
impairment in the current study and the extent to which its presence moderates treatment outcomes.
There were also some important limitations to note on performing the cost-effectiveness analysis. First,
although data were collected on secondary care and social care use at each follow-up time point, the data
were collected via self-report questionnaires, which were not deemed to be accurate enough data sets
to conduct the cost-effective analysis. Therefore, only objective data, obtained from GP administrative
systems, informed the cost analysis. Second, it was not possible to provide a reading of participant
resource use at baseline, as the study design had approvals to collect health resource use data only from
the randomisation date to the study completion date. The baseline was, therefore, outside the period in
which participants had consented to provide information.
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Chapter 9 Conclusions
There is currently little provision of psychosocial care for older adults with depression. Depression isrelatively common among older people and is often associated with long-term health conditions.
The CASPER plus trial represents the largest UK trial-based evaluation of a psychosocial intervention for
this group. It was found to be effective across a range of depression, psychological and quality-of-life
outcomes in the short term. Collaborative care resulted in accelerated improvements in clinical depression
at 4 months’ follow-up. The effects were less apparent but still present at 12 months’ follow-up. The
longer-term benefits at 18 months had disappeared when there was no discernible difference between
those who received collaborative care and those who received usual care. The intervention was delivered
over the telephone by low-intensity psychological therapists, such as those who work in NHS IAPT services.
Qualitative research showed this to be an acceptable and valued treatment by the majority of people who
were offered collaborative care. A concurrent economic evaluation found that the intervention resulted in
gains in QALYs at a cost threshold that is acceptable to the UK health system.
Implications for health care
Collaborative care was acceptable for many of the older adults with depression and could readily be
delivered over the telephone, following a first face-to-face meeting. However, although there is, at the
policy level, a clearly identified aim to increase uptake of IAPT services in older adults,75 this has not as yet
translated to changes in practice. For example, the most recent annual report on the use of IAPT services76
indicates that, of over 1,250,000 referrals to IAPT in April 2014 to March 2015, only 79,000 were adults
aged ≥ 65 years (6.4%). The most recent ONS data (2016)77 indicate that 17.7% of the UK population
is aged ≥ 65 years. As a result, it may be worth exploring other methods of delivering the intervention,
such as through nurses who conduct comorbidity checks or healthy-living workers. The evaluation of the
feasibility and acceptability of delivery by these other professional groups should be a research priority.
This may include nurses but should also include any other professional or paraprofessional group that may
allow the treatment to be delivered at scale. Certainly, health-care providers will need to ensure that IAPT
services have sufficient capacity to enable the provision of collaborative care for older people with depression.
Collaborative care proved clinically effective at improving depression scores and reducing the incidence of
case-level depression for older people with depression. The small to moderate effect size of 0.34 may
represent limited change at the individual level but it has substantial impact at the population level.50
Moreover, the robust cost-effectiveness estimates on using collaborative care to treat depression were
cost-effective under conventional willingness-to-pay thresholds. This study has shown that collaborative care
represents a feasible and effective means of treating depression in primary care. Depression is a relatively
common condition, affecting about 5% of older adults. The CASPER plus trial evidence could be used by
policy-makers and primary care to improve services and reduce the disease burden of our ageing population.
A final implication for health care relates to the higher drop-out rate from the collaborative care arm and what
this would mean for take-up of the intervention in the real world. Some participants found the intervention
intrusive and felt that talking and thinking about their symptoms made them feel uncomfortable. This may
signal a potential problem if collaborative care were offered in NHS services. As with all psychological services,
this type of intervention will not necessarily suit everyone and care should be taken to ascertain the likelihood
of this being the case prior to any referral to such a service. Coupled with this is the finding that the greatest
level of benefit in relation to costs was found for those who engaged with the intervention for more than
five sessions.
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Recommendations for research
Analysis of the CASPER plus trial results highlighted a number of future research priorities listed below in
order of perceived importance.
l First, a large proportion of the CASPER plus trial had at least one long-term physical health condition,
and, although there were some improvements in function and quality of life among participants, there
remains little evidence on the clinical effectiveness and cost-effectiveness of collaborative care at
treating comorbidities. Evidence from a US trial78 that tested collaborative care for the treatment of
comorbid depression and diabetes mellitus found that it helped improve depression care and outcomes
but did not result in improved glycaemic control. Future trials of collaborative care are therefore
required to investigate the clinical effectiveness and cost-effectiveness of collaborative care at
improving physical and mental health outcomes on older adults with multimorbidities. Given the
complexities associated with managing multiple conditions and the increasing number of older adults
in our population as it ages, future research in this area is critical. There may also be value in examining
the effect of collaborative care in the presence of cognitive impairment.
l Second, many patients in the collaborative care arm discontinued treatment or dropped out of the trial.
Further qualitative and quantitative work should explore reasons for this. This should also include
maximising the acceptability and effectiveness of collaborative care for this population and identifying
the most appropriate target population for the intervention.
l Third, translating the research findings into clinical practice will be challenging and would benefit from
further research. This relates both to enabling capacity to deliver the intervention to patients and to be
able to target it at those most likely to complete the process and make use of the resource. Future
research should also evaluate the feasibility and effectiveness of collaborative care when the case
manager is not someone with specific training in mental health. This may include nurses working in
primary care but should also include other professionals.
l Fourth, collaborative care is a complex intervention and there is, as yet, little information on how
different components relate to outcomes both in the short and longer term. Further work is needed to
establish the relationship between treatment components and outcomes.
l Finally, this was a brief intervention and benefit was truncated beyond 12 months. Future research
should be conducted to establish how minimal interventions may be offered to ensure that the early
gains from treatment are sustained. Trials of 12-month top-up sessions for collaborative care (delivered
by telephone) are needed. This would allow the longer term impact of collaborative care and its impact
on relapse rates to be investigated. Depression is a recurrent disorder and it would be useful to judge
longer term impact on relapse and the prevention of future case-level depression.
CONCLUSIONS
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Appendix 1 Regulatory approvals
TABLE 51 Regulatory approvals
Trust Research and development approval granted
NHS East Riding of Yorkshire 18 November 2010
NHS Hull 6 January 2011
NHS North Yorkshire and York 18 November 2010
NHS Leeds 29 September 2011
NHS County Durham 21 October 2011
NHS Darlington 21 October 2011
NHS Middlesbrough 21 October 2011
NHS Stockton-on-Tees 21 October 2011
NHS Hartlepool 21 October 2011
NHS Redcar and Cleveland 21 October 2011
Northumberland Tyne and Wear NHS Foundation Trust 15 February 2013
NHS North of Tyne 5 March 2013
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Appendix 2 CollAborative care for Screen-Positive
EldeRs plus participant invite letter
 
 
 
 
<Patient name>       Our ref: <admin code> 
<Patient address1> 
<Patient address2>       
<Patient address3> 
<Patient postcode> 
 
<Date> 
 
Dear <Patient name> 
 
 
Invitation to help us with CASPER research project 
 
Would you like to help us? Our Practice is supporting research being carried out by the 
University of York.  They have asked us to send details of their study to all patients aged 
65 and over who are registered with our Practice. Are you willing to take part?   
 
This research is looking at the physical and mental health of people who are 65 and 
over.  It wants to find out if there is a better way of providing care for people who are 
feeling down in the dumps, or just fed up with life. In other words, people who are 
depressed. Is this new way going to be better than the way GPs care for their patients 
now? We don’t know yet, so we hope the results of this research will help us decide the 
best way to help you – help us help you! We hope that the study results will improve 
care for people who are finding life difficult. 
 
We are sending you an information leaflet with this letter.  It explains York University’s 
research in detail. It tells you about CASPER – what it is and what it does. There are 2 
forms: one yellow and one blue. Fill in the yellow consent form if you want to take part. 
Send it to the research team in the addressed envelope we have sent you. You don’t 
need a stamp. Fill in the blue form and send it back if you don’t want to take part. You 
don’t have to – it’s up to you. The care you get from your GP won’t be affected in any 
way if you can’t help.  
 
If you have any queries, please contact [local study co-ordinator name and institution] 
on [local phone number]. If there is no answer, leave a message on the answerphone 
and someone will call you back. 
 
Thank you for reading this letter. 
 
Yours sincerely 
 
[Lead GP signature and name] 
GP practice letter head 
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Appendix 3 CollAborative care for Screen-Positive
EldeRs plus participant consent form
  
 
 
                                                
If you wish to take part in the CASPER study, please place your initials in each of the boxes 
below, sign and date this form, and complete the questions overleaf.  Please return 
these forms in the pre-paid envelope provided.  If you (or a relative or friend) would like to 
ask more questions about this study before deciding whether to take part, please do not hesitate 
to contact [local researcher], the local study co-ordinator on [telephone number]. 
All the information on this form will be kept confidential and won’t be released to 
anyone outside the research team             
Please initial 
                              each box 
   
  
   
1. I confirm that I have read and understand the information sheet version 2.10  dated 
4th April 2014 for the above study and have had the opportunity to ask questions by 
phoning the contact number provided.  I agree to take part in the CASPER 
study. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, and without my medical care or legal rights being 
affected. 
3. I understand that sections of my health care records may be looked at by 
researchers from the University of York, and that information held by the NHS 
Information Centre and the NHS Central Register may be used to keep in touch with 
me and follow up my health status for the duration of the study.  
 
4. I understand that information, including my date of birth and postcode, to be shared 
with the NHS Information Centre, specifically for service auditing purposes. I give 
permission for these individuals to have access to my records.
 
5. I agree to my GP being informed of my participation in the study and of any health 
concerns the CASPER study team may become aware of during my participation. 
                                                    
Name of patient 
 
              /         / 
   Today’s Date 
 
 
Signature 
 
  
Your telephone number              
                          
  
 
 
 
 
 
 
 
 
□ Yes, please send me information about related studies       □ No, thank you 
 
□ Yes, please send me information about related studies       □ No, thank you 
<Patient name>                < Admin code> 
<Address1>       <NHS number> 
<Address2> 
<Address3>  
<Postcode> 
 
<Date of birth> <GP code>      <GP practice code>
PARTICIPANT CONSENT FORM 
Admin Code: 
 
INITIALS 
 
 
INITIALS  
 
 
INITIALS 
 
Your mobile number  Your email address 
Other research studies 
Researchers from the CASPER team would like to contact men and women who agree to take part in the 
main CASPER study to see if they would be interested in helping with other related studies – these are 
entirely optional. Please indicate if you would like to be sent information about related studies. 
 
INITIALS  
 
 
INITIALS  
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Appendix 4 CollAborative care for Screen-Positive
EldeRs plus decline form
  
       
 
 
We would find it really helpful to have a wide range of men and women over 
the age of 65 joining this study. 
  
However, we quite understand if you do not wish to take part.  If this is 
the case, we would be grateful if you could tell us the reason(s) why by placing 
a tick in as many boxes as apply to you from the list below:- 
 
I am not interested in taking part in this study 
 
 
 
I would not want to speak / see a case manager  
 
 
 
I feel too unwell to take part in this study        
 
 
 
The information sheet did not tell me enough about the study  
 
 
 
Other reason     
       
    
 
Please give more details here if you would like to:- 
 
 
 
 
 
 
 
 
It would be very helpful if you would be willing to give us some brief details 
about yourself.  We will not be able to identify you from this form, and 
we will not contact you again.  We will use the anonymous information that 
you provide to help us see if there are any differences between those who 
agree to take part and those who decline.  If you wish, please complete the 
background information questions overleaf, and return these forms in 
the pre-paid envelope provided.  Thank you very much. 
 
  
 
 
 
Admin code:   
 
DECLINE FORM 
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Appendix 5 CollAborative care for Screen-Positive
EldeRs plus participant information sheet
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Appendix 6 CollAborative care for Screen-Positive
EldeRs plus background information sheet
Admin code:  
  
Please answer the following questions: 
 
 
 
1. What is your date of birth?  
           
  day       month             year  
2. Are you? 
Male                        Female  
3 a) 
 
Over the past month have you been bothered by 
feeling down, depressed or hopeless? 
 
 
Yes No  
   b) Over the past month have you been bothered by 
having little or no interest or pleasure in doing 
things? 
 
Yes No  
 
4  
 
Have you fallen in the last 12 months? 
Yes No Can’t recall 
5. Are you a carer? Yes No  
6. Are you a smoker? 
 
 
Yes No Don’t know  
7. On average, do you drink 3 or more units of 
alcohol each day? (1½ pints of beer or 3 glasses of 
wine or 3 short measures of spirits)  
 
Yes No Don’t know 
8.  Do you experience any of the following health problems? (tick all that apply) 
 
 Diabetes 
 
 
Osteoporosis High blood 
pressure 
Rheumatoid 
arthritis 
Osteoarthitis 
 Stroke 
 
 
Cancer Respiratory 
conditions  
(e.g. COPD, 
asthma, 
bronchitis) 
Eye condition  
(e.g.cataract, 
glaucoma macular 
degeneration) 
Heart disease 
(e.g.heart  
attack, 
heart failure, 
angina) 
 Other 
 
 
Please state:   
9. Did your education continue after the minimum school leaving age? 
 
Yes No 
10. Do you have a degree or equivalent professional qualification? 
 
Yes No 
11. To which of these ethnic groups do you consider you belong? (Please tick one box) 
 
 White 
 
Asian or Asian British Black or Black British 
 Other ethnic group 
 
Please describe: 
 
  
 
BACKGROUND INFORMATION 
/ 1 9/
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Appendix 7 CollAborative care for Screen-Positive
EldeRs plus baseline questionnaire
CONFIDENTIAL
Baseline Questionnaire
Participant's trial ID number:
Date questionnaire sent:
Day Month Year
/ / 2 0
Funded by:
NIHR HTA code 08/19/04
ISRCTN 02202951
CASPER baseline qr v2.5 4Jan13
-
Organised by:
1836551920
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this study. The responses you give in this questionnaire
will help us find out which is the best way to improve mental well-being amongst those over the
age of 65.
Please answer ALL the questions. Although some of the questions may not seem relevant to
yourself or may appear similar, they do give us valuable information.
If you find it difficult to answer the question, please give the best answer you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross rather than a
tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you should place a
cross firmly in the box next to yes.
Yes
No
Do you drive a car?
If you are asked to write your answer, please do so by entering your answer in the box
provided, for example:
How old are you? 7 5 years
Please use a black or blue pen for all the questions.
Please do not use a pencil or any other coloured pen.
If you have any queries or problems completing this questionnaire please contact your local
study centre:
2108551923
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Please enter the date you are completing this questionnaire:
Day Month Year
/ / 2 0
SECTION 1
This section is about how you have been feeling over the last 2 weeks.
Answer each question by placing a cross in the box that best describes your answer.
1. Little interest or pleasure in doing things
Not at all Several days More than half the days Nearly every day
2. Feeling down, depressed, or hopeless
Not at all Several days More than half the days Nearly every day
3. Trouble falling or staying asleep, or sleeping too much
Not at all Several days More than half the days Nearly every day
4. Feeling tired or having little energy
Not at all Several days More than half the days Nearly every day
5. Poor appetite or overeating
Not at all Several days More than half the days Nearly every day
6. Feeling bad about yourself - that you are a failure or have let yourself or your family down
Not at all Several days More than half the days Nearly every day
7. Trouble concentrating on things, such as reading the newspaper or watching television
Not at all Several days More than half the days Nearly every day
8. Moving or speaking so slowly that other people could have noticed. Or the opposite - being
so fidgety or restless that you have been moving around a lot more than usual
Not at all Several days More than half the days Nearly every day
9. Thoughts that you would be better off dead, or of hurting yourself in some way
Not at all Several days More than half the days Nearly every day
4841551929
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1. Feeling nervous, anxious or on edge
Not at all Several days More than half the days Nearly every day
2. Not being able to stop or control worrying
Not at all Several days More than half the days Nearly every day
3. Worrying too much about different things
Not at all Several days More than half the days Nearly every day
4. Trouble relaxing
Not at all Several days More than half the days Nearly every day
5. Being too restless that it is hard to sit still
Not at all Several days More than half the days Nearly every day
6. Becoming easily annoyed or irritable
Not at all Several days More than half the days Nearly every day
7. Feeling afraid as if something awful might happen
Not at all Several days More than half the days Nearly every day
Over the last 2 weeks, how often have you been bothered by any of the following problems?
7095551923
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SECTION 2
This section is about any physical health problems you may be experiencing.
Please cross one box for each health problem.
During the past 4 weeks, how much have you been bothered by any of the following problems?
1. Stomach pains
Not bothered at all Bothered a little Bothered a lot
2. Back pain
Not bothered at all Bothered a little Bothered a lot
3. Pain in your arms, legs, or joints (e.g. knees, hips)
Not bothered at all Bothered a little Bothered a lot
4. Headaches
Not bothered at all Bothered a little Bothered a lot
5. Chest pain
Not bothered at all Bothered a little Bothered a lot
6. Dizziness
Not bothered at all Bothered a little Bothered a lot
7. Fainting spells
Not bothered at all Bothered a little Bothered a lot
1593551920
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10. Pain or problems during sexual intercourse
Not bothered at all Bothered a little Bothered a lot
11. Constipation, loose bowels, or diarrhoea
Not bothered at all Bothered a little Bothered a lot
12. Nausea, gas, or indigestion
Not bothered at all Bothered a little Bothered a lot
13. Feeling tired or having low energy
Not bothered at all Bothered a little Bothered a lot
14. Trouble sleeping
Not bothered at all Bothered a little Bothered a lot
9. Shortness of breath
Not bothered at all Bothered a little Bothered a lot
8. Feeling your heart pound or race
Not bothered at all Bothered a little Bothered a lot
9615551923
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SECTION 3
This section asks you about how you've been feeling.
Answer each question by placing a cross in the box that best describes your answer.
1a. Over the past month have you been bothered by feeling down, depressed or hopeless?
Yes No
1b. Over the past month have you been bothered by having little or no interest or pleasure
in doing things?
Yes No
I tend to bounce back after illness or hardship2a.
2b. I am able to adapt to change
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
9174551923
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1. In general, would you say your health is:
(please cross one box only)
Excellent Very Good Good Fair Poor
2. During a typical day does your health limit you in moderate activities, such as moving a
table, pushing a vacuum cleaner, bowling or playing golf? If so, how much?
(please cross one box only)
Yes, limited a lot Yes, limited a little No, not limited at all
3. During a typical day does your health limit you in climbing several flights of stairs?
If so, how much?
(please cross one box only)
Yes, limited a lot Yes, limited a little No, not limited at all
4. During the past 4 weeks, how much of the time have you accomplished less than you would
like in regular daily activities as a result of your physical health?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
5. During the past 4 weeks, how much of the time have you been limited in performing any kind
of work or other regular daily activities as a result of your physical health?
(please cross one box only)
6. During the past 4 weeks, how much of the time have you accomplished less than you would
have liked in your work or any other regular daily activities as a result of any emotional
problems (such as feeling depressed or anxious)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
SECTION 4
This section asks for your views about your health. This information will help us keep
track of how you feel and how well you are able to do your usual activities.
Answer each question by placing a cross in the box that best describes your answer.
2105551920
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7. During the past 4 weeks, how much of the time have you done work or other activities less
carefully than usual as a result of any emotional problems (such as feeling depressed or
anxious)?
(please cross one box only)
8. During the past 4 weeks, how much did pain interfere with your normal work (both
outside the home and housework)?
(please cross one box only)
9. This question is about how you feel and how things have been with you during the past 4
weeks. Please give the one answer that comes closest to the way you have been feeling.
How much during the past 4 weeks have you felt calm and peaceful ?
(please cross one box only)
10. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks did you have a lot of energy ?
(please cross one box only)
11. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks have you felt downhearted and depressed?
(please cross one box only)
12. During the past 4 weeks how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting friends, relatives etc.)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
Not at all A little bit Moderately Quite a bit Extremely
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
4219551928
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SECTION 5
This section also asks about your health in general.
By placing a cross in one box in each group below, please indicate which statements
best describes your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain/Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
1584551920
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SECTION 6
This section is about any medication you have been prescribed to improve your
mental well-being.
Are you currently prescribed any of the medicines listed below?
please list any other medications below
If you are prescribed one of these medicines but have stopped taking it for any reason
please place a cross in this box.
Dosulepin
Lofepramine
Citalopram
Mirtazapine
Sertraline
Fluoxetine
Paroxetine
Don’t know
Venlafaxine
Duloxetine
Trazodone
Other
1. 2.
3. 4.
5. 6.
7. 8.
9. 10.
Yes No
If 'Yes', please cross all that apply.
0370551922
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SECTION 7
This section asks about any health care you have received as a patient for any reason
(please do not include any visits to your GP practice).
Answer each question by placing a cross in the box that best describes your answer.
Attending hospital
1a. During the last 6 months have you stayed overnight in hospital?
Yes No Don't know
1b. If 'Yes', On how many separate occasions did you stay overnight in hospital?
Please provide some details for each occasion you stayed in hospital (e.g. hip replacement, fall).
(if you have stayed more than 2 occasions, we will contact you for further details)
1c. First hospital visit
After your hospital visit were you:1d. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
1e. Second hospital visit
After your hospital visit were you:1f. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
(go to 2a)
4973551925
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Other visits to hospital
2a. Have you attended Accident and Emergency in the last 6 months?
Yes No Don't know
2b. If 'Yes', how many times have you attended Accident and Emergency in the last 6
months?
3a. Have you attended Hospital Outpatients in the last 6 months?
Yes No Don't know
3b. If 'Yes', how many times have you attended Hospital Outpatients in the last 6
months?
4a. Have you attended hospital as a day case/procedure patient in the last 6 months?
Yes No Don't know
4b. If 'Yes', how many times have you attended hospital as a day case/procedure in
the last 6 months?
NHS transport services
5a. Have you used a '999' emergency ambulance in the last 6 months?
Yes No Don't know
5b. If 'Yes', how many times have you used a '999' emergency ambulance in the last
6 months?
6a. Have you used the Patient Transport Service in the last 6 months?
Yes No Don't know
6b. If 'Yes', how many times have you used the Patient Transport Service in the last 6
months?
Other NHS services
7a. Have you gone to an NHS Walk-in Centre in the last 6 months?
Yes No Don't know
7b. If 'Yes', how many times have you been to an NHS Walk-in Centre in the last 6
months?
(go to 3a)
(go to 4a)
(go to 5a)
(go to 6a)
(go to 7a)
(go to 8a)
3863551922
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Support services
9a. Do you receive any home help?
Yes No Don't know
9b. Thinking about the last 6 months, of these how many months did you have home help?
(please count any month where you have had a visit)
0 months 1 month 2 months 3 months 4 months 5 months 6 months
9c. Thinking about the last 6 months, typically, how many times a week did home help visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
10a. Does a care worker visit you at home?
Yes No Don't know
10b. Thinking about the last 6 months, of these how many months did a care worker visit you
at home? (please count any month where you have had a visit)
0 months 1 month 2 months 3 months 4 months 5 months 6 months
10c. Thinking about the last 6 months, typically, how many times a week did a care worker visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
8a. Have you called NHS Direct (the NHS telephone helpline) in the last 6 months?
Yes No Don't know
8b. If 'Yes', how many times have you called NHS Direct (the NHS telephone helpline)
in the last 6 months?
(go to 9a)
(go to 10a)
(go to 11a)
8733551923
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12a. Do you go to any community centres?
Yes No Don't know
12b. Thinking about the last 6 months, typically, how many times a week do you go to a
community centre?
0 1-2 2-3 3-4 4+
12c. Which community centres do you attend?
11a. Do you use meals on wheels?
Yes No Don't know
11b. Thinking about the last 6 months, of these how many months did you use meals on
wheels? (please count any month where you have had a visit)
0 months 1 month 2 months 3 months 4 months 5 months 6 months
11c. Thinking about the last 6 months, typically, how many times a week did you use meals on
wheels?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
(go to 12a)
2699551928
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SECTION 8
This section is about your views on how well you understood the different aspects of the
CASPER Study before you signed the consent form.
Each of the 10 questions below relates to a different aspect. Answer each question by
circling the number that best describes your answer
For example:
If you didn't understand them at all, please circle 1.
If you understood it very well, please circle 5.
If you understand it somewhat, please circle a number between 1 and 5.
1. What the researchers are
trying to find out in the study
1 2 3 4 5
I didn't
understand
this at all
I understood
this very well
2. How long you will be in the
study
1 2 3 4 5
3. The treatments and
procedures you will undergo
1 2 3 4 5
4. The possible risks and
discomforts of participating
in the study
1 2 3 4 5
5. The possible benefits to you
of participating in the study
1 2 3 4 5
6. How your participation in
this study may benefit
future patients
1 2 3 4 5
7. The effects of the study on
the confidentiality of your
medical records
1 2 3 4 5
8. Whom you should contact ifyou have questions or
concerns about the study
1 2 3 4 5
9. The fact that participation in
the study is voluntary
1 2 3 4 5
10. Overall, how well did youunderstand the study when
you signed the consent form?
1 2 3 4 5
1228551925
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SECTION 9
This final section is a list of important life events. For each life event please circle 'Yes' if
you have experienced that life event over the last year and 'No' if you have not. For
those that you have experienced, please also indicate the date that the event occurred
with as much accuracy as you can.
Life event Y / N
Timing
Month / Year
You yourself suffered a serious illness,
injury or an assault
A serious illness, injury or assault
happened to a close relative
A close family friend or another relative
(niece, cousin, grandchild) died
Your child, spouse or parent died
You had a separation due to marital
difficulties
You broke off a steady relationship
You became unemployed or you were
seeking work unsuccessfully for more
than one month
You had a serious problem with a close
friend, neighbour or relative
You were sacked from your job
You had a major financial crisis
You had problems with the police and a
court appearance
Something you valued was lost or stolen
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
Yes No /
2716551928
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If you have any general comments about the study, or this questionnaire, please write
them below.
Thank you for completing this questionnaire.
Please return it in the pre-paid envelope provided.
1749551923
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Appendix 8 Exploring risk in research interviews
assessment form
 
Exploring Risk in Research Interviews 
 
Participant ID code:      PHQ-9 Score: 
 
PHQ-9 probing question: “Can you tell me more about why you answered (several days* / more than half the days* /
nearly every day*delete)  to ‘Thoughts that you would be better off dead, or of hurting yourself in some way’?” 
Details of disclosed thoughts (please record verbatim as far as possible)  
 
Plans 
1. Do you know how you would kill yourself?  
If Yes – details 
 
 
 
 
Yes / No 
2. Have you made any actual plans to end your life?  
If Yes – details 
 
 
 
Yes / No 
Actions 
3. Have you made any actual preparations to kill yourself?  
If Yes – details 
 
 
 
 
Yes / No 
4. Have you ever attempted suicide in the past? 
If Yes – details 
 
 
 
Yes / No 
Prevention 
5. Is there anything stopping you killing or harming yourself at the moment?  
If Yes – details 
 
 
 
 
Yes / No 
6. Do you feel that there is any immediate danger that you will harm or kill yourself?  
If Yes – details 
 
 
 
Yes / No 
 
Researcher name:  
Researcher signature:         Date: 
 
 
 
Participant Suicide Intention Form 
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The participant below has expressed thoughts of suicidal intent / self-harm on the PHQ-9 of a 
questionnaire or during their diagnostic interview. 
 
Participant ID code:   
 
 
 
Risk of Suicide / Self-harm identified from 
 
Question 9 of PHQ-9  on a questionnaire 
 
 
 
3 (nearly every day) 
 
 
2 (more than half the days) 
 
 
1 (several days) 
 
 
Question 9 of PHQ-9  during diagnostic interview 
 
 
3 (nearly every day) 
 
 
2 (more than half the days) 
 
 
1 (several days)  
Question 3g of MINI  during diagnostic interview ‘Yes’ to past two weeks (not to past 
episode) 
 
 
 
 
Summary of how procedure was enacted 
 
 
 
___________________________________________________________________ 
 
Researcher nam 
 
 
 
 
Researcher name: 
Researcher signature:      Date: 
 
 
Local clinical lead name: 
Local clinical lead signature:     Date: 
(Which clinician gave advice, what advice was given, was risk judged as passive or active? If advised to contact GP – name 
of practice, name of GP spoken to, date etc.) 
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Appendix 9 CollAborative care for Screen-Positive
EldeRs plus 4-month follow-up questionnaire
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CONFIDENTIAL
Four Month Follow-up Questionnaire
Participant's trial ID number:
Date questionnaire sent:
     Day               Month                      Year
/ / 2 0
Funded by:
NIHR HTA code 08/19/04
ISRCTN 02202951
CASPER  4mth qr v2.3  8Feb12
-
Organised by:
5383130485
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this study.  The responses you give in this questionnaire
will help us find out which is the best way to improve mental well-being amongst those over the
age of 65.
Please answer ALL the questions. Although some of the questions may not seem relevant to
yourself or may appear similar, they do give us valuable information.
If you find it difficult to answer the question, please give the best answer you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross rather than a
tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you should place a
cross firmly in the box next to yes.
Yes
No
Do you drive a car?
If you are asked to write your answer, please do so by entering your answer in the box
provided, for example:
How old are you? 7 5 years
Please use a black or blue pen for all the questions.
Please do not use a pencil or any other coloured pen.
If you have any queries or problems completing this questionnaire please contact your local
study centre:
5178130487
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Please enter the date you are completing this questionnaire:
     Day               Month                      Year
/ / 2 0
SECTION 1
This section is about how you have been feeling over the last 2 weeks.
Answer each question by placing a cross in the box that best describes your answer.
1. Little interest or pleasure in doing things
Not at all Several days More than half the days Nearly every day
2. Feeling down, depressed, or hopeless
Not at all Several days More than half the days Nearly every day
3. Trouble falling or staying asleep, or sleeping too much
Not at all Several days More than half the days Nearly every day
4. Feeling tired or having little energy
Not at all Several days More than half the days Nearly every day
5. Poor appetite or overeating
Not at all Several days More than half the days Nearly every day
6. Feeling bad about yourself - that you are a failure or have let yourself or your family down
Not at all Several days More than half the days Nearly every day
7. Trouble concentrating on things, such as reading the newspaper or watching television
Not at all Several days More than half the days Nearly every day
8. Moving or speaking so slowly that other people could have noticed. Or the opposite - being
so fidgety or restless that you have been moving around a lot more than usual
Not at all Several days More than half the days Nearly every day
9. Thoughts that you would be better off dead, or of hurting yourself in some way
Not at all Several days More than half the days Nearly every day
7866130483
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1. Feeling nervous, anxious or on edge
Not at all Several days More than half the days Nearly every day
2. Not being able to stop or control worrying
Not at all Several days More than half the days Nearly every day
3. Worrying too much about different things
Not at all Several days More than half the days Nearly every day
4. Trouble relaxing
Not at all Several days More than half the days Nearly every day
5. Being too restless that it is hard to sit still
Not at all Several days More than half the days Nearly every day
6. Becoming easily annoyed or irritable
Not at all Several days More than half the days Nearly every day
7. Feeling afraid as if something awful might happen
Not at all Several days More than half the days Nearly every day
Over the last 2 weeks, how often have you been bothered by any of the following problems?
7572130487
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SECTION 2
This section is about any physical health problems you may be experiencing.
Please cross one box for each health problem.
During the past 4 weeks, how much have you been bothered by any of the following problems?
1. Stomach pains
Not bothered at all Bothered a little Bothered a lot
2. Back pain
Not bothered at all Bothered a little Bothered a lot
3. Pain in your arms, legs, or joints (e.g. knees, hips)
Not bothered at all Bothered a little Bothered a lot
4. Headaches
Not bothered at all Bothered a little Bothered a lot
5. Chest pain
Not bothered at all Bothered a little Bothered a lot
6. Dizziness
Not bothered at all Bothered a little Bothered a lot
7. Fainting spells
Not bothered at all Bothered a little Bothered a lot
8. Feeling your heart pound or race
Not bothered at all Bothered a little Bothered a lot
9. Shortness of breath
Not bothered at all Bothered a little Bothered a lot
4665130487
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10. Pain or problems during sexual intercourse
Not bothered at all Bothered a little Bothered a lot
11. Constipation, loose bowels, or diarrhoea
Not bothered at all Bothered a little Bothered a lot
12. Nausea, gas, or indigestion
Not bothered at all Bothered a little Bothered a lot
13. Feeling tired or having low energy
Not bothered at all Bothered a little Bothered a lot
14. Trouble sleeping
Not bothered at all Bothered a little Bothered a lot
I tend to bounce back after illness or hardship1a.
1b. I am able to adapt to change
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
SECTION 3
This section asks you about how you've been feeling.
Answer each question by placing a cross in the box that best describes your answer.
2127130488
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1. In general, would you say your health is:
(please cross one box only)
Excellent Very Good Good Fair Poor
2. During a typical day does your health limit you in moderate actvities, such as moving a
table, pushing a vacuum cleaner, bowling or playing golf? If so, how much?
(please cross one box only)
Yes, limited  a lot Yes, limited a little No, not limited at all
3. During a typical day does your health limit you in climbing several flights of stairs?
If so, how much?
(please cross one box only)
Yes, limited  a lot Yes, limited a little No, not limited at all
4. During the past 4 weeks, how much of the time have you accomplished less than you would
like in regular daily activities as a result of your physical health?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
5. During the past 4 weeks, how much of the time have you been limited in performing any
kind of work or other regular daily activities as a result of your physical health?
(please cross one box only)
6. During the past 4 weeks, how much of the time have you accomplished less than you
would have liked in your work or any other regular daily activities as a result of any
emotional problems (such as feeling depressed or anxious)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
SECTION 4
This section asks for your views about your health. This information will help us keep
track of how you feel and how well you are able to do your usual activities.
Answer each question by placing a cross in the box that best describes your answer.
5006130487
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7. During the past 4 weeks, how much of the time have you done work or other activities less
carefully than usual as a result of any emotional problems (such as feeling depressed or
anxious)?
(please cross one box only)
8. During the past 4 weeks, how much did pain interfere with your normal work (both
outside the home and housework)?
(please cross one box only)
9. This question is about how you feel and how things have been with you during the past 4
weeks. Please give the one answer that comes closest to the way you have been feeling.
How much during the past 4 weeks have you felt calm and peaceful ?
(please cross one box only)
10. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks did you have a lot of energy ?
(please cross one box only)
11. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks have you felt downhearted and depressed?
(please cross one box only)
12. During the past 4 weeks how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting friends, relatives etc.)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
Not at all A little bit Moderately Quite a bit Extremely
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
1417130489
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SECTION 5
This section also asks about your health in general.
By placing a cross in one box in each group below, please indicate which statements
best describes your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain/Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
9366130480
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SECTION 6
This section is about any medication you have been prescribed to improve your mental
well-being.
Are you currently prescribed any of the medicines listed below?
please list any other medications below
If you are prescribed one of these medicines but have stopped taking it for any reason
please place a cross in this box.
Dosulepin
Lofepramine
Citalopram
Mirtazapine
Sertraline
Fluoxetine
Paroxetine
Don’t know
Venlafaxine
Duloxetine
Trazodone
Other
1. 2.
3. 4.
5. 6.
7. 8.
9. 10.
Yes No
If 'Yes', please cross all that apply.
2774130486
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SECTION 7
This final section is about any health care you have received as a patient for any
reason (please do not include any visits to your GP practice).
Answer each question by placing a cross in the box that best describes your answer.
Attending hospital
1a. During the last 4 months have you stayed overnight in hospital?
Yes No Don't know
1b. On how many separate occasions did you stay overnight in hospital?
Please provide some details for each occasion you stayed in hospital (e.g. hip replacement, fall).
(If you have stayed more than 2 occasions, we will contact you for further details)
1c. First hospital visit
After your hospital visit were you:1d. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
1e. Second hospital visit
After your hospital visit were you:1f. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
(go to 2a)
0144130485
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Other visits to hospital
2a. Have you attended Accident and Emergency in the last 4 months?
Yes No Don't know
2b. If 'Yes', how many times have you attended Accident and Emergency in the last 4
months?
3a. Have you attended Hospital Outpatients in the last 4 months?
Yes No Don't know
3b. If 'Yes', how many times have you attended Hospital Outpatients in the last 4
months?
4a. Have you attended hospital as a day case/procedure patient in the last 4 months?
Yes No Don't know
4b. If 'Yes', how many times have you attended hospital as a day case/procedure in
the last 4 months?
NHS transport services
5a. Have you used a '999' emergency ambulance in the last 4 months?
Yes No Don't know
5b. If 'Yes', how many times have you used a '999' emergency ambulance in the last 4
months?
6a. Have you used the Patient Transport Service in the last 4 months?
Yes No Don't know
6b. If 'Yes', how many times have you used the Patient Transport Service in the last 4
months?
Other NHS services
7a. Have you gone to an NHS Walk-in Centre in the last 4 months?
Yes No Don't know
7b. If 'Yes', how many times have you been to an NHS Walk-in Centre in the last 4
months?
(go to 3a)
(go to 4a)
(go to 5a)
(go to 6a)
(go to 7a)
(go to 8a)
1234130486
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TSupport services9a. Do you receive any home help?Yes No Don't know9b. Thinking about the last 4 months, of these how many months did you have home help?
(please count any month where you have had a visit)
0 months 1 month 2 months 3 months 4 months
9c. Thinking about the last 4 months, typically, how many times a week did home help visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
10a. Does a care worker visit you at home?
Yes No Don't know
10b. Thinking about the last 4 months, of these how many months did a care worker visit you
at home? (please count any month where you have had a visit)
0 months 1 month 2 months 3 months 4 months
10c. Thinking about the last 4 months, typically, how many times a week did a care worker visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
8a. Have you called NHS Direct (the NHS telephone helpline) in the last 4 months?
Yes No Don't know
8b. If 'Yes', how many times have you called NHS Direct (the NHS telephone helpline)
in the last 4 months?
(go to 9a)
(go to 10a)
(go to 11a)
1710130485
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12a. Do you go to any community centres?
Yes No Don't know
12b. Thinking about the last 4 months, typically, how many times a week do you go to a
community centre?
0 1-2 2-3 3-4 4+
12c. Which community centres do you attend?
11a. Do you use meals on wheels?
Yes No Don't know
11b. Thinking about the last 4 months, of these how many months did you use meals on
wheels? (please count any month where you have had a visit)
0 months 1 month 2 months 3 months 4 months
11c. Thinking about the last 4 months, typically, how many times a week did you use meals on
wheels?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
(go to 12a)
3872130486
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If you have any general comments about the study, or this questionnaire, please write
them below.
Thank you for completing this questionnaire.
Please return it in the pre-paid envelope provided.
2521130486
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CONFIDENTIAL
Twelve Month Follow-up Questionnaire
Participant's trial ID number:
Date questionnaire sent:
     Day               Month                      Year
/ / 2 0
Funded by:
NIHR HTA code 08/19/04
ISRCTN 02202951
CASPER  12mth qr v2.3  8Feb12
-
Organised by:
0225581328
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this study.  The responses you give in this questionnaire
will help us find out which is the best way to improve mental well-being amongst those over the
age of 65.
Please answer ALL the questions. Although some of the questions may not seem relevant to
yourself or may appear similar, they do give us valuable information.
If you find it difficult to answer the question, please give the best answer you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross rather than a
tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you should place a
cross firmly in the box next to yes.
Yes
No
Do you drive a car?
If you are asked to write your answer, please do so by entering your answer in the box
provided, for example:
How old are you? 7 5 years
Please use a black or blue pen for all the questions.
Please do not use a pencil or any other coloured pen.
If you have any queries or problems completing this questionnaire please contact your local
study centre:
6847581324
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Please enter the date you are completing this questionnaire:
     Day               Month                      Year
/ / 2 0
SECTION 1
This section is about how you have been feeling over the last 2 weeks.
Answer each question by placing a cross in the box that best describes your answer.
1. Little interest or pleasure in doing things
Not at all Several days More than half the days Nearly every day
2. Feeling down, depressed, or hopeless
Not at all Several days More than half the days Nearly every day
3. Trouble falling or staying asleep, or sleeping too much
Not at all Several days More than half the days Nearly every day
4. Feeling tired or having little energy
Not at all Several days More than half the days Nearly every day
5. Poor appetite or overeating
Not at all Several days More than half the days Nearly every day
6. Feeling bad about yourself - that you are a failure or have let yourself or your family down
Not at all Several days More than half the days Nearly every day
7. Trouble concentrating on things, such as reading the newspaper or watching television
Not at all Several days More than half the days Nearly every day
8. Moving or speaking so slowly that other people could have noticed. Or the opposite - being
so fidgety or restless that you have been moving around a lot more than usual
Not at all Several days More than half the days Nearly every day
9. Thoughts that you would be better off dead, or of hurting yourself in some way
Not at all Several days More than half the days Nearly every day
9912581320
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1. Feeling nervous, anxious or on edge
Not at all Several days More than half the days Nearly every day
2. Not being able to stop or control worrying
Not at all Several days More than half the days Nearly every day
3. Worrying too much about different things
Not at all Several days More than half the days Nearly every day
4. Trouble relaxing
Not at all Several days More than half the days Nearly every day
5. Being too restless that it is hard to sit still
Not at all Several days More than half the days Nearly every day
6. Becoming easily annoyed or irritable
Not at all Several days More than half the days Nearly every day
7. Feeling afraid as if something awful might happen
Not at all Several days More than half the days Nearly every day
Over the last 2 weeks, how often have you been bothered by any of the following problems?
9311581323
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SECTION 2
This section is about any physical health problems you may be experiencing.
Please cross one box for each health problem.
During the past 4 weeks, how much have you been bothered by any of the following problems?
1. Stomach pains
Not bothered at all Bothered a little Bothered a lot
2. Back pain
Not bothered at all Bothered a little Bothered a lot
3. Pain in your arms, legs, or joints (e.g. knees, hips)
Not bothered at all Bothered a little Bothered a lot
4. Headaches
Not bothered at all Bothered a little Bothered a lot
5. Chest pain
Not bothered at all Bothered a little Bothered a lot
6. Dizziness
Not bothered at all Bothered a little Bothered a lot
7. Fainting spells
Not bothered at all Bothered a little Bothered a lot
8. Feeling your heart pound or race
Not bothered at all Bothered a little Bothered a lot
9. Shortness of breath
Not bothered at all Bothered a little Bothered a lot
3379581321
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10. Pain or problems during sexual intercourse
Not bothered at all Bothered a little Bothered a lot
11. Constipation, loose bowels, or diarrhoea
Not bothered at all Bothered a little Bothered a lot
12. Nausea, gas, or indigestion
Not bothered at all Bothered a little Bothered a lot
13. Feeling tired or having low energy
Not bothered at all Bothered a little Bothered a lot
14. Trouble sleeping
Not bothered at all Bothered a little Bothered a lot
I tend to bounce back after illness or hardship1a.
1b. I am able to adapt to change
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
SECTION 3
This section asks you about how you've been feeling.
Answer each question by placing a cross in the box that best describes your answer.
6177581320
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1. In general, would you say your health is:
(please cross one box only)
Excellent Very Good Good Fair Poor
2. During a typical day does your health limit you in moderate actvities, such as moving a
table, pushing a vacuum cleaner, bowling or playing golf? If so, how much?
(please cross one box only)
Yes, limited  a lot Yes, limited a little No, not limited at all
3. During a typical day does your health limit you in climbing several flights of stairs?
If so, how much?
(please cross one box only)
Yes, limited  a lot Yes, limited a little No, not limited at all
4. During the past 4 weeks, how much of the time have you accomplished less than you would
like in regular daily activities as a result of your physical health?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
5. During the past 4 weeks, how much of the time have you been limited in performing any
kind of work or other regular daily activities as a result of your physical health?
(please cross one box only)
6. During the past 4 weeks, how much of the time have you accomplished less than you
would have liked in your work or any other regular daily activities as a result of any
emotional problems (such as feeling depressed or anxious)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
SECTION 4
This section asks for your views about your health. This information will help us keep
track of how you feel and how well you are able to do your usual activities.
Answer each question by placing a cross in the box that best describes your answer.
2087581326
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7. During the past 4 weeks, how much of the time have you done work or other activities less
carefully than usual as a result of any emotional problems (such as feeling depressed or
anxious)?
(please cross one box only)
8. During the past 4 weeks, how much did pain interfere with your normal work (both
outside the home and housework)?
(please cross one box only)
9. This question is about how you feel and how things have been with you during the past 4
weeks. Please give the one answer that comes closest to the way you have been feeling.
How much during the past 4 weeks have you felt calm and peaceful ?
(please cross one box only)
10. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks did you have a lot of energy ?
(please cross one box only)
11. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks have you felt downhearted and depressed?
(please cross one box only)
12. During the past 4 weeks how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting friends, relatives etc.)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
Not at all A little bit Moderately Quite a bit Extremely
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
3106581329
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SECTION 5
This section also asks about your health in general.
By placing a cross in one box in each group below, please indicate which statements
best describes your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain/Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
4123581329
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SECTION 6
This section is about any medication you have been prescribed to improve your mental
well-being.
Are you currently prescribed any of the medicines listed below?
please list any other medications below
If you are prescribed one of these medicines but have stopped taking it for any reason
please place a cross in this box.
Dosulepin
Lofepramine
Citalopram
Mirtazapine
Sertraline
Fluoxetine
Paroxetine
Don’t know
Venlafaxine
Duloxetine
Trazodone
Other
1. 2.
3. 4.
5. 6.
7. 8.
9. 10.
Yes No
If 'Yes', please cross all that apply.
3827581329
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SECTION 7
This final section is about any health care you have received as a patient for any
reason (please do not include any visits to your GP practice).
Answer each question by placing a cross in the box that best describes your answer.
Attending hospital
1a. During the last 8 months have you stayed overnight in hospital?
Yes No Don't know
1b. On how many separate occasions did you stay overnight in hospital?
Please provide some details for each occasion you stayed in hospital (e.g. hip replacement, fall).
(If you have stayed more than 2 occasions, we will contact you for further details)
1c. First hospital visit
After your hospital visit were you:1d. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
1e. Second hospital visit
After your hospital visit were you:1f. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
(go to 2a)
8534581329
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Other visits to hospital
2a. Have you attended Accident and Emergency in the last8 months?
Yes No Don't know
2b. If 'Yes', how many times have you attended Accident and Emergency in the last 8
months?
3a. Have you attended Hospital Outpatients in the last 8 months?
Yes No Don't know
3b. If 'Yes', how many times have you attended Hospital Outpatients in the last 8
months?
4a. Have you attended hospital as a day case/procedure patient in the last 8 months?
Yes No Don't know
4b. If 'Yes', how many times have you attended hospital as a day case/procedure in
the last 4 months?
NHS transport services
5a. Have you used a '999' emergency ambulance in the last 8 months?
Yes No Don't know
5b. If 'Yes', how many times have you used a '999' emergency ambulance in the last 8
months?
6a. Have you used the Patient Transport Service in the last 8 months?
Yes No Don't know
6b. If 'Yes', how many times have you used the Patient Transport Service in the last8
months?
Other NHS services
7a. Have you gone to an NHS Walk-in Centre in the last 8 months?
Yes No Don't know
7b. If 'Yes', how many times have you been to an NHS Walk-in Centre in the last 8
months?
(go to 3a)
(go to 4a)
(go to 5a)
(go to 6a)
(go to 7a)
(go to 8a)
5871581320
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TSupport services9a. Do you receive any home help?Yes No Don't know9b. Thinking about the last 8 months, of these how many months did you have home help?
(please count any month where you have had a visit)
0
months
1
month
2
months
3
months
4
months
5
months
6
months
9c. Thinking about the last 8 months, typically, how many times a week did home help visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
10a. Does a care worker visit you at home?
Yes No Don't know
10b. Thinking about the last 8 months, of these how many months did a care worker visit you
at home? (please count any month where you have had a visit)
10c. Thinking about the last 8 months, typically, how many times a week did a care worker visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
8a. Have you called NHS Direct (the NHS telephone helpline) in the last 8 months?
Yes No Don't know
8b. If 'Yes', how many times have you called NHS Direct (the NHS telephone helpline)
in the last 8 months?
(go to 9a)
(go to 10a)
(go to 11a)
7
months
8
months
0
months
1
month
2
months
3
months
4
months
5
months
6
months
7
months
8
months
7132581322
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12a. Do you go to any community centres?
Yes No Don't know
12b. Thinking about the last 8 months, typically, how many times a week do you go to a
community centre?
0 1-2 2-3 3-4 4+
12c. Which community centres do you attend?
11a. Do you use meals on wheels?
Yes No Don't know
11b. Thinking about the last 8 months, of these how many months did you use meals on
wheels? (please count any month where you have had a visit)
11c. Thinking about the last 8 months, typically, how many times a week did you use meals on
wheels?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
(go to 12a)
0
months
1
month
2
months
3
months
4
months
5
months
6
months
7
months
8
months
5898581329
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If you have any general comments about the study, or this questionnaire, please write
them below.
Thank you for completing this questionnaire.
Please return it in the pre-paid envelope provided.
5693581322
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Appendix 11 CollAborative care for
Screen-Positive EldeRs plus 18-month
follow-up questionnaire
CONFIDENTIAL
Eighteen Month Follow-up Questionnaire
Participant's trial ID number:
Date questionnaire sent:
Day Month Year
/ / 2 0
Funded by:
NIHR HTA code 08/19/04
ISRCTN 02202951
CASPER 18mth qr v2.1 28May13
-
Organised by:
0084030094
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this study. The responses you give in this questionnaire
will help us find out which is the best way to improve mental well-being amongst those over the
age of 65.
Please answer ALL the questions. Although some of the questions may not seem relevant to
yourself or may appear similar, they do give us valuable information.
If you find it difficult to answer the question, please give the best answer you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross rather than a
tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you should place a
cross firmly in the box next to yes.
Yes
No
Do you drive a car?
If you are asked to write your answer, please do so by entering your answer in the box
provided, for example:
How old are you? 7 5 years
Please use a black or blue pen for all the questions.
Please do not use a pencil or any other coloured pen.
If you have any queries or problems completing this questionnaire please contact your local
study centre:
9837030099
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Please enter the date you are completing this questionnaire:
Day Month Year
/ / 2 0
SECTION 1
This section is about how you have been feeling over the last 2 weeks.
Answer each question by placing a cross in the box that best describes your answer.
1. Little interest or pleasure in doing things
Not at all Several days More than half the days Nearly every day
2. Feeling down, depressed, or hopeless
Not at all Several days More than half the days Nearly every day
3. Trouble falling or staying asleep, or sleeping too much
Not at all Several days More than half the days Nearly every day
4. Feeling tired or having little energy
Not at all Several days More than half the days Nearly every day
5. Poor appetite or overeating
Not at all Several days More than half the days Nearly every day
6. Feeling bad about yourself - that you are a failure or have let yourself or your family down
Not at all Several days More than half the days Nearly every day
7. Trouble concentrating on things, such as reading the newspaper or watching television
Not at all Several days More than half the days Nearly every day
8. Moving or speaking so slowly that other people could have noticed. Or the opposite - being
so fidgety or restless that you have been moving around a lot more than usual
Not at all Several days More than half the days Nearly every day
9. Thoughts that you would be better off dead, or of hurting yourself in some way
Not at all Several days More than half the days Nearly every day
0422030090
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1. Feeling nervous, anxious or on edge
Not at all Several days More than half the days Nearly every day
2. Not being able to stop or control worrying
Not at all Several days More than half the days Nearly every day
3. Worrying too much about different things
Not at all Several days More than half the days Nearly every day
4. Trouble relaxing
Not at all Several days More than half the days Nearly every day
5. Being too restless that it is hard to sit still
Not at all Several days More than half the days Nearly every day
6. Becoming easily annoyed or irritable
Not at all Several days More than half the days Nearly every day
7. Feeling afraid as if something awful might happen
Not at all Several days More than half the days Nearly every day
Over the last 2 weeks, how often have you been bothered by any of the following problems?
6673030094
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SECTION 2
This section is about any physical health problems you may be experiencing.
Please cross one box for each health problem.
During the past 4 weeks, how much have you been bothered by any of the following problems?
1. Stomach pains
Not bothered at all Bothered a little Bothered a lot
2. Back pain
Not bothered at all Bothered a little Bothered a lot
3. Pain in your arms, legs, or joints (e.g. knees, hips)
Not bothered at all Bothered a little Bothered a lot
4. Headaches
Not bothered at all Bothered a little Bothered a lot
5. Chest pain
Not bothered at all Bothered a little Bothered a lot
6. Dizziness
Not bothered at all Bothered a little Bothered a lot
7. Fainting spells
Not bothered at all Bothered a little Bothered a lot
8. Feeling your heart pound or race
Not bothered at all Bothered a little Bothered a lot
9. Shortness of breath
Not bothered at all Bothered a little Bothered a lot
8745030096
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10. Pain or problems during sexual intercourse
Not bothered at all Bothered a little Bothered a lot
11. Constipation, loose bowels, or diarrhoea
Not bothered at all Bothered a little Bothered a lot
12. Nausea, gas, or indigestion
Not bothered at all Bothered a little Bothered a lot
13. Feeling tired or having low energy
Not bothered at all Bothered a little Bothered a lot
14. Trouble sleeping
Not bothered at all Bothered a little Bothered a lot
I tend to bounce back after illness or hardship1a.
1b. I am able to adapt to change
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
SECTION 3
This section asks you about how you've been feeling.
Answer each question by placing a cross in the box that best describes your answer.
0200030094
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
176
1. In general, would you say your health is:
(please cross one box only)
Excellent Very Good Good Fair Poor
2. During a typical day does your health limit you in moderate activities, such as moving a
table, pushing a vacuum cleaner, bowling or playing golf? If so, how much?
(please cross one box only)
Yes, limited a lot Yes, limited a little No, not limited at all
3. During a typical day does your health limit you in climbing several flights of stairs?
If so, how much?
(please cross one box only)
Yes, limited a lot Yes, limited a little No, not limited at all
4. During the past 4 weeks, how much of the time have you accomplished less than you would
like in regular daily activities as a result of your physical health?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
5. During the past 4 weeks, how much of the time have you been limited in performing any
kind of work or other regular daily activities as a result of your physical health?
(please cross one box only)
6. During the past 4 weeks, how much of the time have you accomplished less than you
would have liked in your work or any other regular daily activities as a result of any
emotional problems (such as feeling depressed or anxious)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
SECTION 4
This section asks for your views about your health. This information will help us keep
track of how you feel and how well you are able to do your usual activities.
Answer each question by placing a cross in the box that best describes your answer.
8149030094
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7. During the past 4 weeks, how much of the time have you done work or other activities less
carefully than usual as a result of any emotional problems (such as feeling depressed or
anxious)?
(please cross one box only)
8. During the past 4 weeks, how much did pain interfere with your normal work (both
outside the home and housework)?
(please cross one box only)
9. This question is about how you feel and how things have been with you during the past 4
weeks. Please give the one answer that comes closest to the way you have been feeling.
How much during the past 4 weeks have you felt calm and peaceful ?
(please cross one box only)
10. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks did you have a lot of energy ?
(please cross one box only)
11. This question is about how you feel and how things have been with you during the past
4 weeks. Please give the one answer that comes closest to the way you have been
feeling. How much during the past 4 weeks have you felt downhearted and depressed?
(please cross one box only)
12. During the past 4 weeks how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting friends, relatives etc.)?
(please cross one box only)
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
Not at all A little bit Moderately Quite a bit Extremely
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
All of the
time
Most of
the time
Some of
the time
A little of
the time
None of
the time
6692030095
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SECTION 5
This section also asks about your health in general.
By placing a cross in one box in each group below, please indicate which statements
best describes your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain/Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
3362030096
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SECTION 6
This section is about any medication you have been prescribed to improve your mental
well-being.
Are you currently prescribed any of the medicines listed below?
please list any other medications below
If you are prescribed one of these medicines but have stopped taking it for any reason
please place a cross in this box.
Dosulepin
Lofepramine
Citalopram
Mirtazapine
Sertraline
Fluoxetine
Paroxetine
Don’t know
Venlafaxine
Duloxetine
Trazodone
Other
1. 2.
3. 4.
5. 6.
7. 8.
9. 10.
Yes No
If 'Yes', please cross all that apply.
3350030093
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SECTION 7
This final section is about any health care you have received as a patient for any
reason (please do not include any visits to your GP practice).
Answer each question by placing a cross in the box that best describes your answer.
Attending hospital
1a. During the last 6 months have you stayed overnight in hospital?
Yes No Don't know
1b. On how many separate occasions did you stay overnight in hospital?
Please provide some details for each occasion you stayed in hospital (e.g. hip replacement, fall).
(If you have stayed more than 2 occasions, we will contact you for further details)
1c. First hospital visit
After your hospital visit were you:1d. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
1e. Second hospital visit
After your hospital visit were you:1f. Transferred to community hospital
Discharged back to your home
Other (please state)
(e.g. for rehabilitation)
(go to 2a)
1410030098
DOI: 10.3310/hta21670 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 67
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bosanquet et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
181
Other visits to hospital
2a. Have you attended Accident and Emergency in the last 6 months?
Yes No Don't know
2b. If 'Yes', how many times have you attended Accident and Emergency in the
last 6 months?
3a. Have you attended Hospital Outpatients in the last 6 months?
Yes No Don't know
3b. If 'Yes', how many times have you attended Hospital Outpatients in the last
6 months?
4a. Have you attended hospital as a day case/procedure patient in the last 6 months?
Yes No Don't know
4b. If 'Yes', how many times have you attended hospital as a day case/procedure
in the last 6 months?
NHS transport services
5a. Have you used a '999' emergency ambulance in the last 6 months?
Yes No Don't know
5b. If 'Yes', how many times have you used a '999' emergency ambulance in the
last 6 months?
6a. Have you used the Patient Transport Service in the last 6 months?
Yes No Don't know
6b. If 'Yes', how many times have you used the Patient Transport Service in the
last 6 months?
Other NHS services
7a. Have you gone to an NHS Walk-in Centre in the last 6 months?
Yes No Don't know
7b. If 'Yes', how many times have you been to an NHS Walk-in Centre in the
last 6 months?
(go to 3a)
(go to 4a)
(go to 5a)
(go to 6a)
(go to 7a)
(go to 8a)
9329030095
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Support services
9a. Do you receive any home help?
Yes No Don't know
9b. Thinking about the last 6 months, of these how many months did you have home help?
(please count any month where you have had a visit)
0
months
1
month
2
months
3
months
4
months
5
months
6
months
9c. Thinking about the last 6 months, typically, how many times a week did home help visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
10a. Does a care worker visit you at home?
Yes No Don't know
10b. Thinking about the last 6 months, of these how many months did a care worker visit you
at home? (please count any month where you have had a visit)
10c. Thinking about the last 6 months, typically, how many times a week did a care worker visit?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
8a. Have you called NHS Direct (the NHS telephone helpline) in the last 6 months?
Yes No Don't know
8b. If 'Yes', how many times have you called NHS Direct (the NHS telephone helpline)
in the last 6 months?
(go to 9a)
(go to 10a)
(go to 11a)
7
months
8
months
0
months
1
month
2
months
3
months
4
months
5
months
6
months
7
months
8
months
7584030096
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12a. Do you go to any community centres?
Yes No Don't know
12b. Thinking about the last 6 months, typically, how many times a week do you go to a
community centre?
0 1-2 2-3 3-4 4+
12c. Which community centres do you attend?
11a. Do you use meals on wheels?
Yes No Don't know
11b. Thinking about the last 6 months, of these how many months did you use meals on
wheels? (please count any month where you have had a visit)
11c. Thinking about the last 6 months, typically, how many times a week did you use meals on
wheels?
0 days 1 day 2 days 3 days 4 days 5 days 6 days 7 days
(go to 12a)
0
months
1
month
2
months
3
months
4
months
5
months
6
months
7
months
8
months
1472030096
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If you have any general comments about the study, or this questionnaire, please write
them below.
Thank you for completing this questionnaire.
Please return it in the pre-paid envelope provided.
6615030090
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Appendix 12 Zero-inflated negative binomial
regression
TABLE 52 Zero-inflated negative binomial regression explaining the effect of collaborative care vs. usual care on
the incidence rate ratio of GP appointments
GP appointments IRR Standard error z p> z 95% CI
Full model
Collaborative care 0.9726 0.0733 –0.3700 0.713 0.8391 to 1.1274
Constant 10.3623 0.5436 44.5700 0.000 9.3498 to 11.4845
Logistic model
Collaborative care 0.5384 0.9378 0.5700 0.566 –1.2996 to 2.3764
Constant –3.9940 0.7827 –5.1000 0.000 –5.5281 to –2.4599
IRR, incidence rate ratio.
N (total) = 357; n (GP appointment > 0) = 343; n (GP appointment = 0)= 14.
TABLE 53 Zero-inflated negative binomial regression explaining the effect of collaborative care vs. usual care on
the incidence rate ratio of GP home visits
GP home visits IRR Standard error z p> z 95% CI
Collaborative care 1.2358 0.5291 0.4900 0.621 0.5340 to 2.8599
Constant 0.6066 0.1356 –2.2400 0.025 0.3914 to 0.9401
Logistic model
Collaborative care 17.3135 15682.5500 0.0000 0.999 –30720 to 30755
Constant –19.0563 15682.5500 0.0000 0.999 –30756 to 30718
IRR, incidence rate ratio.
N (total) = 357; n (GP home visits > 0) = 71; n (GP home visits= 0) = 286.
TABLE 54 Zero-inflated negative binomial regression explaining the effect of collaborative care vs. usual care on
the incidence rate ratio of GP telephone consultations
GP telephone consultation IRR Standard error z p> z 95% CI
Collaborative care 1.3146 0.2366 1.5200 0.129 0.9238 to 1.8707
Constant 2.1911 0.3857 4.4600 0.000 1.5517 to 3.0939
Logistic model
Collaborative care 1.4852 2.2885 0.6500 0.516 –3.0003 to 5.9706
Constant –2.8972 2.7483 –1.0500 0.292 –8.2838 to 2.4894
IRR, incidence rate ratio.
N (total) = 357; n (GP telephone consultation > 0)= 206; n (GP telephone consultation = 0) = 151.
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TABLE 56 Zero-inflated negative binomial regression explaining the effect of collaborative care vs. usual care on
the incidence rate ratio of nurse telephone consultations
Nurse telephone
consultation IRR Standard error z p> z 95% CI
Collaborative care 2.2476 1.0137 1.8000 0.073 0.9285 to 5.4403
Constant 0.3607 0.0757 –4.8600 0.000 0.2390 to 0.5441
Logistic model
Collaborative care 16.5231 3127.0730 0.0100 0.996 –6112 to 6145
Constant –16.7359 3127.0740 –0.0100 0.996 –6146 to 6112
IRR, incidence rate ratio.
N (total) = 357; n (nurse telephone consultation > 0)= 61; n (nurse telephone consultation = 0) = 296.
TABLE 55 Zero-inflated negative binomial regression explaining the effect of collaborative care vs. usual care on
the incidence rate ratio of nurse appointments
Nurse appointment IRR Standard error z p> z 95% CI
Collaborative care 0.9935 0.1244 –0.0500 0.959 0.7774 to 1.2698
Constant 5.3825 0.4368 20.7400 0.000 4.5911 to 6.3104
Logistic model
Collaborative care 14.1944 2213.3500 0.0100 0.995 –4324 to 4352
Constant –18.0387 2213.3490 –0.0100 0.993 –4356 to 4320
IRR, incidence rate ratio.
N (total) = 357; n (nurse appointment > 0)= 299; n (nurse appointment = 0) = 58.
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Appendix 13 CollAborative care for Screen-
Positive EldeRs plus participant interview
consent form
 
 
 
 
 
CASPER Plus Participant Interview Consent Form 
 
 
Contact Name: 
Contact 
Details: 
 
  
Please initial each 
box 
 
1. I confirm that I have read and understand the information sheet 
[v2.1 10Oct12] for this study and have had the opportunity to 
ask questions. 
 
 
2. I understand that my participation in a short interview for this 
study is voluntary and I am free to withdraw at any time without 
giving any reason. 
 
 
3. I understand that the interview will be recorded on a digital 
voice recorder and the sound file will be stored on a secure 
computer at the University of York. 
 
 
4. I understand that the interview will be strictly confidential and I 
will be anonymous in any written reports from the research. 
 
 
5. I understand that anonymous written quotations from the 
interview(s) and observations may be used in presentations and 
in teaching.  
 
 
 
6. I understand that my details (e.g. name, practice, address) will 
be strictly confidential, stored securely at the University of York 
and will not be passed on to any individual within or outside the 
University. 
 
 
7. I agree to take part in the above study by taking part in the 
interview. 
 
 
 
 
 
 
_______________________        ________________    
___________________________ 
Name of Participant (print)   Date    Signature 
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Appendix 14 CollAborative care for Screen-
Positive EldeRs plus case manager/supervisor
interview consent form
 
 
 
 
CASPER Plus Case Manager/Supervisor Interview 
 Consent Form 
 
Contact Name: [Name of researcher] 
 
Contact 
Details: 
Department of Health Sciences, University of  York, YO10 5DD 
 
Tel: [phone number of researcher] Email: [email address of 
researcher] 
 
 
  
  Please initial each 
box 
 
1. I confirm I have read and understand the information sheet 
[v2.1 10Oct12]for this study and have had the opportunity to 
ask questions. 
 
 
2. I understand that my participation in an interview for this study 
is voluntary and I am free to withdraw at any time without 
giving any reason. 
 
 
3. I understand that the interview will be recorded on a digital 
voice recorder and the sound file stored on a secure computer at 
the University of York. 
 
 
4. I understand that the interview will be strictly confidential and 
that I will be anonymous in any written reports from the 
research. 
 
 
5. I understand that anonymous written quotations from the 
interview may be used in presentations and in teaching.  
 
 
6. I understand that my details (e.g. name, address) will be strictly 
confidential, stored securely at the University of York and will 
not be passed on to any individual within or outside the 
University. 
 
 
7. I agree to take part in the above study by taking part in the 
interview. 
 
 
 
 
 
 
Name of Case Manager (print)   Date    Signature 
___________________________ 
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Appendix 15 CollAborative care for Screen-
Positive EldeRs plus general practitioner interview
consent form
 
 
 
 
CASPER Plus GP Interview 
 Consent Form 
 
Contact Name: 
 
Contact 
Details: 
 
 
 
 
  
   Please initial each 
box 
 
1. I confirm I have read and understand the information sheet for 
this study [v2.1 10Oct12] and have had the opportunity to ask 
questions. 
 
 
2. I understand that my participation in an interview for this study is 
voluntary and I am free to withdraw at any time without giving 
any reason. 
 
 
3. I understand that the interview will be recorded on a digital voice 
recorder and the sound file stored on a secure computer at the 
University of York. 
 
 
4. I understand that the interview will be strictly confidential and that 
I will be anonymous in any written reports from the research. 
 
 
5. I understand that anonymous written quotations from the 
interview may be used in presentations and in teaching.  
 
 
6. I understand that my details (e.g. name, address) will be strictly 
confidential, stored securely at the University of York and will not 
be passed on to any individual within or outside the University. 
 
 
7. I agree to take part in the above study by taking part in the 
interview. 
 
 
 
 
________________________        ________________    
___________________________ 
Name of General Practitioner (print)   Date    Signature 
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Appendix 16 Qualitative case manager topic
guide
 
Interview key questions for ‘Collaborative Care’ participants 
 
This guide summarises the main areas to be explored in each interview about views 
and experiences relating to CC.  The questions are intended as a starting point to 
ensure primary issues are covered, whilst allowing flexibility for new issues to 
emerge. 
 
Thank participant for agreeing to be interviewed. Remind them they have consented 
to the interview being digitally recorded, the recording will be stored securely and 
the transcript will be anonymised, but they are welcome to stop the interview at any 
point if they wish. 
 
Understanding and thoughts on BA/Collaborative Care: 
 
• Could you start by telling me why you decided to take part in the study? 
• What were your expectations, what did you expect to happen during the 
study? 
 
Experiences 
 
• What did you think of the experience?  
• How do you refer to/label the problems you’ve been having, what do you call 
it? 
• How did you feel about being allocated a CM? How did you get on with them? 
How flexible would you say they were? 
• What did you feel about the support you received from their CM? 
• Was there anything about the process you didn’t like? (prompt) for example, 
some people have felt the pack was repetitive. 
• Did you feel the care was centred on them? Did you feel in control of process? 
• Apart from time, what do you think you got from your CM? 
• Did you see the sessions with the CM as fitting into a wider CC process? 
• Overall, did you find the process acceptable, valuable and effective? 
 
Other experiences 
• Did participating in CC make a difference to your appointments with their GP? 
• Do you usually see the same GP at the surgery? If not, why not? 
• If you went to GPs about how you were feeling who would you see, and why? 
• If emotional problems are not something they speak to GP about, why is 
that? 
Prompts: Is it a time issue? Do you think GP wouldn’t be interested in non-
medical concern? What would cause you to seek help from GP about mood? 
 
 
 
Interviews with patients as part of the  
CASPER Plus Study 
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• What do you think of the idea that people over 75 should have a named GP? 
• Would you value seeing the same GP each time, or not? 
• What do you think are differences between telephone and face-to-face 
interviews? 
• What are your views on the self-help guide and completing the questionnaire? 
• How did you feel about coming to the end of your sessions? 
 
Has CC made a difference? 
• Has it affected the way you manage low mood?  
• Are you doing anything different now, such as being more active? 
 
Links between how they feel physically and emotionally 
• Do you see physical and emotional conditions as separate? 
• Do you think there’s a link between these two? For example, if you are feeling 
pain do you think that affects your mood? Do they think your physical 
condition changes when your mood improves?  
 
Previous experiences of counselling 
• Have you had any counselling previously… or BA? How did this differ from 
what you have received through CASPER? 
 
Thoughts on seeking out a group 
• Have you looked at joining any possible groups? If not, what sort of group 
would you be interested in? Prompt: e.g one for your peer group/creative 
activities/for a specific condition or specially for carers for example?  
• If it became available in future, would you be interested in refresher sessions 
with the CMs as part of a group? 
 
Medication matters 
• Were you on medication for your mood when receiving CC? If so, did you talk 
to CM about this? 
• Do you see the CM as someone you could talk to about medication? Or do you 
think this is something to talk only to GP about? 
• Do you think the CM and GP might speak to each other about your 
medication? 
• If yes, how would you feel about this? 
 
General questions 
• What would your thoughts be, if CC were introduced at your GP practice? 
• What do you think would be the benefits of this for you? And for others? 
• If it did happen, what barriers would you see to it working?  
• Is it something you believe might work? If so, how might it work best? 
 
Any other thoughts or questions? 
• Any other points or questions? 
• Thank you 
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Appendix 17 Qualitative case manager topic
guide
 
Key Interview Questions for case managers  
This topic guide summarises the main areas to be explored in each interview about 
the CM’s relationships and liaison with Practice Nurses and GPs, their views about 
the effectiveness of collaborative care and their experiences of delivering the 
intervention. 
As with any qualitative interviews, these headings are intended as a starting point to 
ensure the primary issues are covered, whilst allowing flexibility for new issues to 
emerge. All consenting Case Managers working with CASPER Plus participants will be 
interviewed. CMs will be interviewed once during the study, after completing the 
intervention with at least three patient participants. 
 
Introduction and background 
 
Thoughts and views 
• What are your views on CC? 
• What do you think are the benefits or value of the BA intervention? 
• How do you see BA fitting within CC process - do you view BA and CC 
framework as two separate processes? 
• What are your views on the effectiveness of overall CC process? 
• What are our thoughts on participants’ understanding and acceptability of CC? 
• What, apart from time, do you think you give to participants? 
• How do you see your role?  
 
• Views on Medication Management 
• Thoughts on the use of psychological interventions with antidepressants 
• Views on medication management (MM)  
 
• Other views 
• Views on use of manuals/questionnaires/diary 
• Views on supervision (from both CM and supervisor perspective) 
• How do they manage final sessions/ helping participant to continue? 
 
Experiences 
• Broadly, what has been your experience of being involved in the study? 
• Apart from GP and themselves, who do they see in the CC process? e.g. 
participants with LTCs, do you have any communication with specialists, or 
with the GP about participant’s condition? 
• Have you had any involvement with carers or family members of participants? 
If so, what benefits or problems have you experienced when involving carers? 
• Do you think there is a role for carers and family members during BA? 
 
 
 
Interviews with case managers as part of the 
CASPERPlus study 
[CASPERPlusQualitative study case manager – interview topic guide] 
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• How is what you do (CC) different from other types of GP collaboration? 
• How do you manage complex patients?  
• Can you tell me about your experiences or views on links between a patient’s 
emotional and physical condition. (prompt) If one gets better, does the other? 
• How do you manage final sessions with participant? How do you think 
participants view with session? 
• What do you think are the differences between telephone and face-to-face 
interviews?  
• What are your views about the value of the trial? 
 
Operational Questions 
 
Contact with GP 
• How do you see the GPs’ awareness of the CC process within their practice?  
• Letters sent at four stages - has the GP responded to any letters? 
• Which method of communication did GPs prefer, e.g. by telephone/written 
reports on individual patients? 
• How often did GPs like to be contacted?   
• Under what circumstances/at what point in the CC process did GPs prefer to 
be contacted? e.g. urgent cases or risk?  
• How easy has it been to contact GP? 
 
Experiences of medication management 
• How, if at all, do you engage with GP around MM? 
• What have been your experiences so far of MM? Have you had contact with 
GP around patient’s medication? 
• Are you from an IAPT background or other? Has your training influenced your 
approach to MM? 
• Any further thoughts on MM? How do you see MM fitting within primary care 
and IAPT services? 
 
Speculative questions 
• If CC were implemented into the GP practice, what would your thoughts be?  
• If it happened, what barriers do you see, in terms of collaborative working 
with the GPs?  
• Is it something you could see working? If so, how do you suggest it might be 
possible? 
• Any other thoughts on making the CC model a sustainable process? 
• Any thoughts on barriers to the participant? e.g. difficulty reading/deafness. 
 
Any other issues? 
• Are there any other issues you would like to raise? 
• Thank you 
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Appendix 18 Qualitative general practitioner
topic guide
 
Key Questions for GPs 
Thoughts and views  
 
GP’s views on BA and Collaborative Care (CC) 
 
• Why did your practice take part and why did you agree to be interviewed? 
(e.g. interest in mental health or research?) 
• What do you know about the intervention, BA?  
• How do you see BA fitting within CC framework? 
• What is your understanding of CC for mental health? Do you see it as 
different to shared care? What sort of collaboration do you do currently, i.e. 
co-located, face to face? What is your role in delivering this? 
• What are your views on the potential, value and effectiveness of CC?  
• Do you think your patients understand what CC is? Why do you think they get 
involved in research? 
• What do you think of the plan that people over 75 should have a named GP? 
• How do they see your own role in managing depression for older people?  
• What do you do as a GP for this group?  
• What is your usual treatment pathway for patients with moderate to severe 
depression? 
• If medication, how do you see the CM’s involvement (if at all) in this area of 
patient care? 
• How do you see the role of the CM? CM has been described as the glue that 
keeps CC together, would you agree? 
• Are you aware of any contact by the CMs with patients’ carers or families? 
• Has your awareness of CC affected your attitude to identifying or addressing 
depression in older people?  
Experiences: 
• Since we’ve started recruiting from your practice, what has been your 
experience in general? 
• What is the practice procedure for dealing with mental health? (prompt) e.g. 
is there a GP to whom patients automatically gravitate?  
• Your experiences of delivering CC for older people with depression? 
 
 
 
Interviews with GPs as part of the CASPERPlus 
study 
Key Questions 
[CASPERPlus Qualitative study – GP Key Questions 
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Experiences of Medication Management: 
• Have any CMs contacted you about any patient medication issues? 
• How do you think medication management might fit in with collaborative care 
delivered through primary care? 
 
Operational Questions 
Preferred method of communication. 
• How, and how often would you prefer to be contacted?   
• At what point in the process? 
• Do you view letters from CMs? (sent at four stages) 
1. at consent stage 
2. with patient’s GDS-15 score and management plan 
3. after four or five sessions 
4. on completion 
• What is the usual process in the practice when receiving these letters? 
•  Do you remember seeing any of these letters? Did you respond to them? 
•  Have you spoken to the CMs personally?  
 
Speculative questions 
• If CC were implemented into practice, what would your thoughts be?  
• Is this something you could see working?  
• What barriers do you see?  
• How do you think it might be possible? 
• What do you see as your role in Collaborative Care? 
 
Views on CM’s role? 
• What do you see as the CM’s role, e.g. medication management? 
• How would you like this role to work? 
• What are your thoughts on CMs working within the practice? 
 
Perceived differences between telephone and face-to-face contact 
• What do you see as the differences between telephone and face-to-face 
contact between CMs and their patients? 
• Any other thoughts on making the CC model a sustainable process? 
 
Any other issues? 
• Any other issue you would like to raise 
• Thank you 
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Appendix 19 Qualitative demographics tables
A ll eight case managers who agreed to be interviewed were female and aged between 27 and 50 years.All case managers had been trained as NHS PWPs as part of the IAPT initiative. They each had several
years experience of delivering low-intensity psychological interventions. In addition, two of the case
managers were involved in training case managers for the CASPER plus trial and in their supervision.
TABLE 57 Demographics of patient participants
Identification number Sex
Age range
(years)
Index of Multiple
Deprivation number
(decile)
Face to face
or telephone?
Urban/rural
general practice
PT1 Female 75–80 1 Face to face Urban
PT2 Male 75–80 9 Face to face Urban
PT3 Male 65–70 5 Face to face Rural
PT4 Male 81–85 8 Face to face Rural
PT5 Male 65–70 2 Face to face Urban
PT6 Female 65–70 10 Face to face Rural
PT7 Female 65–70 10 Face to face Rural
PT8 Female 65–70 10 Face to face Urban
PT9 Male 65–70 2 Face to face Urban
PT10 Female 65–70 8 Telephone Urban
PT11 Female 75–80 9 Face to face Urban
PT12 Female 65–70 9 Telephone Urban
PT1(withdrawn) Male 65–70 6 Face to face Rural
TABLE 58 Demographics of case managers interviewed
Identification number Sex Years of experiencea Interview type
CASE MANAGER1 Female 8 Face to face
CASE MANAGER2 Female 9 Face to face
CASE MANAGER3 Female 4 Face to face
CASE MANAGER4 Female 4 Face to face
CASE MANAGER5 Female 4 Telephone
CASE MANAGER6 Female 3 Telephone
CASE MANAGER7 Female 3 Telephone
CASE MANAGER8 Female 5 Face to face
a Experience in years of delivering a low-intensity psychological intervention.
DOI: 10.3310/hta21670 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 67
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bosanquet et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
201
TABLE 59 Demographics of GPs interviewed
Identification number Sex Practice size
Index of Multiple
Deprivation numbera
Urban/rural
general practice
GP1 Male 14,886 5 Urban
GP2 Male 10,150 6 Urban
GP3 Male 19,879 10 Rural
GP4 Female 18,083 8 Rural
GP5 Male 24,353 5 Urban
GP6 Male 15,915 4 Urban
GP7 Male 6961 6 Urban
GP8 Female 13,000 3 Urban
GP9 Female 18,083 8 Rural
GP10 Female 11,893 6 Rural
GP11 Male 7183 10 Rural
GP12 Male 15,432 5 Rural
a Lower numbers indicate a lower SES.
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Appendix 20 CollAborative care for Screen-
Positive EldeRs plus protocol version 2.1 (original)
CASPER PLUS Trial Protocol v2.1 30Mar12 
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Overview 
As a sub-study of The CASPER Study, CASPER PLUS is a trial of a primary 
care-based intervention for older people with depression. Depression in older 
people is common and associated with poor quality of life, increased morbidity 
and mortality and increased health and social care use. It is under-recognised 
and sometimes inadequately treated in primary care. Current management is 
mostly limited to the prescription of anti-depressants; where there may be 
poor concordance. 
 
Psychological treatments may not be offered or available in practice; and the 
evidence for psychological interventions uses models of care which are of a 
higher intensity such that they could not feasibly be delivered in primary care 
in sufficient volume to meet the needs of older people. An intervention known 
as collaborative care involves a brief patient-centred psycho-social package 
of care delivered by by a case manager working to a defined protocol; 
medication management and with supervision of the case manager by a 
specialist, which facilitates liaison across the primary /secondary interface. 
Collaborative Care has shown promising trial results in the United States. 
However the transferability of this model of service to the UK NHS cannot be 
assumed. NICE has identified this as an important intervention that should be 
subject to further trials. 
 
CASPER PLUS will run seamlessly as part of the recruitment procedures of a 
cohort of older people with depression with whom we will conduct trials to 
inform practice and policy (the CASPER older persons’ cohort multiple RCT - 
cmRCT). Using this same cohort, we seek to conduct the definitive trial of 
collaborative care in older people with above threshold, major depressive 
disorder. Since we already identify people with ‘sub threshold’ depression in 
the existing cohort, we can conduct this important trial relatively quickly and at 
lower cost. The conduct of this trial will significantly enhance the randomised 
evidence base in the care of older people with depression, and will inform 
future service provision; satisfying a research priority identified by NICE. 
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1. Background 
 
Depression accounts for the greatest burden of disease among all mental 
health problems, and is expected to become the second-highest among all 
general health problems by 2020.[1] By the age of 75, 1 in 7 older people 
meet formal diagnostic criteria for depression. Projected demographic 
changes mean that population strategies to tackle depression will increasingly 
have to address the specific needs of older people.[2] Amongst older people, 
depressive syndromes often affect people with chronic medical illnesses, 
cognitive impairment, social isolation or disability. 
 
Older people with a long-term condition are five times more likely to suffer 
depression. 50% of people with Parkinson’s disease will suffer depression, 
25% following stroke, 20% with coronary heart disease, 24% neurological 
disease and 42% chronic lung disease.[3] Beyond personal suffering and 
family disruption, depression worsens the outcomes of many medical 
disorders and promotes disability. The impairments in quality of life associated 
with depression are comparable to those of major physical illness. Amongst 
older people, a clinical diagnosis of major depression is the strongest 
predictor for impaired quality of life (QoL).[4]  
 
Current UK policies under the Quality and Outcomes Framework (QOF) 
advocate case-finding for depression amongst those with chronic physical 
health problems such as heart disease and diabetes. [5] Once detected, 
evidence supported guidelines advocate the prescription of anti-depressant 
drugs and appropriate provision of psychological care.[6,7] However, an 
enduring critique has been that depression is not well managed even when 
this is revealed through case-finding.[2] Management in primary care usually 
involves the prescription of antidepressant medication, with poor concordance 
and suboptimal dosages. The provision of psychological or social 
interventions addressing issues of poor adaptation, loss, depressive thinking 
or social withdrawal is woefully inadequate. For example, there has been 
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minimal provision of psychological treatment for older people under the 
Improving Access to Psychological Therapies (IAPT) programme. 
 
Despite being encouraged to case-find for depression in older people there is 
little evidence that this has translated into better management for this 
disorder. The current proposal introduces a feasible intervention for this group 
of patients which is known as ‘Collaborative care’. 
 
The role of collaborative care 
The vast majority of depression in older people can (quite appropriately) be 
managed entirely in primary care, without recourse to specialist mental health 
services.[2,6,8] A range of individual treatments have been shown to be 
effective in the management of depression in older people, including anti-
depressants and psychosocial interventions.[6] However, a repeated 
observation amongst all people with depression has been the failure to 
integrate these effective elements of care into routine primary care 
services.[9] Similarly the volume of people with depression necessitates that 
low intensity interventions are the only feasible strategy that can be used in 
managing depression within the population.  
 
Despite recent investment under the Improving Access to Psychological 
Therapies (IAPT) initiative, the capacity for specialist mental health services to 
provide this care is constrained and demand would quite quickly outstrip 
supply. Hence any feasible strategy will be both low intensity and offered 
within primary care.[10] 
 
The ubiquity of depression in primary care settings and the poor 
integration/co-ordination of care have led to strategies to re-engineer the 
delivery of care. This form of care borrows much from chronic disease 
management and facilitates the delivery of effective forms of treatment (such 
as pharmacotherapy and/or brief psychological therapy). This model of care is 
often referred to as collaborative care or case management.[11] According 
to a recent BMJ editorial on the management of depression in older people 
‘Innovations in the management of depression have been evaluated. The best 
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results come from models that use multifaceted interventions and principles of 
collaborative care.’ [2] We would concur with this observation and the 
CASPER research group has contributed much to the evidence base of 
collaborative care and in the evaluation/implementation of this model of care 
to the UK. We have for example, conducted the definitive reviews of this 
intervention, [13,14] and have completed the first trial of collaborative care in 
the UK.[14] We have recently completed an MRC-funded evaluation of clinical 
and cost effectiveness of Collaborative Care in depressed working age adults 
(PI Richards). Within the new Improving Access to Psychological Therapies 
(IAPT) programme, we have implemented this model of care for over 7000 
working age adults with depression in demonstration sites.[15] We have also 
developed computer-based case management systems to facilitate symptom 
management and supervision of case managers (the PC-MIS system). 
 
Our own reviews in this area have shown collaborative care to be a potentially 
effective and efficient means of delivering care for depression. Based upon 
analyses of 36 trials (12,000 participants), we have shown that collaborative 
care is effective in the short and medium term in alleviating depressive 
symptoms and improving quality of life. [12] Moreover collaborative care is 
known to be cost effective in reducing healthcare utilisation and in improving 
overall quality of life. [16] See CASPER protocol for details of the United 
States IMPACT study of collaborative care in older adults (aged over 60). 
 
1.2 The wider CASPER Study 
The CASPER study (see Appendix 1) - a cohort study and randomised 
controlled trial looking at the effectiveness of collaborative care in older 
patients with sub-threshold depression [14] - uses a database screening 
approach in recruiting patients. A randomised controlled trial would be the 
best approach to evaluate its effects.  
 
1.3 Research Objectives 
The research objectives of the CASPER PLUS sub-study are: 
1. To establish the clinical effectiveness of a collaborative care 
intervention for older people with screen-positive above-threshold 
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(‘major depressive episode’) depression within a definitive RCT.  
2. To examine the cost effectiveness of a collaborative care intervention 
for older people with screen-positive above-threshold (‘major 
depressive episode’) depression within a definitive RCT.  
 
2. Method 
2.1 Design 
As a sub-study of the CASPER trial, CASPER PLUS will follow the same 
design and recruit from the same wider cohort, using a pragmatic multi-
centred randomised controlled trial. Patients will be randomly allocated to one 
of two interventions: 
 
1. Collaborative care with behavioural activation and active surveillance 
2. Usual primary care management of above-threshold depression (major 
depressive episode) offered by the patient’s GP, in line with NICE 
depression guidance and local service provision 
 
2.2 Inclusion / exclusion criteria 
For the CASPER PLUS sub-study all patients at participating CASPER GP 
practices who have been identified as eligible to receive an invitation mailing 
will be included. Those patients identified at the screening phase as having 
above-threshold, case level depression will be eligible to enter the CASPER 
PLUS sub study.  
 
Inclusion criteria  
CASPER participants will be identified by comprehensive screening strategies 
in primary care (replicating that which is incentivised in QOF-compliant case 
finding for those with CHD and diabetes). Our target population will be older 
people (aged 65 and above) who screen-positive for depression on the 
recommended QOF 2 question brief depression screen (sometimes referred 
to as the ‘Whooley’ questions after their initial validation study [21]), but who 
on further assessment have DSM-IV Major Depressive Disorder (MDD).[22] 
The Whooley questions are detailed in Box 1. [21,23] 
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Box 1: QOF-compliant (DEP1) brief screening questions 
 
The exclusion criteria are: 
 Known alcohol dependency (as recorded on GP records) 
 Any known co-morbidity that would in the GP’s opinion make entry to 
the trial inadvisable (e.g. recent evidence of self harm, known current 
thoughts of self harm, significant cognitive impairment) 
 Other factors that would make an invitation to participate in the trial 
inappropriate (e.g. recent bereavement; terminal malignancy) 
 Known to be experiencing psychotic symptoms (as recorded on GP 
records) 
 
2.3 Recruitment and Randomisation 
 
2.4 Intervention 
Collaborative Care with behavioural activation and active surveillance  
Patients who meet our pragmatic inclusion criteria will be individually 
randomised into one of two intervention groups: (1) Collaborative Care 
(including Behavioural Activation) intervention with medication monitoring and 
management, or (2) usual care. This is a pragmatic trial [20] and we will 
impose few restrictions on routine practice and will have no direct influence on 
the prescription of medication (which will remain entirely in the control of 
GPs). The actual delivery of this service within the pilot trial will be studied 
using a concurrent process evaluation – utilising a mixed methods research 
design.  
 
1. ‘Over the past month have you been bothered by feeling down, 
depressed or hopeless?’  
2. ‘Over the past month, have you been bothered by having little interest or 
pleasure in doing things? A positive answer to one or both of these 
questions raises the possibility of depression and necessitates a full 
assessment for the presence or absence of clinically significant depressive 
syndrome.  
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Eligible participants who have consented to be in the trial will be randomised 
to a treatment group using the computer-based York Trials Unit telephone 
randomisation service.  
 
Our experimental intervention will be a bespoke collaborative care designed 
and delivered specifically for those aged 65 or over with above threshold, 
case-level depression over 6-8 weekly sessions. The intervention manual has 
been adapted from the existing CASPER manual used in the pilot study. 
Collaborative care will be delivered by a case manager (a primary care mental 
health worker) within a 'stepped care framework', such that those whose 
depression deteriorates are 'stepped up' from low intensity care to a more 
intensive form of management including medication monitoring.  
 
The five core components of the intervention are described below: 
 
1. PATIENT-CENTRED ASSESSMENT AND ENGAGEMENT: patients 
are first assessed in their own residential setting. The severity of 
depression and associated behavioural and social deficits are 
assessed. The presence of depressive symptoms and behavioural 
deficits are described and patient information materials are given. 
 
2. SYMPTOM MEASUREMENT AND MONITORING: a standardised 
assessment of symptom severity is made. Symptom tracking (to judge 
response, failure to respond or deterioration) is then made at all 
subsequent patient contacts. 
 
 
3. MEDICATION MANAGEMENT: the prescription of anti-depressant 
medication is entirely at the discretion of the General Practitioner. We 
will encourage GPs to consider NICE guidance in their prescribing 
decisions. The concordant use of medication by patients will be 
encouraged by the case manager if a prescription has been initiated by 
the GP.  Patient concerns (such as addiction) and non-compliance will 
be addressed during sessions.  There will be active liaison with GPs to 
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encourage follow up patient appointments with the GP if poor 
concordance is noted. 
 
4. ACTIVE FOLLOW-UP: all patients are followed up by the CM for eight 
weeks using face to face meetings or telephone contacts. Our own 
experience is that telephone contacts are acceptable and that patients 
can be engaged using this means of communication.[18] We have 
adapted this means of delivery in the light of the specific needs of those 
over 75.  
 
 
5. DELIVERY OF BEHAVIOURAL ACTIVATION (BA): patients are 
offered the option of behavioural activation delivered over eight 
sessions by their case manager. BA consists of a structured 
programme of reducing the frequency of negatively reinforced avoidant 
behaviours in parallel with increasing the frequency of positively 
reinforcing behaviours to improve functioning and raise mood. During 
this time patients will remain under the medical care of their General 
Practitioner.  We have demonstrated that BA is potentially effective in 
older adults.[17] and have recently demonstrated the effectiveness of 
this approach in working age adults.[19]  
 
Higher intensity treatments for depression will be facilitated by the GP and by 
conventional mental health services for older people, and will not be directly 
influenced by this trial. The additional elements of collaborative care include: 
telephone support; symptom monitoring and active surveillance (facilitated by 
computerised case management systems – PC-MIS); medication monitoring; 
low intensity psychosocial intervention (behavioural activation). The work of 
case managers is supervised by an older persons’ mental health specialist 
(old age psychiatrist or psychologist). 
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Control intervention  
Participants allocated to the control condition will receive usual primary care 
management of case level depression offered by their GP, in line with NICE 
depression guidance and local service provision.  
 
 
Recruitment method  
Screening of all over 65s from GP practice lists: in our existing portfolio of 
trials at the York Trials Unit, we have pioneered the use of postal screening 
questionnaires sent to all over 75s based upon practice registers. This has 
resulted in above-target recruitment to our trials in falls and osteoporosis by 
this method. We would follow up all participants who return screening 
questionnaires and express an interest in finding out about the trial. The pilot 
study of CASPER has been successful in recruiting 100 participants and met 
criteria for retention during the first year of the study. 
 
2.5 Outcome measures 
Primary outcome: We will measure depression severity at four months by self 
report using the Patient Health Questionnaire 9 – PHQ9. We will also 
measure outcome at 12 and 18 months using the PHQ9 to examine any 
sustained impact of the intervention.  
 
Our secondary outcome is binary and is the presence/absence of depression 
diagnosis as ascertained by interview. For this secondary measure we will use 
a criterion-based assessment of depression according to the American 
Psychiatric Association DSM-IV (established by the validated interviewer-
administered diagnostic schedule MINI). We will also measure DSM-IV 
depression status at 4, 12 months and 18 months (using the PHQ9); health 
related quality of life (SF-12); health-state utility (EQ5D) at 4 months, 12 
months and 18 months. 
 
2.6 Qualitative study 
In addition to the quantitative data collected in the nested trial, we will collect 
qualitative data obtained from focus groups.  
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3. Statistical considerations 
3.1 Sample size  
Our overall sample size for our definitive trial will be 450 (225 per arm). The 
sample size of our definitive trial is inexorably linked to (1) the specified 
minimally important difference; (2) ICC and (3) caseload size. A conservative 
assumption of an ability to detect an effect size of 0.35, based upon 
ICC=0.02 and caseload size 20 will require 180 participants in the intervention 
arm. This effect size is in line with the IMPACT US trial [25]
 
and the point 
estimate from our UK pilot trial. 
 
 
TABLE: SAMPLE SIZE CALCULATION INCORPORATING ICC VALUES, CASELOAD 
SIZES AND LOSS TO FOLLOW UP  
 
Effect size* (based 
upon US trial and UK 
pilot trial.  
Conventional 
sample size 
(assumes no 
clustering)  
Caseload 
size  
Plausible ICC 
within 
therapists’ 
caseloads  
Design 
Effect/Inflation 
factor  
Effective 
sample size 
(adjusted for 
clustering)  
Inflation for 
20% loss to 
follow up 
(final sample 
size)  
D=0.35  260  20  0.02  1.38  360  450  
 
3.2 Analysis 
Statistical analysis of clinical data  
We will analyse the data on an intention to treat basis. The primary outcome 
of depression severity (a continuous outcome as measured by a score on the 
PHQ9 depression severity measure) will be used in a linear regression model 
to compare collaborative care with usual care. The analysis will be adjusted 
for baseline depression severity (as measured by the PHQ9) and 
physical/functional limitations (as measured by the SF36 physical functioning 
scale).[24] Standardised effect sizes and the corresponding 95% confidence 
intervals will be presented for the primary outcome of depression severity. 
Two-sided 95% confidence intervals will be calculated.  
 
For each outcome measure the number of non-responders will be calculated 
for each treatment group and response rates compared. We will undertake 
sensitivity analyses to explore the impact of missing data using multiple 
imputations by chained equations which will be performed using the ICE 
package in Stata. All secondary analyses will be conducted using linear or 
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logistic regression, depending on the outcome measure, adjusting for the 
same covariates as the primary analysis. All analyses will adjust for within-
therapist clustering using multi-level modelling with the Huber-White sandwich 
estimator.  
 
3.3 Analysis of economic data  
The economic evaluation will take the form of within-trial cost-utility analysis 
that will determine the incremental cost per quality adjusted life year for 
treatment with collaborative care against usual care in individuals with 
depression. The primary analyses will be conducted from the UK NHS and 
personal and social services (PSS) perspective following NICE evaluation 
guidance.  
 
Primary and secondary healthcare and societal costs will include intervention-
related costs, health service use costs and personal social services costs, in 
line with the recommendations by NICE. The cost data will be collected to fully 
reflect the management of depression and its cost in both collaborative care 
and usual care group, and these will be analysed within a societal 
perspective. Intervention (and control) group costs will be based on the 
delivery costs within the trial and include supervision and appropriate capital 
and overhead amounts. Patient questionnaires and case record review will be 
used to collect data on the use of health services and personal social 
services. Unit costs for these items will be drawn from the NHS reference 
costs and the personal social services resource use databases.  
 
The effectiveness of the intervention will be evaluated using the standard 
quality of life measures which have been shown to be sensitive to change in 
relation to depression, and also physical healthcare problems common 
amongst older adults. These will be collected at regular intervals using patient 
questionnaires. These will then be evaluated over the 18 months trial period to 
estimate the total quality-adjusted life years for both intervention and control 
groups.  
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Economic analyses will compare the costs and effectiveness at the final 18-
month follow-up of collaborative versus usual care to capture the economic 
impact of events such as relapse, although we will conduct an initial 
preliminary analysis at six months to coincide with the primary clinical 
analyses. Although the distribution of costs is commonly skewed in 
populations of this kind, analyses will compare mean costs using standard 
parametric t-tests with covariates for pre-specified baseline stratification 
factors plus baseline costs. The robustness of the parametric tests will be 
confirmed using bias-corrected, non-parametric bootstrapping.  
 
We will explore the joint distribution of costs and effects in a cost-
effectiveness analysis (CEA) using an incremental approach to determine the 
incremental cost-effectiveness ratio with uncertainty estimates around it. The 
cost-effectiveness acceptability curve (CEAC) will be used to represent the 
probability that collaborative care is cost-effective compared to usual care for 
a range of maximum monetary values (ceiling ratios) that a UK decision 
maker may be willing to pay for an increase in one unit of quality-adjusted life 
years. This is the recommended decision-making approach to dealing with the 
uncertainty that exists around the estimates of expected costs and expected 
effects associated with the interventions under investigation and uncertainty 
regarding the maximum cost-effectiveness ratio that a decision-maker would 
consider acceptable.  
 
Furthermore, a net benefit analysis will be undertaken to evaluate the net 
monetary gain that can be achieved with implementation of collaborative care. 
The net benefit approach will estimate the monetary gain by weighting the 
incremental quality-adjusted life years by ceiling ratios and taking away the 
incremental cost of the intervention. This in turn will allow the decision makers 
to determine the value of the intervention in terms of monetary gains. 
 
3.4 Qualitative analysis  
 
Our qualitative analysis aims, as outlined in The CASPER Trial protocol are:  
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1. To inform the efficient conduct of the main trial phase (recruitment, 
randomisation and follow up). 
2. To refine the content and delivery of the collaborative care intervention 
based on early experience from the pilot phase of the trial.  
3. To understand the barriers and facilitators to the delivery, uptake and 
implementation of collaborative care for older people. 
 
4. Ethical issues 
 
NRES approval has been received to conduct the CASPER study, using the 
recruitment method described above. We are aware that older people with 
above-threshold depression (experiencing a major depressive episode) 
represent a vulnerable group. However, we do not anticipate any major ethical 
issues since we will only offer interventions recommended in recent guidance 
issued by NICE. Where participation in the trial is felt to be detrimental to 
health and wellbeing, we will not make an approach to participate. Participants 
will not be denied any form of care that is currently available in the NHS by 
participating in the trial, since participants allocated to usual care will still have 
full access to NICE recommended treatments, subject to local provision of 
services. 
 
4.1 Anticipated risks and benefits 
The trial does not involve new medicinal products or any invasive/potentially 
harmful procedures and is therefore considered low risk for participants. 
All participants will receive usual GP care, and therefore no treatment will be 
withheld by participating in this trial. This trial may in fact benefit individual 
participants, since collaborative care is not routinely offered to our target 
group (screen-positive sub-threshold and above-threshold depression). By 
participating in this trial, participants will also receive a more intensive level of 
monitoring than that normally received in primary care. Participants who 
become more depressed or become suicidal will be more readily identified 
and directed to appropriate care. 
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4.2 Informing participants of anticipated risks and benefits  
The Patient Information Sheet will provide potential participants with 
information about the possible benefits and anticipated risks of taking part in 
the study either as a participant in the epidemiological cohort or additionally in 
the trial. Participants will be given the opportunity to discuss this issue with 
their GP or trial co-ordinator prior to consenting to participate. The trial co-
ordinator will inform the participant if new information comes to light that may 
affect the participant’s willingness to participate in the trial.  
 
4.3 Obtaining consent 
Potential participants will receive an information pack about the trial. The pack 
will contain an invitation letter, Patient Information Sheet, a consent and a 
decline form and demographic questionnaire. The Patient Information Sheet 
will be produced using the current guidelines for researchers on writing 
information sheets and consent forms, posted on the NRES website.  
 
4.4 Retention of study documentation 
All data will be stored for a minimum of 5 years after the end of final analysis 
of the study and will be accessed by the Trial Statistician. All paper records 
will be stored in secure storage facilities. Personal identifiable paper records 
will be stored separately from anonymised paper records. All electronic 
records will be stored on a password protected server within York Trials Unit. 
 
5. Project Timetable 
November 2011 HTA approval of the CASPER PLUS RCT 
gained 
February 2012 CASPER PLUS collaborative care manual 
produced for use in trial. 
Mar-Apr 2012 Submission of application for substantial 
amendment to REC, CLRN and local R&D 
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April-May 2012 Approval letters gained from Ethics committee, 
all local PCTs and R&Ds. Amendment 
approved. 
June 2012 Recruitment to CASPER PLUS RCT begins in 
Leeds and York. Primary care mental health 
workers begin work, and patients studied in 
concurrent process evaluation to refine 
intervention.  
July  2013 Recruitment to the sub-study trial ends 
Dec 2014 Follow up period of sub-study trial ends 
 
6. PPI strategy 
 
To enhance our service user and public involvement strategy, we are 
collaborating with a new initiative, funded by NIHR HTA Programme, the 
CASPER PPI strategy will be led by Dr June Wainwright, the Service User 
Representative for the NIHR Mental Health Research Network. Our PPI 
strategy has two key components: (i) involving service user representatives in 
the CASPER-PLUS research programme; and (ii) disseminating our research 
in a format appropriate for service users. With regard to (i), we will establish a 
trial management group (TMG); which will meet monthly to oversee the 
progress of the trial and include service user representation. Service users will 
also: check our understanding of key concepts; advise on our approach; 
inform the interpretation of results and comment on reports and academic 
papers. The TMG for the project will consist of a service user with lived 
experience of depression (our service user and carer collaborator JW has 
lived experience of depression). We will also invite a service user/carer to sit 
on the Trial Steering Committee (TSC). JW will facilitate the recruitment of the 
service user/carer to the TSC through her extensive and long-standing links 
with networks of users and carers in the mental health area and her 
experience of involvement in research. JW currently runs a training 
programme (based in the southern section of the regional MHRN which 
includes York) to support users and carers who wish to contribute to research. 
We are therefore confident we will be able to recruit an additional service user 
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to Trial Steering Committee, and that they will receive support from JW to be 
an active participant. JW will be able to provide continued service user input to 
the research team beyond the TMG and will be an active member of the 
project team. We now include a cost item for PPI/service user involvement, so 
that this activity can be supported and users’ contribution can be reimbursed 
in line with recommendations from INVOLVE. 
 
7. Monitoring Adverse Events  
All serious adverse events that are treatment related will be recorded and 
immediately reported to the Data Monitoring and Ethics Committee (DMEC), 
MHRA trial sponsor and ethics committee except those that the CASPER 
protocol identifies as not requiring immediate reporting. The immediate report 
will be followed up by a detailed, written report and further information if 
requested. Inherent in the nature of the population under scrutiny is the risk of 
suicide and deliberate self-harm. We will follow good clinical practice in 
monitoring for suicide risk during all patient encounters with trial participants. 
Where any risk to patients due to expressed thoughts of self-harm is 
encountered, we will report these directly to the GP (with the patients’ 
expressed permission) or will seek advice from the general practitioner if there 
are any concerns about immediate risk. Serious adverse events that are fatal 
or life-threatening will be recorded and reported to the TSC and ethics 
committee within 7 days of knowledge of such cases. All other suspected 
serious unexpected adverse events will be reported to the DMEC, MHRA, trial 
sponsor and ethics committee within 15 days of first knowledge.  All serious 
adverse events that are treatment related will be recorded and immediately 
reported to the Data Monitoring and Ethics Committee (DMEC), MHRA trial 
sponsor and ethics committee except those that the protocol or investigator’s 
brochure identifies as not requiring immediate reporting. The immediate report 
will be followed up by a detailed, written report and further information if 
requested. Inherent in the nature of the population under scrutiny is the risk of 
suicide and deliberate self-harm. We will follow good clinical practice in 
monitoring for suicide risk during all patient encounters with trial participants. 
Where any risk to patients due to expressed thoughts of self-harm is 
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encountered, we will report these directly to the GP (with the patients’ 
expressed permission) or will seek advice from the general practitioner if there 
are any concerns about immediate risk. Serious adverse events that are fatal 
or life-threatening will be recorded and reported to the TSC and ethics 
committee within 7 days of knowledge of such cases. All other suspected 
serious unexpected adverse events will be reported to the DMEC, MHRA, trial 
sponsor and ethics committee within 15 days of first knowledge.  
 
We will follow the same suicide protocol as CASPER. For details, see 
Appendix 4 of the CASPER Trial protocol. 
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9. Appendices 
 
GP/Practice Recruitment to CASPER cmRCT 
Practice database screening of all over 65s & send Patient Letter of 
Invitation 
Baseline questionnaire for depression (inc. the ‘Whooley 
questions’, PHQ, SF12 Health Economics questions) 
Telephone assessment for eligibility (using the MINI, PHQ9) 
Ineligible (below 
threshold) 
Randomisation 
4 month 
follow-up 
12 month 
follow-up 
Collaborative 
Care  
4 month 
follow-up 
12 month 
follow-up 
12 month 
follow-up 
Usual GP 
Care 
4 month 
follow-up 
DSM-IV Major 
Depressive 
Disorder 
Randomisation 
Collaborative 
Care 
4 month follow-
up 
12 month 
follow-up 
12 month 
follow-up 
Usual GP Care 
4 month follow-
up 
DSM-IV sub-
threshold 
depression 
CASPER Trial – identification, recruitment & progress 
CASPER Plus Trial – recruitment & progress 
18 month 
follow-up 
18 month 
follow-up 
CASPER-PLUS trial CASPER trial 
Appendix 1: The CASPER Study Design and Flowchart 
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Appendix 2: Data Collection Schedule 
 
   Invitation Baseline Depression 
assessment 
4 mth 
follow 
up 
12 mth  
follow up 
18mth 
follow up 
          
       
Consent/Decline form •      
Demographic 
questionnaire • 
     
Whooley questionnaire • •     
Physical health 
problems • 
     
Falls questions •      
         
         
PHQ-9  • • • • • 
SF-12    •  • • • 
EQ-5D    •  • • • 
GAD-7    •  • • • 
PHQ-15    •  • • • 
CD-RISC2    •  • • • 
Medication 
questionnaire 
 •  • • • 
         
         
Diagnostic interview 
(MINI) 
  •    
         
         
Economic evaluation  •  • • • 
Objective medication 
data 
 •  • • • 
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Appendix 3: CASPER Study – overview of phased approach and timeline 
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CASPER PLUS: An RCT sub-study of  
The CASPER Study 
 
 
Collaborative Care in Screen-Positive 
Elders – The CASPER PLUS Trial 
 
 
 
 
 
 
Trial Protocol  
 
 
 
                                                                              The CASPER Study is funded by: 
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The CASPER Research Collaborative 
 
Chief Investigator:  Prof Simon Gilbody1 
Grant Co-applicants: Dr Joy Adamson1 
    Prof Carolyn Chew-Graham3 
Mr David Ekers4 
    Dr Catherine Hewitt1 
    Dr John Holmes2 
Dr Dean McMillan1 
    Dr Natasha Mitchell1 
Mr Stephen Parrott1 
Prof David Richards5 
    Dr Karen Spilsbury1 
    Prof David Torgerson1  
    York Trials Unit 
 
Other contacts 
Trial Co-ordinator:  Dr Helen Lewis1 
Collaborator:  Dr June Wainwright 
 
1. Department of Health Sciences, Seebohm Rowntree Building, 
University of York, Heslington, York, YO10 5DD. 
2. Leeds Institute of Health Sciences, Charles Thackrah Building, 
University of Leeds, 101 Clarendon Road, Leeds, LS2 9LJ. 
3. National Primary Care Research & Development Centre, Williamson 
Building, Oxford Road, University of Manchester, Manchester, M13 
9PL. 
4. Centre for Mental Health Research, University of Durham, Durham, 
TS17 6BH. 
5. School of Psychology, Washington Singer Laboratories, University of 
Exeter, Perry Road, Exeter, EX4 4QG. 
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Overview 
As a sub-study of The CASPER Study, CASPER PLUS is a trial of a primary 
care-based intervention for older people with depression. Depression in older 
people is common and associated with poor quality of life, increased morbidity 
and mortality and increased health and social care use. It is under-recognised 
and sometimes inadequately treated in primary care. Current management is 
mostly limited to the prescription of anti-depressants; where there may be 
poor concordance. 
 
Psychological treatments may not be offered or available in practice; and the 
evidence for psychological interventions uses models of care which are of a 
higher intensity such that they could not feasibly be delivered in primary care 
in sufficient volume to meet the needs of older people. An intervention known 
as collaborative care involves a brief patient-centred psycho-social package 
of care delivered by a case manager working to a defined protocol; medication 
management and with supervision of the case manager by a specialist, which 
facilitates liaison across the primary /secondary interface. Collaborative Care 
has shown promising trial results in the United States. However the 
transferability of this model of service to the UK NHS cannot be assumed. 
NICE has identified this as an important intervention that should be subject to 
further trials. 
 
CASPER PLUS will run seamlessly as part of the recruitment procedures of a 
cohort of older people with depression with whom we will conduct trials to 
inform practice and policy (the CASPER older persons’ cohort multiple RCT - 
cmRCT). Using this same cohort, we seek to conduct the definitive trial of 
collaborative care in older people with above threshold, major depressive 
disorder. Since we already identify people with ‘sub threshold’ depression in 
the existing cohort, we can conduct this important trial relatively quickly and at 
lower cost. The conduct of this trial will significantly enhance the randomised 
evidence base in the care of older people with depression, and will inform 
future service provision; satisfying a research priority identified by NICE. 
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1. Background 
 
Depression accounts for the greatest burden of disease among all mental 
health problems, and is expected to become the second-highest among all 
general health problems by 2020.[1] By the age of 75, 1 in 7 older people 
meet formal diagnostic criteria for depression. Projected demographic 
changes mean that population strategies to tackle depression will increasingly 
have to address the specific needs of older people.[2] Amongst older people, 
depressive syndromes often affect people with chronic medical illnesses, 
cognitive impairment, social isolation or disability. 
 
Older people with a long-term condition are five times more likely to suffer 
depression. 50% of people with Parkinson’s disease will suffer depression, 
25% following stroke, 20% with coronary heart disease, 24% neurological 
disease and 42% chronic lung disease.[3] Beyond personal suffering and 
family disruption, depression worsens the outcomes of many medical 
disorders and promotes disability. The impairments in quality of life associated 
with depression are comparable to those of major physical illness. Amongst 
older people, a clinical diagnosis of major depression is the strongest 
predictor for impaired quality of life (QoL).[4]  
 
Current UK policies under the Quality and Outcomes Framework (QOF) 
advocate case-finding for depression amongst those with chronic physical 
health problems such as heart disease and diabetes. [5] Once detected, 
evidence supported guidelines advocate the prescription of anti-depressant 
drugs and appropriate provision of psychological care.[6,7] However, an 
enduring critique has been that depression is not well managed even when 
this is revealed through case-finding.[2] Management in primary care usually 
involves the prescription of antidepressant medication, with poor concordance 
and suboptimal dosages. The provision of psychological or social 
interventions addressing issues of poor adaptation, loss, depressive thinking 
or social withdrawal is woefully inadequate. For example, there has been 
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minimal provision of psychological treatment for older people under the 
Improving Access to Psychological Therapies (IAPT) programme. 
 
Despite being encouraged to case-find for depression in older people there is 
little evidence that this has translated into better management for this 
disorder. The current proposal introduces a feasible intervention for this group 
of patients which is known as ‘Collaborative care’. 
 
The role of collaborative care 
The vast majority of depression in older people can (quite appropriately) be 
managed entirely in primary care, without recourse to specialist mental health 
services.[2,6,8] A range of individual treatments have been shown to be 
effective in the management of depression in older people, including anti-
depressants and psychosocial interventions.[6] However, a repeated 
observation amongst all people with depression has been the failure to 
integrate these effective elements of care into routine primary care 
services.[9] Similarly the volume of people with depression necessitates that 
low intensity interventions are the only feasible strategy that can be used in 
managing depression within the population.  
 
Despite recent investment under the Improving Access to Psychological 
Therapies (IAPT) initiative, the capacity for specialist mental health services to 
provide this care is constrained and demand would quite quickly outstrip 
supply. Hence any feasible strategy will be both low intensity and offered 
within primary care.[10] 
 
The ubiquity of depression in primary care settings and the poor 
integration/co-ordination of care have led to strategies to re-engineer the 
delivery of care. This form of care borrows much from chronic disease 
management and facilitates the delivery of effective forms of treatment (such 
as pharmacotherapy and/or brief psychological therapy). This model of care is 
often referred to as collaborative care or case management.[11] According 
to a recent BMJ editorial on the management of depression in older people 
‘Innovations in the management of depression have been evaluated. The best 
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results come from models that use multifaceted interventions and principles of 
collaborative care.’ [2] We would concur with this observation and the 
CASPER research group has contributed much to the evidence base of 
collaborative care and in the evaluation/implementation of this model of care 
to the UK. We have for example, conducted the definitive reviews of this 
intervention, [13,14] and have completed the first trial of collaborative care in 
the UK.[14] We have recently completed an MRC-funded evaluation of clinical 
and cost effectiveness of Collaborative Care in depressed working age adults 
(PI Richards). Within the new Improving Access to Psychological Therapies 
(IAPT) programme, we have implemented this model of care for over 7000 
working age adults with depression in demonstration sites.[15] We have also 
developed computer-based case management systems to facilitate symptom 
management and supervision of case managers (the PC-MIS system). 
 
Our own reviews in this area have shown collaborative care to be a potentially 
effective and efficient means of delivering care for depression. Based upon 
analyses of 36 trials (12,000 participants), we have shown that collaborative 
care is effective in the short and medium term in alleviating depressive 
symptoms and improving quality of life. [12] Moreover collaborative care is 
known to be cost effective in reducing healthcare utilisation and in improving 
overall quality of life. [16] See CASPER protocol for details of the United 
States IMPACT study of collaborative care in older adults (aged over 60). 
 
1.2 The wider CASPER Study 
The CASPER study (see Appendix 1) - a cohort study and randomised 
controlled trial looking at the effectiveness of collaborative care in older 
patients with sub-threshold depression [14] - uses a database screening 
approach in recruiting patients. A randomised controlled trial would be the 
best approach to evaluate its effects.  
 
1.3 Research Objectives 
The research objectives of the CASPER PLUS sub-study are: 
1. To establish the clinical effectiveness of a collaborative care 
intervention for older people with screen-positive above-threshold 
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(‘major depressive episode’) depression within a definitive RCT.  
2. To examine the cost effectiveness of a collaborative care intervention 
for older people with screen-positive above-threshold (‘major 
depressive episode’) depression within a definitive RCT.  
 
2. Method 
2.1 Design 
As a sub-study of the CASPER trial, CASPER PLUS will follow the same 
design and recruit from the same wider cohort, using a pragmatic multi-
centred randomised controlled trial until completion of the CASPER trial 
recruitment phase. Following this, CASPER Plus will adopt a more focused 
approach to recruitment in General Practice, concentrating on searches for 
patients with known depression or known to be at greater risk of depression. 
 
Patients will be randomly allocated to one of two interventions: 
 
1. Collaborative care with behavioural activation and active surveillance 
2. Usual primary care management of above-threshold depression (major 
depressive episode) offered by the patient’s GP, in line with NICE 
depression guidance and local service provision 
 
2.2 Inclusion / exclusion criteria 
For the CASPER PLUS sub-study all patients at participating CASPER GP 
practices who have been identified as eligible to receive an invitation mailing 
will be included. Those patients identified at the screening phase as having 
above-threshold, case level depression will be eligible to enter the CASPER 
PLUS sub study.  
 
Inclusion criteria  
CASPER participants will be identified by comprehensive screening strategies 
in primary care (replicating that which is incentivised in QOF-compliant case 
finding for those with CHD and diabetes). Our target population will be older 
people (aged 65 and above) who screen-positive for depression on the 
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recommended QOF 2 question brief depression screen (sometimes referred 
to as the ‘Whooley’ questions after their initial validation study [21]), but who 
on further assessment have DSM-IV Major Depressive Disorder (MDD).[22] 
The Whooley questions are detailed in Box 1. [21,23] 
Box 1: QOF-compliant (DEP1) brief screening questions 
 
The exclusion criteria are: 
 Known alcohol dependency (as recorded on GP records) 
 Any known co-morbidity that would in the GP’s opinion make entry to 
the trial inadvisable (e.g. recent evidence of self harm, known current 
thoughts of self harm, significant cognitive impairment) 
 Other factors that would make an invitation to participate in the trial 
inappropriate (e.g. recent bereavement; terminal malignancy) 
 Known to be experiencing psychotic symptoms (as recorded on GP 
records) 
 Actively engaged in a psychological intervention or therapy at the time 
of randomisation (screened at diagnostic interview). 
 
2.3 Recruitment and Randomisation 
 
2.4 Intervention 
Collaborative Care with behavioural activation and active surveillance  
Patients who meet our pragmatic inclusion criteria will be individually 
randomised into one of two intervention groups: (1) Collaborative Care 
(including Behavioural Activation) intervention with medication monitoring and 
management, or (2) usual care. This is a pragmatic trial [20] and we will 
1. ‘Over the past month have you been bothered by feeling down, 
depressed or hopeless?’  
2. ‘Over the past month, have you been bothered by having little interest or 
pleasure in doing things? A positive answer to one or both of these 
questions raises the possibility of depression and necessitates a full 
assessment for the presence or absence of clinically significant depressive 
syndrome.  
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impose few restrictions on routine practice and will have no direct influence on 
the prescription of medication (which will remain entirely in the control of 
GPs). The actual delivery of this service within the pilot trial will be studied 
using a concurrent process evaluation – utilising a mixed methods research 
design.  
 
Eligible participants who have consented to be in the trial will be randomised 
to a treatment group using the computer-based York Trials Unit telephone 
randomisation service.  
 
Our experimental intervention will be a bespoke collaborative care designed 
and delivered specifically for those aged 65 or over with above threshold, 
case-level depression over 6-8 weekly sessions. The intervention manual has 
been adapted from the existing CASPER manual used in the pilot study. 
Collaborative care will be delivered by a case manager (a primary care mental 
health worker) within a 'stepped care framework', such that those whose 
depression deteriorates are 'stepped up' from low intensity care to a more 
intensive form of management including medication monitoring.  
 
The five core components of the intervention are described below: 
 
1. PATIENT-CENTRED ASSESSMENT AND ENGAGEMENT: patients 
are first assessed in their own residential setting, GP practice or by 
telephone. The severity of depression and associated behavioural and 
social deficits are assessed. The presence of depressive symptoms 
and behavioural deficits are described and patient information materials 
are given or sent in advance to the participant. 
 
2. SYMPTOM MEASUREMENT AND MONITORING: a standardised 
assessment of symptom severity is made. Symptom tracking (to judge 
response, failure to respond or deterioration) is then made at all 
subsequent patient contacts. 
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3. MEDICATION MANAGEMENT: the prescription of anti-depressant 
medication is entirely at the discretion of the General Practitioner. We 
will encourage GPs to consider NICE guidance in their prescribing 
decisions. The concordant use of medication by patients will be 
encouraged by the case manager if a prescription has been initiated by 
the GP.  Patient concerns (such as addiction) and non-compliance will 
be addressed during sessions.  There will be active liaison with GPs to 
encourage follow up patient appointments with the GP if poor 
concordance is noted. 
 
4. ACTIVE FOLLOW-UP: all patients are followed up by the CM for eight 
weeks using face to face meetings or telephone contacts. Our own 
experience is that telephone contacts are acceptable and that patients 
can be engaged using this means of communication.[18] We have 
adapted this means of delivery in the light of the specific needs of those 
over 65.  
 
 
5. DELIVERY OF BEHAVIOURAL ACTIVATION (BA): patients are 
offered the option of behavioural activation delivered over eight 
sessions by their case manager. BA consists of a structured 
programme of reducing the frequency of negatively reinforced avoidant 
behaviours in parallel with increasing the frequency of positively 
reinforcing behaviours to improve functioning and raise mood. During 
this time patients will remain under the medical care of their General 
Practitioner.  We have demonstrated that BA is potentially effective in 
older adults.[17] and have recently demonstrated the effectiveness of 
this approach in working age adults.[19]  
 
Higher intensity treatments for depression will be facilitated by the GP and by 
conventional mental health services for older people, and will not be directly 
influenced by this trial. The additional elements of collaborative care include: 
telephone support; symptom monitoring and active surveillance (facilitated by 
computerised case management systems – PC-MIS); medication monitoring; 
APPENDIX 21
NIHR Journals Library www.journalslibrary.nihr.ac.uk
236
CASPER PLUS Trial Protocol   v2.6 4Apr14 
low intensity psychosocial intervention (behavioural activation). The work of 
case managers is supervised by an older persons’ mental health specialist 
(old age psychiatrist or psychologist). 
 
For the purpose of quality evaluation and to ensure fidelity to the Collaborative 
Care model, we propose to record a sub-sample of patient consultations with 
around 6 - 8 Case Managers who deliver the intervention to 3 – 4 participants 
each (24 – 32 participants in total). As a secondary aim, we wish to use the 
recordings to refine the content or delivery of the intervention.  
 
To gain an overview of how the treatment progresses, we would aim to record 
a maximum of 4 sessions of the 8-10 consultations that Case Managers have 
with participants. We would purposively sample Case Managers with different 
backgrounds, including those with long-term experience of working with 
psychosocial interventions for older people as well as others with less 
experience. 
 
 
 
Control intervention  
Participants allocated to the control condition will receive usual primary care 
management of case level depression offered by their GP, in line with NICE 
depression guidance and local service provision.  
 
Recruitment method  
Screening of all over 65s from GP practice lists: in our existing portfolio of 
trials at the York Trials Unit, we have pioneered the use of postal screening 
questionnaires sent to all over 75s based upon practice registers. This has 
resulted in above-target recruitment to our trials in falls and osteoporosis by 
this method. We will follow those participants who sign the consent form, 
return screening questionnaires and  meet the inclusion criteria for the 
CASPER Plus trial. Following the completion of the recruitment phase of the 
CASPER trial, all ineligible participants will be thanked for their interest in the 
study but not followed up. The pilot study of CASPER has been successful in 
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recruiting 100 participants and met criteria for retention during the first year of 
the study. In addition to sending postal screening questionnaires, participants 
may be recruited directly by GPs.  
 
2.5 Outcome measures 
Primary outcome: We will measure depression severity at four months by self 
report using the Patient Health Questionnaire 9 – PHQ9. We will also 
measure outcome at 12 and 18 months using the PHQ9 to examine any 
sustained impact of the intervention.  
 
Our secondary outcome is binary and is the presence/absence of depression 
diagnosis as ascertained by interview. For this secondary measure we will use 
a criterion-based assessment of depression according to the American 
Psychiatric Association DSM-IV (established by the validated interviewer-
administered diagnostic schedule MINI). We will also measure DSM-IV 
depression status at 4, 12 months and 18 months (using the PHQ9); health 
related quality of life (SF-12); health-state utility (EQ5D) at 4 months, 12 
months and 18 months. 
 
2.6 Qualitative study 
In addition to the quantitative data collected in the nested trial, we will collect 
qualitative data obtained from focus groups and/or face to face interviews.  
3. Statistical considerations 
3.1 Sample size  
Our overall sample size for our definitive trial will be 450 (225 per arm). The 
sample size of our definitive trial is inexorably linked to (1) the specified 
minimally important difference; (2) ICC and (3) caseload size. A conservative 
assumption of an ability to detect an effect size of 0.35, based upon 
ICC=0.02 and caseload size 20 will require 180 participants in the intervention 
arm. This effect size is in line with the IMPACT US trial [25]
 
and the point 
estimate from our UK pilot trial. 
 
 
TABLE: SAMPLE SIZE CALCULATION INCORPORATING ICC VALUES, CASELOAD 
SIZES AND LOSS TO FOLLOW UP  
APPENDIX 21
NIHR Journals Library www.journalslibrary.nihr.ac.uk
238
CASPER PLUS Trial Protocol   v2.6 4Apr14 
Effect size* (based 
upon US trial and UK 
pilot trial.  
Conventional 
sample size 
(assumes no 
clustering)  
Caseload 
size  
Plausible ICC 
within 
therapists’ 
caseloads  
Design 
Effect/Inflation 
factor  
Effective 
sample size 
(adjusted for 
clustering)  
Inflation for 
20% loss to 
follow up 
(final sample 
size)  
D=0.35  260  20  0.02  1.38  360  450  
 
3.2 Analysis 
Statistical analysis of clinical data  
We will analyse the data on an intention to treat basis. The primary outcome 
of depression severity (a continuous outcome as measured by a score on the 
PHQ9 depression severity measure) will be used in a linear regression model 
to compare collaborative care with usual care. The analysis will be adjusted 
for baseline depression severity (as measured by the PHQ9) and 
physical/functional limitations (as measured by the SF36 physical functioning 
scale).[24] Standardised effect sizes and the corresponding 95% confidence 
intervals will be presented for the primary outcome of depression severity. 
Two-sided 95% confidence intervals will be calculated.  
 
For each outcome measure the number of non-responders will be calculated 
for each treatment group and response rates compared. We will undertake 
sensitivity analyses to explore the impact of missing data using multiple 
imputations by chained equations which will be performed using the ICE 
package in Stata. All secondary analyses will be conducted using linear or 
logistic regression, depending on the outcome measure, adjusting for the 
same covariates as the primary analysis. All analyses will adjust for within-
therapist clustering using multi-level modelling with the Huber-White sandwich 
estimator.  
 
3.3 Analysis of economic data  
The economic evaluation will take the form of within-trial cost-utility analysis 
that will determine the incremental cost per quality adjusted life year for 
treatment with collaborative care against usual care in individuals with 
depression. The primary analyses will be conducted from the UK NHS and 
personal and social services (PSS) perspective following NICE evaluation 
guidance.  
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Primary and secondary healthcare and societal costs will include intervention-
related costs, health service use costs and personal social services costs, in 
line with the recommendations by NICE. The cost data will be collected to fully 
reflect the management of depression and its cost in both collaborative care 
and usual care group, and these will be analysed within a societal 
perspective. Intervention (and control) group costs will be based on the 
delivery costs within the trial and include supervision and appropriate capital 
and overhead amounts. Patient questionnaires and case record review will be 
used to collect data on the use of health services and personal social 
services. Unit costs for these items will be drawn from the NHS reference 
costs and the personal social services resource use databases.  
 
The effectiveness of the intervention will be evaluated using the standard 
quality of life measures which have been shown to be sensitive to change in 
relation to depression, and also physical healthcare problems common 
amongst older adults. These will be collected at regular intervals using patient 
questionnaires. These will then be evaluated over the 18 months trial period to 
estimate the total quality-adjusted life years for both intervention and control 
groups.  
 
Economic analyses will compare the costs and effectiveness at the final 18-
month follow-up of collaborative versus usual care to capture the economic 
impact of events such as relapse, although we will conduct an initial 
preliminary analysis at six months to coincide with the primary clinical 
analyses. Although the distribution of costs is commonly skewed in 
populations of this kind, analyses will compare mean costs using standard 
parametric t-tests with covariates for pre-specified baseline stratification 
factors plus baseline costs. The robustness of the parametric tests will be 
confirmed using bias-corrected, non-parametric bootstrapping.  
 
We will explore the joint distribution of costs and effects in a cost-
effectiveness analysis (CEA) using an incremental approach to determine the 
incremental cost-effectiveness ratio with uncertainty estimates around it. The 
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cost-effectiveness acceptability curve (CEAC) will be used to represent the 
probability that collaborative care is cost-effective compared to usual care for 
a range of maximum monetary values (ceiling ratios) that a UK decision 
maker may be willing to pay for an increase in one unit of quality-adjusted life 
years. This is the recommended decision-making approach to dealing with the 
uncertainty that exists around the estimates of expected costs and expected 
effects associated with the interventions under investigation and uncertainty 
regarding the maximum cost-effectiveness ratio that a decision-maker would 
consider acceptable.  
 
Furthermore, a net benefit analysis will be undertaken to evaluate the net 
monetary gain that can be achieved with implementation of collaborative care. 
The net benefit approach will estimate the monetary gain by weighting the 
incremental quality-adjusted life years by ceiling ratios and taking away the 
incremental cost of the intervention. This in turn will allow the decision makers 
to determine the value of the intervention in terms of monetary gains. 
 
3.4 Qualitative analysis  
 
Our qualitative analysis aims, as outlined in The CASPER Trial protocol are:  
 
1. To inform the efficient conduct of the main trial phase (recruitment, 
randomisation and follow up). 
2. To refine the content and delivery of the collaborative care intervention 
based on early experience from the pilot phase of the trial.  
3. To understand the barriers and facilitators to the delivery, uptake and 
implementation of collaborative care for older people. 
 
4. Ethical issues 
 
NRES approval has been received to conduct the CASPER study, using the 
recruitment method described above. We are aware that older people with 
above-threshold depression (experiencing a major depressive episode) 
represent a vulnerable group. However, we do not anticipate any major ethical 
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issues since we will only offer interventions recommended in recent guidance 
issued by NICE. Where participation in the trial is felt to be detrimental to 
health and wellbeing, we will not make an approach to participate. Participants 
will not be denied any form of care that is currently available in the NHS by 
participating in the trial, since participants allocated to usual care will still have 
full access to NICE recommended treatments, subject to local provision of 
services. 
 
4.1 Anticipated risks and benefits 
The trial does not involve new medicinal products or any invasive/potentially 
harmful procedures and is therefore considered low risk for participants. 
All participants will receive usual GP care, and therefore no treatment will be 
withheld by participating in this trial. This trial may in fact benefit individual 
participants, since collaborative care is not routinely offered to our target 
group (screen-positive sub-threshold and above-threshold depression). By 
participating in this trial, participants will also receive a more intensive level of 
monitoring than that normally received in primary care. Participants who 
become more depressed or become suicidal will be more readily identified 
and directed to appropriate care. 
 
4.2 Informing participants of anticipated risks and benefits  
The Patient Information Sheet will provide potential participants with 
information about the possible benefits and anticipated risks of taking part in 
the study either as a participant in the epidemiological cohort or additionally in 
the trial. Participants will be given the opportunity to discuss this issue with 
their GP or trial co-ordinator prior to consenting to participate. The trial co-
ordinator will inform the participant if new information comes to light that may 
affect the participant’s willingness to participate in the trial.  
 
4.3 Obtaining consent 
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Potential participants will receive an information pack about the trial. The pack 
will contain an invitation letter, Patient Information Sheet, a consent and a 
decline form and demographic questionnaire. The Patient Information Sheet 
will be produced using the current guidelines for researchers on writing 
information sheets and consent forms, posted on the NRES website.  
 
4.4 Retention of study documentation 
All data will be stored for a minimum of 5 years after the end of final analysis 
of the study and will be accessed by the Trial Statistician. All paper records 
will be stored in secure storage facilities. Personal identifiable paper records 
will be stored separately from anonymised paper records. All electronic 
records will be stored on a password protected server within York Trials Unit. 
 
5. Project Timetable 
November 2011 HTA approval of the CASPER PLUS RCT 
gained 
February 2012 CASPER PLUS collaborative care manual 
produced for use in trial. 
Mar-Apr 2012 Submission of application for substantial 
amendment to REC, CLRN and local R&D 
April-May 2012 Approval letters gained from Ethics committee, 
all local PCTs and R&Ds. Amendment 
approved. 
June 2012 Recruitment to CASPER PLUS RCT begins in 
Leeds and York. Primary care mental health 
workers begin work, and patients studied in 
concurrent process evaluation to refine 
intervention.  
July  2013 Recruitment to the sub-study trial ends 
Dec 2014 Follow up period of sub-study trial ends 
 
6. PPI strategy 
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To enhance our service user and public involvement strategy, we are 
collaborating with a new initiative, funded by NIHR HTA Programme, the 
CASPER PPI strategy will be led by Dr June Wainwright, the Service User 
Representative for the NIHR Mental Health Research Network. Our PPI 
strategy has two key components: (i) involving service user representatives in 
the CASPER-PLUS research programme; and (ii) disseminating our research 
in a format appropriate for service users. With regard to (i), we will establish a 
trial management group (TMG); which will meet monthly to oversee the 
progress of the trial and include service user representation. Service users will 
also: check our understanding of key concepts; advise on our approach; 
inform the interpretation of results and comment on reports and academic 
papers. The TMG for the project will consist of a service user with lived 
experience of depression (our service user and carer collaborator JW has 
lived experience of depression). We will also invite a service user/carer to sit 
on the Trial Steering Committee (TSC). JW will facilitate the recruitment of the 
service user/carer to the TSC through her extensive and long-standing links 
with networks of users and carers in the mental health area and her 
experience of involvement in research. JW currently runs a training 
programme (based in the southern section of the regional MHRN which 
includes York) to support users and carers who wish to contribute to research. 
We are therefore confident we will be able to recruit an additional service user 
to Trial Steering Committee, and that they will receive support from JW to be 
an active participant. JW will be able to provide continued service user input to 
the research team beyond the TMG and will be an active member of the 
project team. We now include a cost item for PPI/service user involvement, so 
that this activity can be supported and users’ contribution can be reimbursed 
in line with recommendations from INVOLVE. 
 
7. Monitoring Adverse Events  
All serious adverse events that are treatment related will be recorded and 
immediately reported to the Data Monitoring and Ethics Committee (DMEC), 
MHRA trial sponsor and ethics committee except those that the CASPER 
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protocol identifies as not requiring immediate reporting. The immediate report 
will be followed up by a detailed, written report and further information if 
requested. Inherent in the nature of the population under scrutiny is the risk of 
suicide and deliberate self-harm. We will follow good clinical practice in 
monitoring for suicide risk during all patient encounters with trial participants. 
Where any risk to patients due to expressed thoughts of self-harm is 
encountered, we will report these directly to the GP (with the patients’ 
expressed permission) or will seek advice from the general practitioner if there 
are any concerns about immediate risk. Serious adverse events that are fatal 
or life-threatening will be recorded and reported to the TSC and ethics 
committee within 7 days of knowledge of such cases. All other suspected 
serious unexpected adverse events will be reported to the DMEC, MHRA, trial 
sponsor and ethics committee within 15 days of first knowledge.  All serious 
adverse events that are treatment related will be recorded and immediately 
reported to the Data Monitoring and Ethics Committee (DMEC), MHRA trial 
sponsor and ethics committee except those that the protocol or investigator’s 
brochure identifies as not requiring immediate reporting. The immediate report 
will be followed up by a detailed, written report and further information if 
requested. Inherent in the nature of the population under scrutiny is the risk of 
suicide and deliberate self-harm. We will follow good clinical practice in 
monitoring for suicide risk during all patient encounters with trial participants. 
Where any risk to patients due to expressed thoughts of self-harm is 
encountered, we will report these directly to the GP (with the patients’ 
expressed permission) or will seek advice from the general practitioner if there 
are any concerns about immediate risk. Serious adverse events that are fatal 
or life-threatening will be recorded and reported to the TSC and ethics 
committee within 7 days of knowledge of such cases. All other suspected 
serious unexpected adverse events will be reported to the DMEC, MHRA, trial 
sponsor and ethics committee within 15 days of first knowledge.  
 
We will follow the same suicide protocol as CASPER. For details, see 
Appendix 4 of the CASPER Trial protocol. 
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9. Appendices 
GP/Practice Recruitment to CASPER cmRCT 
Practice database screening of all over 65s & send Patient Letter of 
Invitation 
Baseline questionnaire for depression (inc. the ‘Whooley 
questions’, PHQ, SF12 Health Economics questions) 
Telephone assessment for eligibility (using the MINI, PHQ9) 
Ineligible (below 
threshold) 
Randomisation 
4 month 
follow-up 
12 month 
follow-up 
Collaborative 
Care  
4 month 
follow-up 
12 month 
follow-up 
12 month 
follow-up 
Usual GP 
Care 
4 month 
follow-up 
DSM-IV Major 
Depressive 
Disorder 
Randomisation 
Collaborative 
Care 
4 month follow-
up 
12 month 
follow-up 
12 month 
follow-up 
Usual GP Care 
4 month follow-
up 
DSM-IV sub-
threshold 
depression 
CASPER Trial – identification, recruitment & progress 
CASPER Plus Trial – recruitment & progress 
18 month 
follow-up 
18 month 
follow-up 
CASPER-PLUS trial CASPER trial 
Appendix 1a: The CASPER Study Design during CASPER recruitment 
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GP/Practice Recruitment to CASPER cmRCT 
Practice database screening of all over 65s & send Patient Letter of 
Invitation 
Baseline questionnaire for depression (inc. the ‘Whooley 
questions’, PHQ, SF12 Health Economics questions) 
Telephone assessment for eligibility (using the MINI, PHQ9) 
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4 month 
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12 month 
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depression –  
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Appendix 1b: The CASPER Study Design post CASPER recruitment 
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Appendix 2: Data Collection Schedule 
 
   Invitation Baseline Depression 
assessment 
3 mth 
follow 
up 
12 mth  
follow up 
18mth 
follow up 
          
       
Consent/Decline form •      
Demographic 
questionnaire • 
     
Whooley questionnaire • •     
Physical health 
problems • 
     
Falls questions •      
         
         
PHQ-9  • • • • • 
SF-12    •  • • • 
EQ-5D    •  • • • 
GAD-7    •  • • • 
PHQ-15    •  • • • 
CD-RISC2    •  • • • 
Medication 
questionnaire 
 •  • • • 
         
         
Diagnostic interview 
(MINI) 
  •    
         
         
Economic evaluation  •  • • • 
Objective medication 
data 
 •  • • • 
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Appendix 3: CASPER Study – overview of phased approach and timeline 
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       Trial Manager (45 months) 
                                                       Trial co-ordinator (39 months) 
                                                       Trial Secretary (39 months) 
                                                       Qualitative Researcher (24 months) 
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Full trial – determine 
clinical & cost-
effectiveness; 
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